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Immune-mediated polyneuropathies cover a spectrum of potentially treatable disorders 
of the peripheral nervous system leading to variable levels of weakness and sensory 
disturbances. Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating 
polyradiculoneuropathy (CIDP) are important disorders in this spectrum. Both GBS and 
CIDP show a diversity in clinical symptoms, response to treatment and outcome. In the 
papers in this thesis we investigate what determines this variation in disease course 
and treatment response. The focus of the first part of this thesis is on the spectrum of 
GBS and CIDP as well as its subtypes such as recurrent GBS, acute-onset CIDP (A-CIDP), 
and GBS with treatment-related fluctuations (GBS-TRF). The second part of the thesis 
focusses on the treatment of GBS and CIDP with IV immunoglobulins (IVIg).
GuIllAIn-BArré SynDrOme
In 1916, two French soldiers with acute flaccid paralysis and a high cerebrospinal fluid 
(CSF) protein level with a normal cell count were described by Guillain, Barré and Strohl.1 
This syndrome became known as the Guillain-Barré syndrome (GBS) and nowadays it is 
the most common severe acute paralytic neuropathy worldwide.2 The diagnosis of GBS 
is based mainly on the clinical characteristics of progressive symmetric muscle weakness 
with reduced or absent tendon reflexes of the arms and legs.3, 4 Other common symp-
toms are cranial nerve dysfunction (resulting in facial palsy, double vision or swallowing 
difficulties), sensory symptoms and pain. Important symptoms to recognise and moni-
tor closely are weakness of respiratory muscles and autonomic dysfunction which may 
require ICU admittance and artificial ventilation. GBS is often a severe disease, and about 
25% of patients require artificial ventilation for some period of time.2 A variant of GBS 
is the Miller Fisher syndrome (MFS), characterised by ophthalmoplegia, ataxia and are-
flexia.5 MFS patients in general show a milder disease course than GBS, but progression 
to GBS can occur (GBS-MFS overlap syndrome).6 GBS is often preceded by an infection 
such as a respiratory tract - or gastrointestinal infection, and sometimes by a vaccina-
tion, which may induce an autoimmune response attacking the peripheral nerves and 
spinal roots. Whether vaccinations can lead to recurrences of GBS is unknown. Preceding 
infections of GBS are Campylobacter jejuni (C. jejuni), cytomegalovirus, Epstein-Barr virus, 
Mycoplasma pneumoniae, Haemophilus influenza, hepatitis E virus, and recently Zika 
virus has also been suggested to be associated with GBS as well.7 8-11 Molecular mimicry 
between microbial agents and peripheral nerve antigens (gangliosides) play an impor-
tant role in the pathogenesis of GBS after infection with C. jejuni.12 Although C. jejuni 
infections are common, only one in 2000-5000 individuals with a C. jejuni infection will 
eventually develop GBS.13 Since only a small subset of individuals develops this post-
infectious polyneuropathy, host susceptibility factors are likely to play an important role 
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as well in the development of the disease.14 A key factor in the development of GBS after 
C. jejuni-infection in many patients is the production of antibodies to gangliosides that 
cross-react against neural antigens. These antibodies are neurotoxic and their fine speci-
ficity is associated with the type of clinical deficits: antibodies to GM1 are associated with 
pure motor GBS and antibodies to GQ1b are related to MFS or oculomotor dysfunction 
in GBS, which is in accordance with the spatial distribution of these gangliosides in the 
peripheral nervous system.15
On a yearly basis, about 200-250 individuals in the Netherlands develop GBS, which 
can occur at all ages, although the frequency increases with age. The annual incidence 
rate of GBS in Europe and North America is 1-2 per 100.000.13 The main clinical symp-
tom of GBS is rapidly developing limb weakness which should by definition reach its 
maximum within 4 weeks of onset, but most patients already reach their maximum 
weakness within 2 weeks.7 This is followed by a plateau phase of variable duration 
(generally weeks to months), followed by a recovery phase which can take years (Figure 
1).2 Patients often have an increased CSF protein level but this is not mandatory for 
the diagnosis. The CSF protein level might be normal especially in the early phase of 
the disease.16 CSF examination is more important to rule out an increased cell count 
which should lead to further investigation for other diseases that can mimic GBS such 
as Lyme’s disease, cytomegalovirus or HIV-infection, or leptomeningeal malignancies. 
Months 
Infection 
Serum antibodies to gangliosides 
Progression Plateau phase Recovery phase Disability 
Weeks Years 
S
e
v
e
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figure 1. Guillain-Barré syndrome time course2
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Electromyography (EMG) can be helpful to confirm the diagnosis and to distinguish the 
demyelinating subtype from the pure axonal form. Currently, the distinction between an 
axonal and a demyelinating subtype of GBS is of predominant importance for research 
purposes. In Europe and North America the demyelinating form (acute inflammatory 
demyelinating polyradiculoneuropathy or AIDP) is the most common form whereas 
the axonal form (acute motor axonal neuropathy or AMAN or acute motor and sensory 
axonal neuropathy or AMSAN) is more common in China and Japan.17, 18 It is important to 
recognise that the results of EMG in GBS can be normal in the early phase of the disease, 
and therefore the usefulness of EMG is often limited in the acute phase. EMG however 
can be helpful, especially when there are abnormalities indicating a polyneuropathy, or 
when there is doubt about the diagnosis. Criteria supporting the diagnosis of GBS as 
well as criteria that function as a “red flag” for the diagnosis are listed in Table 1. Table 2 
shows differential diagnostic possibilities of GBS.
Table 1. Diagnostic criteria for Guillain-Barré syndrome3, 21
features required for the diagnosis
Progressive motor weakness of arms and legs
Reduced or absent tendon reflexes
features strongly supportive of the diagnosis
Progression of symptoms over days till maximum of 4 weeks
Relative symmetry
Mild sensory symptoms or signs
Cranial nerve involvement
Autonomic dysfunction
Pain
Increased CSF protein level
Typical electro diagnostic features
No other identifiable cause
features that should raise doubt about the diagnosis
Fever at onset
Bladder or bowel dysfunction at onset
Sharp sensory level
Increased CSF cell count (>50×106/L) or polymorph nuclear cells in CSF
Marked persistent asymmetry
Sensory signs with limited weakness at onset
Severe pulmonary dysfunction at onset
Slow progression with limited weakness and no respiratory involvement
Another identifiable cause of acute polyneuropathy
14
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Table 2. Differential diagnosis of GBS 2, 22, 23
metabolic
Diabetic polyradiculopathy/plexopathy
Vitamin deficiency (B1, B12)
Hypophosphatemia
Hypermagnesaemia
Hypokalaemia
Inflammatory or autoimmune
A-CIDP
Myasthenia Gravis
LEMS1
Poly- or dermatomyositis
Vasculitis
Transverse myelitis
ADEM2
Infectious
Lyme’s disease
HIV
Poliomyelitis
West-Nile virus myelitis
Diphtheria
Botulism
Rabies
Cytomegalovirus
neoplastic
Leptomeningeal carcinomatosis/malignancies
Drug induced
Disulfiram
Nitrofurantoin
Chemotherapeutic drugs
Hereditary
Porphyria
Intoxication
Arsenic neuropathy
Thallium
Shell fish or puffer fish poisoning
Tick paralysis
Alcoholic neuropathy
Spinal cord or brainstem injury
Spinal stenosis or disc prolapse
Epidural abscess or haematoma
15
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Even after full recovery of muscle strength, many patients are bothered, even years 
later, by severe fatigue interfering with their daily activities.19, 20 A multidisciplinary prac-
tical guideline has been published in 2010 in the Netherlands that covers many aspects 
of GBS; regarding its diagnosis and treatment, including physiotherapy and revalidation. 
This guideline (multidisciplinaire richtlijn Guillain-Barré syndrome) can be downloaded 
at www.vsn.nl. It also contains information about long-term symptoms such as pain and 
fatigue. We evaluated the levels of pain and fatigue experienced by patients long after 
the initial phase of their disease.
CHrOnIC InflAmmATOry DemyelInATInG POlyrADICulOneurOPATHy
The first case of chronic and recurrent neuritis was probably already described in 1890, 
but the concept of steroid-responsive chronic or relapsing neuritis followed much later 
in 1958.24, 25 Various names have been used since then until in 1982 the term chronic 
inflammatory demyelinating polyradiculoneuropathy (CIDP) was given to the disorder 
and this description has been used ever since.26 The features of CIDP are in many ways 
similar to those in GBS, but weakness is usually less severe in CIDP. Patients with CIDP 
have limb muscle weakness, most often with clear proximal involvement, and decreased 
or absent reflexes.27 Most patients have sensory involvement as well, but CIDP can mani-
fest as a pure motor neuropathy.28 Although pain is present in many GBS patients, not 
much is known about the occurrence of pain in CIDP.29-31
In CIDP about one third of patients report a preceding infection or vaccination as a 
trigger which is considerably lower than in GBS where two-third reports such a trig-
ger.32 Not much is known regarding the safety of vaccinations in CIDP patients. CIDP is 
a chronic polyradiculoneuropathy that develops by definition over more than 8 weeks, 
distinguishing this disorder from its acute counterpart: GBS. The disease course of 
CIDP can be either monophasic, chronic or relapsing. The diagnosis of CIDP is based on 
clinical characteristics combined with electro diagnostic findings.33 EMG examination is 
Table 2. Differential diagnosis of GBS 2, 22, 23 (continued)
Anterior spinal artery occlusion
Atlantoaxial dislocation
Brain stem stroke
Other
ICU-acquired weakness
Acute rhabdomyolysis
1 Lambert-Eaton myasthenic syndrome
2 Acute disseminated encephalomyelitis
16
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essential and must display features of demyelination to establish the diagnosis of CIDP.33 
Similar to GBS, the CSF protein level is most often increased in CIDP and an increased 
CSF protein level supports the diagnosis.33 A normal CSF protein level can occur in CIDP 
but an increased cell count should raise the suspicion for other diagnostic possibilities. 
Criteria supporting the diagnosis of CIDP as well as criteria that function as a “red flag” 
for the diagnosis are listed in Table 3. CIDP can be difficult to diagnose and has a very 
broad differential diagnosis (Table 4). In difficult diagnostic cases, a MRI scan of the 
brachial plexus or a nerve ultrasound can be helpful.34-37 A nerve biopsy can be used 
to exclude another diagnosis such as amyloidosis or vasculitis, but is rarely needed.33, 38 
Diabetes or the presence of another autoimmune disease or a monoclonal gammopathy 
Table 3. Diagnostic criteria for chronic inflammatory demyelinating polyradiculoneuropathy3
features required for the diagnosis
Progressive motor weakness of arms and legs
Reduced or absent tendon reflexes
Electro diagnostic criteria for primary demyelination
features strongly supportive of the diagnosis
Progression of symptoms over more than 8 weeks
Sensory symptoms or signs
Increased CSF protein level
Proximal muscle weakness
features that should raise doubt about the diagnosis
Respiratory muscle weakness
Bladder or bowel dysfunction at onset
Sharp sensory level
Increased CSF cell count (>50×106/L) or polymorph nuclear cells in CSF
Marked persistent asymmetry
Autonomic dysfunction
Severe ataxia or tremor at onset
Family history of (hereditary) neuropathies or clear muscle atrophy at onset
Systemic complaints (weight loss, lymphadenopathy, skin changes)
Another identifiable cause of chronic polyneuropathy
features that rule out the diagnosis
IgM paraprotein with anti-MAG antibodies1
Paraprotein related haematological disorders such as POEMS syndrome2 (often increased VEGF3), 
Waldenström’s macroglobulinemia, multiple myeloma, lymphoma
Alternative diagnosis; such as MMN4, amyloidosis, hereditary neuropathy
1 Myelin-Associated Glycoprotein
2 Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal gammopathy, Skin changes
3 Vascular Endothelial Growth Factor
4 Multifocal Motor Neuropathy
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Table 4. Differential diagnosis of CIDP
metabolic
Diabetic polyradiculopathy/plexopathy
Uremic polyneuropathy
Hepatic polyneuropathy
Vitamin deficiency (B1, B6, B12)
Tangier disease
Inflammatory
Recurrent GBS
GBS-TRF
MMN1
Paraprotein with anti-MAG antibodies
POEMS2 syndrome
CANOMAD3
Sarcoidosis
SLE4
Sjögren’s syndrome
Amyloidosis
Vasculitis
Infectious
Lyme’s disease
Syphilis
HIV
Hepatitis C
Varicella zoster virus
Cytomegalovirus
neoplastic
Multiple myeloma or osteosclerotic myeloma
Leptomeningeal carcinomatosis
Lymphoma
Leukaemia
Cryoglobulinemia
Drug induced
Amiodarone
Intrathecal methotrexate
Tacrolimus
Hereditary
CMT5 type 1A, B, C, CMTX
HNPP6
Metachromatic leucodystrophy or adrenomyeloneuropathy
Porphyria
18
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of undetermined significance (MGUS) does not exclude the diagnosis of CIDP as long as 
the clinical and EMG features are compatible with CIDP. It is unknown whether CIDP pa-
tients more often have other autoimmune disorders. In case of an IgM paraprotein, the 
presence of anti-MAG (myelin-associated glycoprotein) antibodies should be examined. 
If a patient has a more slowly progressive disease with predominantly distal weakness 
and sensory symptoms, the presence of anti-MAG antibodies rule out the diagnosis of 
CIDP. These patients should be classified as an IgM anti-MAG related polyneuropathy 
and treated accordingly.
This differential diagnosis list as presented represents the most common differential 
diagnostic possibilities. It should be noted that some disorders are probably associated 
with CIDP (mainly in case reports) such as HIV, hepatitis, SLE, connective tissue disease, 
sarcoidosis, thyroid gland disorders, inflammatory bowel disease, glomerulonephritis 
and bone marrow transplantation and therefore do not rule out the diagnosis of CIDP.
THe SPeCTrum Of GBS AnD CIDP
GBS has traditionally been separated from its chronic counterpart CIDP by the dura-
tion of progressive weakness.4 Preceding infections, involvement of cranial nerves or 
weakness of respiratory muscles are more often encountered in GBS than in CIDP, but 
can occur in both. Several subforms of GBS and CIDP exist; such as recurrent GBS, GBS 
with treatment-related fluctuations (GBS-TRF) and acute-onset CIDP (A-CIDP). Although 
GBS is generally a monophasic disorder, TRFs and recurrences can occur. How often GBS 
patients show a recurrence and what predisposes them for a recurrent GBS is currently 
unknown. CIDP usually runs a progressive or relapsing course but may be monophasic 
resembling GBS, and requiring only a single course of treatment. How often this happens 
Table 4. Differential diagnosis of CIDP (continued)
Refsum’s disease
Intoxication
Lead or arsenic neuropathy
Idiopathic
CIAP7
1 Multifocal Motor Neuropathy
2 Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal gammopathy, Skin changes.
3 Chronic sensory Ataxic Neuropathy, Opthalmoplegia, IgM paraprotein, cold Agglutinins,
Disialosyl antibodies
4 Systemic Lupus Erythematosus
5 Charcot-Marie-Tooth
6 Hereditary Neuropathy with susceptibility to Pressure Palsies
7 Chronic Idiopathic Axonal Polyneuropathy
19
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is unknown. Additionally, CIDP patients with an acute or subacute onset, resembling 
GBS, do exist. Although it can sometimes be difficult to distinguish GBS from CIDP it is 
important to do so because treatment and prognosis can be different.
CASE 1
“A 42-year-old woman complained of severe pain and soon thereafter she developed progressive weakness and 
sensory disturbances, which reached their nadir in less than 4 weeks. She showed a near complete recovery. Seven 
years later, after a flu, she had similar symptoms that peaked in less than 2 weeks. Sixteen years later she had 
another episode of progressive weakness after a flu-like infection that developed in one week. Five years after the 
previous episode, she developed a 4th episode after a bout of diarrhoea of progressive weakness that developed 
over a few hours.
Despite treatment with IVIg, she needed artificial ventilation and had severe autonomic dysfunction complicated 
by an asystole. She was successfully resuscitated and eventually discharged to a rehabilitation centre. A year later 
she was using a walker but was independent in her daily life activities. ”
Although GBS is most often a monophasic disorder, recurrences like in case 1 can occur. 
Five patients who fully recovered from an initial episode of GBS have been described who 
had another acute episode years later. 39 The clinical features of rapid progressive weak-
ness, return of normal reflexes as well as the long asymptomatic intervals distinguished 
them from CIDP. 39 All had similar antecedent infections as well as similar symptoms 
over time. 39 Another 12 patients with recurrent GBS have been reported with a total of 
32 episodes (1-6 recurrences). 40 Vaccinations may be associated with the recurrence of 
GBS as well.41 It is unknown why only some patients develop a recurrence of GBS and 
whether symptoms and triggers may differ between episodes.
CASE 2
“A twenty-year-old man complained of muscle aches after a flu infection. Two days later he had tingling in his 
limbs. Whilst at the general practitioner he fell off the examination couch and could not get up by himself. At 
hospital admission a few hours later he had a tetraparesis and areflexia. CSF showed a normal protein level. He 
was treated with IVIg and over the following week his muscle strength of arms and legs improved quickly. Just a 
few days later he developed bilateral facial palsy and progressive weakness, and he was successfully re-treated 
with another IVIg course.”
Most often GBS follows a monophasic course but some patients like the one described 
in case 2, experience a worsening after an initial improvement to treatment; the so 
called treatment-related fluctuations (TRFs).42 Ten out of 95 GBS patients who had 
been treated with a course of plasma exchange (PE) showed worsening after an initial 
improvement. 43 Eight of these patients were treated with a repeated course of PE which 
was then followed by a clinical improvement, and during follow-up none of these pa-
tients developed CIDP. 43 Similar worsening after treatment was seen in GBS patients 
treated with IVIg.42 Re-treating these TRF patients with another IVIg course also led to 
an improvement. 42 The prospective GRAPH study showed that a diagnosis of A-CIDP is 
more likely than GBS-TRF if a patient deteriorates after ≥ 8 weeks of onset or ≥ 3 times. 44
20
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CASE 3
“A 52-year-old woman developed sensory disturbances after a flu infection. Two days later she was unable 
to walk. Maximum disability was reached in 6 days. Over the next few months she had several exacerbations 
needing IVIg treatment, and she was treated subsequently with IVIg once every month for the next 7 years.”
Case 3 describes a patient who was diagnosed initially with GBS due to the onset phase 
of less than 4 weeks but who turned out to have acute-onset CIDP (A-CIDP). A prospec-
tive study found that 5% of patients initially diagnosed with GBS actually had A-CIDP, 
all with an onset phase of < 4 weeks.44 Seven patients with a monophasic episode of 
progressive weakness over the course of 4-8 weeks have been classified as subacute 
idiopathic demyelinating polyneuropathy (SIDP).45 These patients had predominantly 
motor dysfunction and were relatively mildly affected, none needed artificial ventila-
tion.45 All patients clearly responded to prednisone or had a spontaneous recovery.45 An 
acute-onset has been reported in 15% of CIDP patients.32 It can be difficult to distinguish 
GBS-TRF from A-CIDP, but a diagnosis of A-CIDP is more likely when a patients deterio-
rates after 8 weeks from onset or 3 times or more.44 Whether GBS and CIDP can co-occur 
in the same patient has not been determined yet. The whole spectrum of GBS and CIDP 
including its overlap or sub forms including some of our research questions of this thesis 
are shown in Figure 2.
TreATmenT Of GBS AnD CIDP
In GBS, both PE and IVIg are proven to be beneficial, but in recent years most patients 
are treated with IVIg.46, 47 48 49 IVIg contains a huge number of different human immu-
noglobulins (IgG antibodies) derived from pooled blood of several thousands of blood 
donors and is given by IV infusion. The exact working mechanism is unknown but prob-
ably multifactorial. IVIg has only proven its benefit so far when given within two weeks 
from onset of weakness in GBS patients who are unable to walk independently.47, 50 IVIg 
is usually the first treatment choice; it is readily available and had a better side-effect 
profile and because of its convenience patients are more likely to complete the course.47 
Despite the clinical variation between GBS patients, all are treated with one standard 
IVIg course (2 g/kg over 5 days). Not all GBS patients however respond in a similar way 
and it is unknown whether this standard course is appropriate for all, irrespective of 
their clinical course, severity or prognosis.
It has not yet been investigated whether mildly affected patients or patients with MFS 
may benefit from IVIg treatment.51 Despite the absence of proof from RCTs, and more 
based upon expert opinion, it has been recommended to treat severely affected MFS 
patients and MFS patients who develop a GBS-MFS overlap syndrome with IVIg.52 The 
same has been advocated for mildly affected GBS patients who show fast progression 
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within the first two weeks or who develop severe autonomic dysfunction, bulbar or 
facial weakness.52 When GBS patients develop a TRF, another full IVIg course (2 g/kg) is 
recommended (expert opinion). Despite IVIg treatment, GBS has a high morbidity, with 
25% of patients needing artificial ventilation and 20% of patients remaining severely 
disabled after half a year, and a mortality rate of about 3-5%. 53 Surprisingly, steroids 
alone are ineffective in GBS. When added to IVIg, intravenous methylprednisolone might 
have a small positive effect on the short-term outcome compared to IVIg alone.54
In CIDP, IVIg, PE and corticosteroids are proven to be effective; although the evidence 
for a positive treatment effect of corticosteroids is less strong.55-59 It is currently unknown 
why some patients do not respond to IVIg and if various IVIg brands differ in clinical 
efficacy. CIDP patients are treated initially with a loading course of IVIg (2 g/kg) but most 
patients need intermittent IVIg treatment for several years, for a median duration of 
about 5 years, ranging up to even more than 30 years (P.A. van Doorn, personal com-
munication). In contrast to GBS, monotherapy with corticosteroids can be effective in 
CIDP. IVIg is the first choice of treatment in many hospitals because of its convenience 
and better side-effects profile. IVIg however is an expensive treatment and the time to 
reach a clinical remission (without treatment) might be longer with IVIg compared to IV 
corticosteroid treatment.60 As most CIDP patients improve after IVIg, steroids or PE, the 
diagnosis should be reconsidered in a patient that does not respond to one of these 
treatments.61 CIDP patients who become unresponsive to therapy should be checked 
again for the appearance of a monoclonal protein or signs of malignancy.62 Effective 
dosages and the frequency of IVIg administration required seem to vary largely between 
patients and it is not known what determines this variation. Variation in the required 
dose and interval of IVIg in CIDP might be due to differences in IVIg catabolism. It is 
unknown if high peak serum IgG levels are needed, or if more constant serum IgG levels 
are preferable.
OBjeCTIVeS
The research described in this thesis focusses on GBS and CIDP including its overlapping 
variants.
The aims of this thesis are:
1. To gain a better understanding of the spectrum of GBS and CIDP
2. To obtain more information about the presence of (other) autoimmune diseases and 
the risk of vaccinations in GBS and CIDP
3. To study the efficacy of IVIg in GBS and CIDP in more detail
4. To improve treatment options in GBS and CIDP
23
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In order to study questions related to these objectives we use GBS and CIDP cohorts 
(Dutch GBS study group, the Erasmus MC cohort of inflammatory neuropathies, and 
a Canadian CIDP cohort), as well as a survey of GBS and CIDP members of the Dutch 
society of neuromuscular disorders.
The studies in this thesis are intended to answer the following questions (related to 
aim 1 and 2):
1) Can GBS and CIDP co-occur in a single patient?
2) How often does GBS reoccur, and why do some patients have recurrences? Do pa-
tients with recurrences show the same symptoms and triggers each time?
3) What is the chance of developing a recurrence of GBS or an increase of symptoms of 
CIDP after a vaccination?
4) Do (other) autoimmune diseases occur more frequently in GBS and CIDP?
Although treatment with IVIg is relatively successful in most GBS and CIDP patients, 
many questions remain (related to aim 3 and 4):
1) How often is IVIg effective as a first treatment in CIDP? What is the chance that an IVIg 
non-responder improves after a second or third treatment modality? Why do not all 
GBS and CIDP patients improve after a standard course of IVIg?
2) Is one brand of IVIg more effective than another product?
3) Is the standard IVIg dose (2 g/kg) suitable for all GBS patients, or do some patients 
need a higher dosage or another course?
4) What determines the variation in dosage and frequency of IVIg maintenance treat-
ment required and how should maintenance IVIg treatment be given? How can the 
efficacy of IVIg maintenance treatment in CIDP be improved?
5) What is the variation in serum IgG levels before and after IVIg in GBS and CIDP? Are 
serum IgG levels useful to monitor or predict the treatment response?
These questions are investigated in the following studies as described in this thesis.
OuTlIne
Chapter 2 covers the spectrum of GBS and CIDP. In Chapter 2.1 the clinical charac-
teristics of 32 recurrent GBS patients are described and compared with those of 476 
non-recurrent patients. Four patients who had separate episodes of both GBS and 
CIDP that fulfilled the clinical and diagnostic criteria of these disorders are presented 
in Chapter 2.2. In Chapter 2.3 the results of a survey of 461 members of the Dutch 
society of neuromuscular disorders with the diagnosis of GBS or CIDP are described. 
Recurrences, vaccinations and long-term symptoms such as pain, fatigue and quality of 
life are described.
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Chapter 3 covers the treatment of CIDP. An overview of different treatment op-
tions in CIDP is given in Chapter 3.1. In Chapter 3.2 the results of a RCT comparing 
two different brands of immunoglobulins in CIDP is given (CIC study). In Chapter 3.3 
the results of a retrospective study in 281 patients from two large university hospitals 
(Erasmus MC, University Medical Centre Rotterdam, the Netherlands and London Health 
Sciences Centre London Ontario, Canada) being treated with IVIg as a first treatment 
modality are described. The response to IVIg as well as the response to second or even 
third treatment modalities was studied. In addition, clinical factors that were associated 
with a good response to IVIg were assessed. Chapter 3.4 contains a review regarding 
maintenance treatment of IVIg in CIDP. The rationale and outline of a dose response trial 
of IVIg in CIDP (DRIP study) that we are currently performing is described in Chapter 
3.5. This multi-centre randomised placebo-controlled trial investigates whether high 
frequency low dosage IVIg treatment is more effective than low frequency high dosage 
as maintenance treatment for CIDP.
Chapter 4 describes serum IgG levels in IVIg-treated GBS and CIDP. Chapter 4.1 shows 
the results of a study of serum IgG levels in 174 GBS patients treated with a standard 
course of IVIg (2 g/kg). We investigated whether serum IgG levels are related to the 
outcome. The variability of serum IgG levels in clinically stable but IVIg-dependent CIDP 
patients receiving maintenance treatment of IVIg is described in Chapter 4.2.
In Chapter 5, the results of these chapters are discussed in a broader perspective and 
in relation to the current literature, and suggestions for further research are given.
In Chapter 6 the observations from the studies, as described in Chapter 2-4, are sum-
marised.
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ABSTrACT
Background: Guillain-Barré syndrome (GBS) is generally considered to be monophasic, 
but recurrences do occur in a presently undefined subgroup of patients.
Objectives: To determine which subgroup of patients develops a recurrence and to 
establish whether preceding infections and neurological symptoms are similar in sub-
sequent episodes.
methods: A recurrence was defined as two or more episodes that fulfilled the NINCDS 
criteria for GBS, with a minimum time between episodes of two months (when fully 
recovered in between) or four months (when only partially recovered). Patients with a 
treatment-related fluctuation or chronic inflammatory demyelinating polyneuropathy 
with acute onset were excluded. The clinical characteristics of recurrent GBS patients 
were compared with those of 476 non-recurrent patients.
results: 32 recurrent GBS patients, who had a total of 81 episodes, were identified. The 
clinical symptoms in a first episode were similar to the following episodes in individual 
patients, being GBS or its variant Miller Fisher syndrome (MFS) but never both. While 
neurological symptoms in subsequent episodes were often similar, the severity of the 
symptoms and the nature of the preceding infections varied. Recurrent patients (mean 
age 34.2 years) were younger than non-recurrent patients (mean age 46.9; p = 0.001) 
and more often had MFS (p = 0.049) or milder symptoms (p = 0.011).
Conclusions: Genetic or immunological host factors may play an important role in 
recurrent GBS, since these patients can develop similar symptoms after different pre-
ceding infections. Recurrences occur more frequently in patients under 30, with milder 
symptoms and in MFS.
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InTrODuCTIOn
Guillain-Barré syndrome (GBS) is an acute polyradiculoneuropathy leading to flaccid pa-
resis. Its annual incidence rate is 0.75 to 2 per 100.000.1, 2 GBS is a heterogeneous disease 
in which approximately two-thirds of patients report a preceding incident, usually an 
infection, such as diarrhoea or an upper-respiratory-tract infection.
Although GBS is considered to be monophasic, recurrences are reported in 2-5% of 
patients.3, 4 It is unknown why some patients have a recurrence and whether this occurs 
more frequently in a distinct subgroup of patients. It is suggested that recurrent GBS 
patients may have similar clinical symptoms in subsequent episodes, while having the 
same or different triggering events.4 It is important to distinguish between recurrent 
GBS patients and GBS patients with treatment-related fluctuations (GBS-TRF) or chronic 
inflammatory demyelinating polyneuropathy with acute onset (A-CIDP) especially be-
cause the treatment regimen for CIDP is different.5
The purpose of this study is to establish whether recurrent GBS patients have 
similar neurological symptoms in subsequent episodes and to determine whether 
these patients can be distinguished from non-recurrent patients based on their clinical 
characteristics. We additionally investigate whether recurrent GBS patients have similar 
infections prior to each episode, if the severity varies in subsequent episodes and if the 
interval between episodes tends to get longer or shorter. By analysing these features, 
we also aim to determine the relevance of host susceptibility factors in GBS.
meTHODS
Subjects and methods
To determine whether the type of neurological symptoms or the type of preceding in-
fections are similar in subsequent episodes, we studied 32 recurrent GBS patients. These 
patients were identified from the Erasmus MC GBS databank, which contains information 
on patients enrolled in clinical studies between 1985-2008. Additional patients came to 
our attention on patient meetings organized by the Dutch Society for Neuromuscular 
disorders (VSN). Medical records or letters were screened and missing or indistinct items 
were clarified by contacting the patients or treating doctors.
All cases were re-evaluated (by KK and PD) using the criteria of the National Institute 
of Neurological and Communicative Diseases and Strokes (NINCDS) for GBS.6 Patients 
were also included when they fulfilled the criteria for Miller Fisher syndrome (MFS), a 
GBS variant characterized by areflexia, ataxia and opthalmoplegia.1 The severity of each 
episode was graded according to the GBS disability scale.7
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The GBS disability scale is a seven-point disability scale, ranging from no symptoms 
(zero points) to death (six points). Patients who were able to walk with or without sup-
port (GBS disability scale ≤ 3) were considered as “mildly affected”, whereas patients who 
were bedbound (GBS disability scale ≥ 4) were categorised as “severely affected”.
We defined a recurrent patient as one having two or more episodes that fulfilled the 
NINCDS criteria for GBS, either with a minimum interval ≥ 4 months between the epi-
sodes if the patient did not recover completely (GBS disability scale ≥ 2); or ≥ 2 months 
when there was a complete or near-complete recovery (GBS disability scale ≤1) after the 
previous episode.
We excluded GBS-TRF and A-CIDP patients.5 GBS-TRF was defined as (1) improvement 
in the GBS disability scale of at least one grade or improvement in the MRC sum score 
more than five points after completion of therapy (2 g IVIg/kg body weight in 2-5 days), 
followed by a worsening of the GBS disability scale of at least one grade or a decrease in 
the MRC sum score of more than five points within the first 2 months after the disease 
onset or (2) stabilisation for more than 1 week after completion of therapy, followed by a 
worsening of the GBS disability scale of more than one grade or more than five points on 
the MRC sum score within the first 2 months after disease onset.5, 8 A-CIDP was defined 
as a CIDP patient in whom the nadir of the first episode was within 8 weeks of onset and 
the consecutive course was chronic, as in CIDP.9
Information was obtained concerning age, sex, cranial nerve involvement, preceding 
type of infection and/or trigger, GBS disability scale at nadir, and time between recur-
rences. Antecedent infections were classified clinically either as upper-respiratory tract 
or as diarrhoea/gastrointestinal. Reported influenza or flu-like infections were classified 
as upper-respiratory-tract infections. Information was also obtained about the presence 
of other autoimmune or immune-mediated disease.
To investigate whether recurrent patients can be distinguished from non-recurrent 
patients, we compared the clinical characteristics with those of non-recurrent GBS 
patients admitted with a diagnosis of GBS between 1987 and 1996 in The Netherlands.2
We compared the groups with respect to age, sex, MFS, cranial nerve dysfunction, the 
need for artificial respiration, severity of the symptoms and preceding triggers.
Statistical analysis
For statistical analyses, an unpaired t test and χ² test were performed, to compare char-
acteristics of recurrent and non-recurrent GBS patients. If appropriate, the Fisher exact 
test was used. SPSS for Windows (version 15.0, SPSS, Chicago) was used for all statistical 
analyses, and p values < 0.05 were regarded as significant.
37
Recurrent GBS
Ch
ap
te
r 2
.1
reSulTS
Forty-eight patients were considered as potentially eligible. Sixteen patients were ex-
cluded: three with GBS-TRF and six with A-CIDP; three due to missing information about 
clinical symptoms during one of the possible episodes, and four because they did not 
fulfill the diagnostic criteria for GBS.
We identified 32 recurrent patients, 21 males and 11 females, who had a total of 81 
episodes of GBS. Of these 32 patients, four had recurrent MFS, and three were known 
with another autoimmune disease (two inflammatory bowel disease and one hyperthy-
roidism). In the group of non-recurrent GBS patients, 11 were known to have one of the 
following autoimmune disorders: rheumatoid arthritis, polyarthritis nodosa, spondylitis 
ankylopoetica, sarcoidosis, thyroid gland disease or inflammatory bowel disease. The 
clinical characteristics of the recurrent GBS patients during their first episode are listed 
in Table 1.
Seven recurrent GBS patients had three episodes, two had four episodes, and two had 
five episodes. All patients with at least four episodes were female. The mean age during 
the first episode was 34.2 (range: 1-87) and of the first recurrence 42.1 (range: 5-88). 
The interval between recurrences ranged from 2 months to 37 years. The mean interval 
Table 1. Comparison of baseline characteristics of recurrent and non-recurrent Guillain-Barré syn-
drome (GBS) patients
GBS patients
p value
recurrent
(during first episode)
(n =32)
non-recurrent
(n = 476)
Age, years, mean (SD) 34.2 (23.9) 46.9 (21.5) 0.001
Age < 30 years 44% 22% 0.006
Male 66% 60% 0.505
Cranial nerve dysfunction 38% 42% (472) 0.654
Miller Fisher syndrome 13% 4% 0.049
Sensory-motor symptoms 72% 62% (474) 0.275
Artificial respiration needed 16% 18% (472) 0.691
Mildly affected* 59% 37% (450) 0.011
Known with other autoimmune disease 9% 2% 0.051
Preceding vaccination 6% 3% (475) 0.219
Preceding gastrointestinal infection 13% 17% (475) 0.541
Preceding respiratory infection 28% 37% (475) 0.299
The number in parentheses is number of patients on whom information was available (if different from the 
total).
* GBS disability scale ≤ 3
Chapter 2.1
38
between all recurrences was 7 years. Most patients had a long interval between subse-
quent episodes, only two patients had an interval of 2 months in between episodes with 
near complete recovery. The mean GBS-disability score at nadir was 3.1 for the first two 
episodes, increasing to 3.8 for the fourth episode. The characteristics of all episodes are 
shown in Table 2.
The GBS disability scale, type of preceding infection and neurological symptoms (pure 
motor or sensory-motor) were compared with the previous episode. The characteristics 
during a recurrence were compared with those during the previous episode (Figure 1).
In individual patients, a preceding infection in two subsequent episodes was reported 
17 times. Eleven times the infections were reported as either respiratory or gastrointes-
tinal, whereas six times a gastrointestinal infection was reported prior to one episode 
and a respiratory infection before the other. Two patients had an upper-respiratory-tract 
infection preceding three episodes and a gastrointestinal before another. Four patients 
had a serologically confirmed infection prior to one episode; one patient had a varicella 
zoster virus and a Mycoplasma pneumoniae; one a herpes simplex virus infection and 
two a Campylobacter infection.
One patient reported a tetanus vaccination as a trigger in two subsequent episodes. 
Another patient, with inflammatory bowel disease, had two episodes of GBS after 
starting treatment with the drug Salazopyrine. In the two patients, reporting the same 
trigger in subsequent episodes, neurological symptoms developed faster in the second 
episode. Two other patients reported a vaccination (influenza/flu virus or hepatitis virus) 
as a trigger prior to one of the episodes.
In 18 out of 49 successive episodes (36%) there was a more severe GBS disability scale 
at nadir; in 16 (33%) a less severe GBS disability scale and in 15 (31%) the GBS disability 
scale was equal in comparison with the previous episode.
Table 2. Characteristics per Guillain-Barré syndrome (GBS) episode
no of
patients
Age, years,
mean (SD)
Time between
recurrences,
years, mean (SD)
GBS disability
scale nadir,
mean (SD)
mean GBS
disability scale
after 6-12 months
1st episode 32 34.2 (23.9) - 3.1 (1.2) 1.0 (29)
1st recurrence 32 42.1 (23.2) 7.9 (10.8) 3.1 (1.1) 1.1 (24)
2nd recurrence 11 48.0 (25.8) 6.0 (6.3) 3.4 (1.2) 1.4 (8)
3rd recurrence 4 46.0 (24.3) 5.8 (3.1) 3.8 (1.0) 1.5 (4)
4th recurrence 2 30.0 4.0 3.0 2.0 (2)
The number in parentheses is the number of patients on whom information was available (if different from 
the total).
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Most patients had either pure motor or sensory-motor symptoms in subsequent 
episodes (Figure 1). None of the patients initially had GBS in one episode followed by 
MFS in a subsequent episode.
One patient had right-sided oculomotor nerve dysfunction in four subsequent epi-
sodes, and another patient had three episodes with right-sided oculomotor nerve and 
abducens nerve palsy, accompanied by dysphagia. One patient had acute motor axonal 
neuropathy (AMAN) with moderate recovery five times over a period of 14 years.
In the recurrent group, patients more often had MFS (13% vs 4%, p = 0.049) and were 
more frequently < 30 years (44% vs 22%, p = 0.006) and more often had a mild course 
(59% vs. 37%, p = 0.011) compared with the non-recurrent group. The mean age was 
lower in the recurrent group than in the non-recurrent group (34.2 vs 46.9, 95% CI: -20.4 
to -4.9, p = 0.001). Clinical characteristics of recurrent and non-recurrent patients are 
listed in Table 1.
                                       
f-score nadir Count
Increasing 18
Decreasing 16
Same 15
Time interval Count
Increasing 6
Decreasing 10
Same 1
Longer 
35% 
Shorter 
59% 
Same 
6% 
Time-interval between episodes 
n=17 
Different 
35% 
Same 
65% 
Preceding type of infection †  
Different 
8% 
Same 
92% 
Pure motor or sensory-motor symptoms 
n=49 
n=17 
n=49 
More 
36% 
Less 
33% 
Same 
31% 
Severity of weakness (GBS disability scale) 
n=49 
                                                                                                                             
figure 1. recurrence characteristics, compared with the previous episode of Guillain-Barré syn-
drome (GBS)
† Gastrointestinal or upper-respiratory-tract infection.
n = number of two subsequent episodes from which information was available.
For example:
n = 17 means patients reported an infection 17 times before two sequential episodes.
n = 49 means the GBS disability scale was reported in two sequential episodes 49 times.
Chapter 2.1
40
DISCuSSIOn
The patients with a recurrent GBS in our study showed similar signs and symptoms dur-
ing every episode despite having different types of symptoms of a preceding infection. 
This may indicate that genetic and immunological host factors partly determine the 
clinical phenotype irrespective of the preceding infection. The recurrent patients were 
younger and more often had MFS and a milder course of disease, which suggests that a 
distinct subgroup of patients has a higher susceptibility of recurring.
To our knowledge, this is the largest group of recurrent GBS patients described so far, 
and a comparison with non-recurrent patients has not been documented before. We 
excluded GBS-TRF and A-CIDP patients. One study reported 12 “recurrent” patients with 
a progressive phase of less than 8 weeks, therefore not excluding the possibility that 
some of these patients had A-CIDP or subacute GBS.3 Distinguishing between recurrent 
GBS, GBS-TRF and A-CIDP can be difficult but is clinically relevant because treatment 
may differ. In a previous study, we found that nine out of 11 patients with GBS-TRF had 
their TRF within 9 weeks from onset, and most patients having an exacerbation after 9 
weeks eventually developed CIDP.5
Whether clinical symptoms and preceding infections differ in recurrent patients has 
already been addressed in other case studies and is controversial.10- 12 Two studies have 
reported different antecedent events in individual recurrent GBS patients.10, 11 In con-
trast, another study described similar antecedent illnesses in individual recurrent GBS 
patients.12 Unfortunately, infection serology in this group of patients was not always 
testable since serum was not systematically obtained. Two of our patients appeared to 
have had recurrences after the same specific triggers, one after the drug Salazopyrine 
and one after a tetanus vaccination; both showed a shorter time between trigger expo-
sure and symptom onset the following episode. Tetanus toxoid vaccination as a trigger 
for GBS with a shorter symptom onset in subsequent episodes has been reported previ-
ously.13 The drug Salazopyrine has not previously been described as a trigger for GBS, 
but ulcerative colitis has.14 We cannot exclude that these events occurred coincidental or 
that there had not been a subclinical preceding infection in this patient.
In subsequent episodes, most of the recurrent GBS patients had either pure motor 
or sensory-motor symptoms. Some patients had very specific symptoms during subse-
quent episodes, such as unilateral cranial nerve palsy at the same site. We cannot explain 
this specific finding, but it could be related to a local susceptibility of neural tissue 
related epitopes as replicated laterality of cranial nerve dysfunction has been described 
before in MFS.15, 16
Our observations identify a trend towards shorter intervals between subsequent re-
currences, and a more severe deficit with each recurrence. The GBS disability scale is not 
a linear scale, but a tendency to accumulate neurological deficits after each episode has 
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been reported previously.4 It has been established that patients over 50 years of age are 
more likely to have a worse recovery, which may explain that disability becomes worse 
after each subsequent recurrence.17 Recurrent patients are more likely to have MFS than 
non-recurrent patients. The presence of anti-GQ1b antibodies in almost all MFS patients 
highlights the importance of immunological factors in this disorder. Since females are 
more susceptible to autoimmune diseases, it is of interest that the recurrent patients 
with at least four episodes were all female. Three of the recurrent GBS patients were 
known with another autoimmune disease, which suggests that genetic host factors are 
relevant.
The mean age was significantly lower in the recurrent group compared with non-
recurrent GBS patients. Age as a risk factor for a recurrent GBS has not been described 
before, but it has for CIDP. The mean age of relapsing CIDP patients (27 years) is reported 
to be significantly lower compared with CIDP patients with a non-relapsing course (51 
years).18
Due to the retrospective nature of our study, we cannot estimate unbiased the exact 
incidence of recurrent GBS, but as there were 32 recurrent patients out of a total of 524, 
the crude estimated prevalence will be around 6%. We cannot exclude the fact that 
some non-recurrent GBS patients have developed a recurrence outside the geographic 
boundary of the study area or after the 10-year study period. It is possible that some 
“non-recurrent” patients had their first GBS episode just before the end of the study 
period, which would have limited the chance of recording a recurrence.
Individual patients developed either GBS during all episodes or MFS, never both. 
Because recurrent GBS patients were significantly younger, more mildly affected and 
more often had MFS, neurologists should be aware that these patients are more prone 
to recurrences. Since similar neurological symptoms can occur after different infections, 
this study further indicates that immunological and genetic host factors play a role in 
determining the clinical phenotype in recurrent GBS.
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InTrODuCTIOn
Although Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating 
polyneuropathy (CIDP) have been considered as separate entities, some authors have 
argued that they may be part of a continuum of inflammatory demyelinating neuropa-
thies.1 2, 3 GBS is defined as having a progressive onset phase of less than 4 weeks; CIDP of 
at least 2 months. 4-6 However, some CIDP patients have an acute onset, resembling GBS, 
and some patients with GBS may relapse or experience treatment-related fluctuations 
(TRFs).1, 7 We describe four patients all having had separate episodes of both GBS and 
CIDP that fulfilled the clinical and diagnostic criteria.4-6 These four patients came to our 
attention during a period of twenty years in which over 700 GBS and 150 CIDP patients 
were seen or enrolled in clinical studies. Most GBS patients were followed up for a period 
of 1 year, the majority of CIDP patients for many years.
reSulTS
Patient 1
A 46-year-old man developed weakness and numbness in his limbs, worsening over 
1 year. He fulfilled the clinical and electrodiagnostic criteria for CIDP and responded 
well to intravenous immunoglobulin (IVIg) treatment, every two weeks. The IVIg dos-
age was reduced several times with immediate deterioration as a result. Treatment was 
continued for 6 years and then stopped; thereafter he remained in remission. Twelve 
years later, he developed tetraparalysis and facial palsy within 48 hours, 2 weeks after a 
bout of diarrhoea. He fulfilled criteria for GBS. He was treated with IVIg, and he required 
artificial ventilation for 2 months. He reached a near complete recovery and no new 
episodes occurred (Table 1).
Patient 2
A 33-year-old man developed progressive weakness and paraesthesia in all limbs over 
the course of 1 week. Three days later he was unable to walk. He fulfilled diagnostic 
criteria for GBS. After IVIg, he initially improved, but 9 days later, he developed facial 
palsy and opthalmoplegia and he was re-treated with IVIg. He subsequently became 
tetraplegic needing artificial ventilation. Initially it was thought that he had TRFs, al-
though after five exacerbations all rapidly responding to IVIg, a diagnosis of CIDP was 
more appropriate. His symptoms required maintenance IVIg treatment for two and a 
half years. Electrodiagnostic studies were compatible with CIDP (Table 1).
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Patient 3
A 34-year-old man developed a rapidly progressive tetraparesis after an episode of 
diarrhoea. He was diagnosed with GBS and recovered fully after IVIg treatment. Five 
years later, he was readmitted with similar symptoms that had developed over 1 week. A 
lumbar puncture showed a normal protein level of 0.43 g/l. Two to three months later his 
symptoms returned and were successfully treated with IVIg. One and a half years later he 
experienced another relapse over a 2-month period. His disease course suggested CIDP, 
and during another IVIg treatment his symptoms stopped and did not recur (Table 1). 
Electrodiagnostic studies were compatible with the diagnosis of CIDP.
Patient 4
A 39-year-old man developed tingling sensations and weakness in his limbs after a flu 
vaccination earlier that month. He then developed bilateral facial palsy and fulfilled di-
agnostic criteria for GBS. Within 3 days he needed artificial ventilation, which continued 
for 6 weeks. He recovered slowly. Twenty-nine years later, he developed progressive 
weakness and numbness over a period of 2 months, compatible with CIDP. No preceding 
illness or vaccination was reported. Electrodiagnostic studies were compatible with the 
diagnosis of CIDP. He has been successfully treated with maintenance IVIg treatment, 
every 4 weeks, for a period of 1 year so far (Table 1).
Table 1. Case characteristics
Case episode Sex Age Diagnosis
Preceding
infection/
incident
Cranial nerve
dysfunction
need for
artificial
respiration
1 1 M 46 CIDP - - -
1 2 M 64 GBS Gastrointestinal VII +
2 1 M 33 GBS Cytomegalovirus VII,ophtalmoplegia +
2 2 M 34 CIDP - - -
3 1 M 34 GBS Gastrointestinal - -
3 2 M 39 Recurrent GBS with TRF - - -
3 3 M 40 CIDP - - -
4 1 M 39 GBS Flu-vaccination VII +
4 2 M 68 CIDP - - -
GBS, Guillain-Barré syndrome; CIDP, chronic inflammatory demyelinating polyneuropathy; TRF, treatment-
related fluctuation.
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DISCuSSIOn
These case histories show that GBS and CIDP can occur in the same patient, and underline 
the difficult differential diagnosis of GBS or acute CIDP. Patient 1 initially had a course fully 
compatible with CIDP. Many years later he developed an acute polyneuropathy with se-
vere weakness and respiratory failure after a gastrointestinal infection, a classic example 
of GBS. Patient 2 had a GBS-like acute onset with respiratory insufficiency, but finally 
developed CIDP. He experienced five exacerbations and needed maintenance IVIg for 
more than 2 years thereafter, which suggests that the diagnosis of CIDP with acute and 
severe onset was more appropriate.7 Patient 3 experienced two episodes of weakness 
with acute onset after an infection, suggesting recurrent GBS. The minor deteriorations 
after each IVIg treatment were considered to be TRFs. The progressive symptoms which 
developed 1 year later over a longer period of 2 months were compatible with CIDP. 5 
Patient 4 had rapidly progressing symptoms of GBS after a flu vaccination. Twenty-nine 
years later weakness gradually returned: this episode was compatible with CIDP. The 
patient improved but required intermittent IVIg treatment.
Case histories of patients with multiple episodes of weakness and characteristics of 
both GBS and CIDP are rare.3, 8 One patient with GBS-like deterioration after administra-
tion of IVIg for CIDP has been reported.9 These four case histories in which individual 
patients were affected with both GBS and CIDP suggest that in a proportion of patients 
GBS and CIDP may constitute a clinical continuum, or that there are common host fac-
tors which influence susceptibility to these disorders. Apart from striking similarities, 
GBS and CIDP also show clear differences. Anti-ganglioside antibodies are frequently 
detected in GBS, but generally absent in CIDP.10 Preceding infections are less frequently 
reported in CIDP, but infections during the course of CIDP may clearly worsen symp-
toms.10 It should be noted that most CIDP patients improve after steroids, whereas GBS 
patients do not.11 On the other hand, most GBS and CIDP patients improve after IVIg 
or plasma-exchange. Patients with subacute idiopathic demyelinating polyradiculoneu-
ropathy with progressive weakness of 4-8 weeks have been described, and this entity 
bridges the gap between GBS and CIDP.2, 12
Although we are aware that most patients clearly fit the diagnostic criteria of GBS or 
CIDP alone and that patients having separate episodes of GBS and CIDP are extremely 
uncommon, it is important to be aware of the possibility that both GBS and CIDP can 
co-occur in a single patient and should be diagnosed and treated accordingly. Although 
it can not be excluded that individuals get both GBS and CIDP by chance, these case 
descriptions may indicate that in some patients CIDP and GBS are part of a clinical and 
pathophysiological continuum instead of fully separate entities.
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ABSTrACT
We determined the frequency of recurrent Guillain-Barré syndrome (GBS), whether vac-
cinations led to recurrences of GBS or an increase of disability in chronic inflammatory 
demyelinating polyradiculoneuropathy (CIDP) and we assessed the prevalence of pain, 
fatigue and the impact on quality of life after GBS and CIDP. Additionally, we assessed 
the presence of common auto-immune disorders.
Four hundred and sixty-one members of the Dutch society of neuromuscular disorders 
received a questionnaire. Two hundred and forty-five GBS and seventy-six CIDP patients 
were included (response rate 70%). Nine patients had a confirmed recurrent GBS, and 
two patients had experienced both GBS and CIDP. Common auto-immune diseases were 
reported in 9% of GBS and 5% of CIDP patients. None of the 106 GBS patients who re-
ceived a flu vaccination (range 1-37 times, total 775 vaccinations) reported a recurrence 
thereafter. Five out of twenty-four CIDP patients who received a flu-vaccination (range 
1-17 times) reported an increase in symptoms. Pain or severe fatigue was reported in 
about 70% of patients after the diagnosis of GBS (median 10 years) or after onset of CIDP 
(median 6 years), and quality of life was significantly reduced.
Flu-vaccinations seem relatively safe. GBS and CIDP patients often experience pain, 
fatigue and a reduced quality of life for many years after the diagnosis.
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InTrODuCTIOn
Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyradiculo-
neuropathy (CIDP) are immune-mediated polyneuropathies associated with a variable 
clinical course and outcome. GBS patients usually reach their maximum disability within 
4 weeks of onset compared to at least 2 months for CIDP patients.1,2
Although GBS is considered as a monophasic disorder, some patients experience a 
recurrence of GBS or even develop a separate episode of CIDP.3,4 Additionally, some CIDP 
patients may develop GBS.4 In this study, we aimed to obtain more information about the 
frequency of recurrent GBS and the occurrence of both GBS and CIDP in single patients. 
Additionally, we evaluated the levels of pain, fatigue and quality of life experienced by 
patients for an extended period after the initial phase of their disease. Pain has been 
documented as one of the symptoms that can precede and accompany GBS but in CIDP 
this has hardly been studied.5-7
Reports about recurrences of GBS or relapses of CIDP following vaccinations are rare, 
which suggests that this risk is low.8 As we aimed to study a large number of patients 
that might have had multiple vaccinations over time, this information would add to the 
discussion whether GBS and CIDP patients could safely have vaccinations or not.
mATerIAlS AnD meTHODS
In June 2008, 461 members of the Dutch society of neuromuscular disorders (Vereniging 
Spierziekten Nederland) with GBS or CIDP were sent a combined set of questionnaires 
composed by the researchers. Patients were asked to return the questionnaires only if 
they were diagnosed with GBS, the cranial nerve variant Miller Fisher syndrome (MFS) 
or CIDP. Furthermore, they were asked to report the disorder they were diagnosed with. 
To increase the response rate, patients were sent two reminder letters. The study was 
approved by the Medical Ethical Committee of the Erasmus MC, Rotterdam, The Neth-
erlands.
The questionnaires concentrated on 4 areas; preceding vaccinations (within 8 weeks 
before the onset of GBS or CIDP), family members with GBS or CIDP, the occurrence 
of common auto-immune diseases and persistent symptoms at a variable time-point 
after the diagnosis (the moment of completing the questionnaire). The combined set of 
questionnaires contained various standardised and well evaluated subquestionnaires to 
be filled in for the present situation at the time of completion: the numeric pain rating 
scale (NPRS) for pain, the fatigue severity scale (FSS) for fatigue, the hospital anxiety 
and depression scale (HADS) for anxiety and depression and the short form (36) health 
survey (SF-36, Dutch acute version 1) for quality of life.
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Severe pain was defined as a score of ≥ 7 on the NPRS.9 The FSS ranges from one (no 
signs of fatigue) to seven (most disabling fatigue score). Severe fatigue was defined as a 
mean FSS score of ≥ 5.0 (≥ 95th percentile in healthy controls), and corrected for depres-
sion as scored on the HADS.10
SF-36 percentage scores were transformed to norm-based scores using a T-score 
transformation (mean = 50, SD = 10), giving the opportunity to compare the results from 
one domain meaningfully with those from other domains, and in particular to compare 
these with the distribution of scores in the general Dutch population (n = 1742).11-13 A 
high SF-36 score is an indication of a better health status, and scores below 50 are inter-
preted as below average in the general Dutch population. Missing values that could not 
be traced were substituted with person-specific estimates if the respondent answered 
at least 50% of the items in a domain according to the half-scale rule from the SF-36 
developers.12 In the case of missing values in the other standardised questionnaires or 
when other major items were lacking, such as diagnosis or severity at nadir, patients 
were contacted to obtain missing information. Data were checked by two researchers 
(K.K. and M.B.E.). When patients reported having had recurrent GBS, both GBS and CIDP, 
or having relatives with GBS or CIDP, medical information was obtained and verified by 
the researchers (K.K. and P.D.). When evaluating fatigue, patients were considered mildly 
affected by their disease when they were able to walk unaided (GBS-disability scale 
score ≤ 2) at nadir.14
Differences in characteristics, and self-reported pain, fatigue, and quality of life were 
calculated using the χ² test, Fisher exact test, Mann-Whitney U test or t-test. Spearman’s 
correlation coefficient (rs) was used to analyse the correlation between fatigue and GBS 
disability score or the time since diagnosis. A p value < 0.05 was considered significant. 
Data were analysed using SPSS version 15.0.
reSulTS
A total of 323 questionnaires were returned: a response rate of 70%. Two patients were 
excluded; one with a chronic idiopathic axonal polyneuropathy and one with an un-
known diagnosis. Patients completed the questionnaire after a variable time from onset 
of GBS (median 10 years, range 0-62) or CIDP (median 6 years, range 0-29).
Of the 321 patients, 245 were diagnosed with GBS and 76 with CIDP. Of the 245 GBS 
patients, four had MFS and five had an MFS/GBS overlap. One patient had Bickerstaff en-
cephalitis. Nineteen GBS patients reported recurrent GBS, and in nine of these patients 
(4%) we could confirm this, but in the other 10 it remained unclear from the medical 
information available whether these patients had indeed had another GBS episode. Two 
patients had both GBS and CIDP. One of these patients has been described previously.4
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Eight GBS patients and one CIDP patient had a relative with an immune-mediated 
polyneuropathy, which was verified by checking medical records. Six GBS patients had a 
first till fourth degree relative with GBS. One GBS patient had a grandson with CIDP and 
another had a cousin with multifocal motor neuropathy. One CIDP patient had a brother 
with CIDP.
Twenty-three GBS (9%) and eight (11%) CIDP patients reported a preceding vaccina-
tion, within 8 weeks form onset of symptoms. The most often reported vaccination was 
a flu vaccination (Figure 1).
None of the 106 GBS patients who received a flu vaccination (range 1-37 times, in total 
775 vaccinations) in the years after they experienced GBS reported a recurrence of GBS. 
Of the 24 patients who received a flu vaccination (range 1-17 times) after being diag-
nosed with CIDP, five reported an increase in symptoms after one or more vaccinations.
Twenty-three patients with GBS (9%) and four patients with CIDP (5%) are currently 
diagnosed with a common auto-immune disease, most often a thyroid disorder (Figure 2).
10%
7%
23%
3%
57%
Other
Multiple
Hepatitis
Tetanus
Flu
Preceding vaccination
n = 31
figure 1. reported vaccinations prior to onset of Guillain-Barré syndrome or chronic inflammatory 
demyelinating polyradiculoneuropathy
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Pain was reported in 71% of GBS and in 72% of CIDP patients long after the diagnosis, 
and severe pain in 8% of GBS and 17% of CIDP patients. Several years after the diagnosis, 
severe fatigue was still prominent, and 45% of GBS and 25% of CIDP patients experienced 
fatigue as their most disabling symptom (Table 1). Severe fatigue was more pronounced 
in the patients who were still severely affected as assessed with the GBS-disability scale, 
than in the mildly affected patients (85% vs 68%, p=0.008), and the GBS-disability score 
correlated weakly with the FSS score (rs = 0.5, p < 0.01). Fatigue was not significantly 
related to the time since start of the GBS symptoms (rs = 0.04, p = 0.5).
CIDP patients scored significantly lower than the GBS patients on three items of physi-
cal functioning (Table 1). GBS and CIDP patients scored significantly lower in all physical 
health items of the SF-36 as well as in two items of mental health (vitality and social 
functioning) when compared with the normal Dutch population (Figure 3).13
7%
19%
7%
30%
19%
19% Other
Psoriasis
Sjogren/ SLE
Thyroid gland disorders
Rheumatic disorders
Inammatory bowel disease
Other auto-immune diseases 
n = 27
figure 2. reported auto-immune diseases in patients with Guillain-Barré syndrome or chronic in-
flammatory demyelinating polyradiculoneuropathy
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Table 1. long-term symptoms in Guillain-Barré syndrome (GBS) and chronic inflammatory demyelin-
ating polyradiculoneuropathy (CIDP)
Patients
p value
GBS
(n = 245)
CIDP
(n = 76)
Time since diagnosis, y 10 (0-62) 6 (0-29) 0.001
Age when participating in this study, y 59 (7-94) 59 (9-85) NS
Disability (GBS-disability score)
Median (range) 2 (0-4) 2 (0-4) NS
Pain (NPRS)
Median (range) 2.2 (0-10) 2.3 (0-8) NS
Severe pain# 8% 17% 0.028
Depression (HADS)
Depressed 6% 9% NS
Fatigue (FSS)
Median (range) 5.8 (1-7) 5.9 (1-7) NS
Severe fatigue* 69% 74% NS
Quality of Life (SF-36)
Physical functioning 36.2 (13.7) 32.6 (13.2) 0.046
Role-physical 41.7 (11.8) 38.6 (11.2) 0.042
Bodily pain 46.5 (10.7) 45.3 (12.0) NS
General health 44.6 (11.5) 39.1 (11.7) <0.001
Vitality 43.6 (10.6) 41.2 (10.2) NS
Social functioning 45.8 (9.0) 46.2 (9.2) NS
Role-emotional 50.0 (10.0) 50.0 (10.8) NS
Mental health 50.0 (9.3) 50.1 (9.8) NS
NS = not significant (p > 0.05)
Continuous or categorical variables presented as median (range) and compared using Mann-Whitney U 
test.
Numeric variables presented as percentage and compared using c2- test or Fisher exact test.
Continuous variables regarding the SF-36 are presented as norm-based mean scores (SD) using a T-score 
transformation (mean = 50, SD 10) according to the general Dutch population and compared using t-test.
NPRS = numeric pain rating scale
HADS = hospital anxiety and depression scale
FSS = fatique severity scale
SF-36 = Short Form (36) health survey
# NPRS ≥ 7.
* FSS ≥ 5.0 corrected for depression.
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DISCuSSIOn
The frequency of recurrent GBS (4%) in the current study is comparable with the 2-6% 
that has been described previously.3,15 We found two patients who had had both GBS 
and CIDP. Although the combination of having both GBS and CIDP could be by chance, 
these patients support the hypothesis that GBS and CIDP may constitute a clinical con-
tinuum or that there are common host factors which influence susceptibility to these 
disorders.4 We identified nine patients (eight GBS and one CIDP) having a relative with an 
immune-mediated polyneuropathy, which may suggest, but does not prove, a genetic 
susceptibility factor; some of these patients have been described previously.16 The GBS 
and CIDP patients included in our study had a slightly higher prevalence of common 
auto-immune diseases than the 5% previously reported in the general population.17
Our study indicates that the risk of developing another GBS episode after a flu vac-
cination is small. This confirms a recent study that found no evidence of an increased 
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figure 3. Sf-36 health survey in Guillain-Barré syndrome and chronic inflammatory demyelinating 
polyradiculoneuropathy patients (norm-based scoring)
* = p < 0.001.
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risk of GBS after seasonal influenza vaccination.18 Another study has also suggested a 
low risk following vaccination, where only 4% (11/311) of GBS patients and 8% (5/65) of 
CIDP patients experienced a recurrence of symptoms following a vaccination.19 
The occurrence of pain long after the diagnosis of GBS in our study was similar to the 
69% that has been described before in 50 GBS patients long after the diagnosis (median 
10 years).20 Severe fatigue was also a major complaint even long after the diagnosis of GBS 
or CIDP. Fatigue is reported to occur more often in patients with an immune-mediated 
neuropathy than in healthy controls (median 6.1 vs. median 2.9, p < 0.0001).10 In a group 
of 113 patients with an immune-mediated neuropathy, severe fatigue appeared to be 
present in 80% of patients several years (median 5.1 years) after the diagnosis.10 Some of 
these patients were probably also included in our study, but our study contained three 
times more GBS as well as CIDP patients and the median time from disease onset was 
longer. We did not find a correlation between the time since diagnosis and the presence 
of fatigue. In contrast to what has been reported previously, our study suggests that se-
vere fatigue was more pronounced in patients who were more severely affected by the 
disease at the time of completing the questionnaire. Both GBS and CIDP patients scored 
significantly lower on the SF-36 than the general Dutch population, except for two items 
regarding mental health, which has been described before.20,21 When we compared GBS 
patients with those having CIDP, CIDP patients scored significantly lower on three items 
regarding physical health. This has not been reported before but can be explained by 
the chronic and often still active course of disease in CIDP.
Our study was a survey of members of a patient organisation, which may have given 
rise to several methodological limitations. As only members from a patient organisation 
were included, selection bias could have occurred. Patients who are or remain a member 
of a patient organisation are probably more likely to be severely affected. Patients were 
asked to return the questionnaire if they were diagnosed with GBS or CIDP. As we could 
not verify the diagnosis in all patients, some patients with another diagnosis might have 
been included. The retrospective nature of part of the questionnaires could have intro-
duced recall bias. It is difficult to draw firm conclusions from a questionnaire in which 
patients report their recurrences after vaccinations themselves. It seems that patients 
are more likely to respond to a questionnaire when they did experience a recurrence.
Furthermore, the fact that not all patients responded to our questionnaire might 
have introduced some bias, although some members might have not replied due to the 
fact that they had been diagnosed with another disease or were healthy relatives of a 
patient. Strong points of our study are the large number of GBS and CIDP patients and 
the extended length of time between diagnosis and questionnaire completion.
The occurrence of recurrent GBS, GBS and CIDP in single patients or in families, and 
the slightly higher rate of common auto-immune diseases in GBS and CIDP patients 
may indicate a certain, possibly genetic, susceptibility factor. The common seasonal flu 
Chapter 2.3
62
vaccinations seem relatively safe in patients who have had GBS or still have active CIDP. 
Several years after the diagnosis of GBS (median 10 years) or CIDP (median 6 years) a 
significant number of patients still have residual symptoms, such as pain and severe 
fatigue, as well as a reduced quality of life, which clearly warrants recognition and sup-
port when possible.
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ABSTrACT
Chronic inflammatory demyelinating polyneuropathy (CIDP) is an immune-mediated 
disorder with variable symptoms and severity that can be difficult to diagnose. Intra-
venous immunoglobulin, plasma exchange and corticosteroids have all been proven 
to be beneficial in randomised controlled trials, although the proof for steroids is less 
clear. Although these treatments are likely to be similar in efficacy they differ in terms 
of their cost, availability and adverse effects. These characteristics should be taken into 
account when deciding which treatment to offer a patient. If there is no response to the 
first treatment option, one of the other treatments should be tried. Patients with a pure 
motor CIDP may deteriorate after steroid treatment.
Some patients do not respond or become refractory or intolerant to these conven-
tional treatments. Those who become unresponsive to therapy should be checked 
again for the appearance of a monoclonal protein or other signs of malignancy. Over 
the years, small non-randomised studies have reported possible beneficial effects 
of various immunosuppressive agents. A Cochrane review concluded that currently 
there is insufficient evidence to decide whether these immunosuppressive drugs are 
beneficial in CIDP. When giving immunosuppressive drugs, one should be aware that 
some might even cause demyelinating disease. It is difficult to prove beneficial effects 
of these newer treatments since they are only tried in small groups of patients, who are 
refractory to other treatments, and often in combination with other treatments. CIDP 
patients can deteriorate during or after infections or improve spontaneously, making 
it more difficult to judge treatment efficacy. Various treatments for CIDP are described 
such as azathioprine, cyclosporin, cyclophosphamide, interferons, methotrexate, myco-
phenolate mofetil, rituximab, and etanercept. An overview of these newer treatments, 
their mode of action, adverse effects and potential place in the spectrum of treatments 
for CIDP based on previous reports and their level of evidence is given.
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InTrODuCTIOn
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is characterized by 
proximal and distal weakness of the extremities, sensory disturbances, and reduced or 
absent tendon reflexes.1, 2 It is a relatively rare disorder with an estimated prevalence of 
1-2 per 100.000.3, 4 The course of CIDP can be relapsing-remitting or chronic and pro-
gressive.5 Many patients with CIDP have a chronic disease course lasting several years. 
Some patients with active CIDP have been receiving immunomodulatory treatment for 
over 25 years (personal observations). The diagnosis of CIDP is made based on clinical 
and electrodiagnostic criteria.1, 2 An elevated protein level in cerebrospinal fluid without 
pleiocytosis or the findings on nerve biopsy may support the diagnosis but are not 
mandatory.1 CIDP can be associated with various other concomitant diseases, such as 
diabetes mellitus.1, 5 In general, CIDP has a progressive phase of >8 weeks.1, 2 The duration 
of progression differentiates CIDP from Guillain-Barré syndrome (GBS), a rapidly progres-
sive polyneuropathy, which has a progressive phase of <4 weeks.6 However, about 16% 
of CIDP patients do have an acute onset like GBS.7, 8
CIDP is a heterogeneous disorder that can be difficult to diagnose.5 There are numerous 
chronic polyneuropathies and making the diagnosis of CIDP can be difficult; however, 
it is important to make the diagnosis because CIDP is a potentially treatable disorder.
Mildly affected patients should not always be treated since spontaneous recovery 
can occur and the risk of adverse effects may not outweigh the potential benefits of 
treatment.9 The treatment of CIDP consists of anti-inflammatory, immunosuppressive 
and immunomodulating drugs. The following three treatments have been shown to be 
effective in randomised controlled trials: intravenous immunoglobulin (IVIg)10-13, plasma 
exchange (PE)14, 15 and corticosteroids16. Only 60-80% of patients with CIDP improve with 
one of these three treatments17 and some patients, for unknown reasons, respond better 
to one treatment than to another.18 In a group of 44 CIDP patients, 39% responded to 
initial therapy, and of the non-responders, 35% responded to second treatment and 
27% of the patients who needed a third treatment showed a response.19 Overall, 66% 
responded to one of the three main treatments.19
CIDP patients can have a spontaneous improvement of muscle weakness and sensory 
disturbances, making it difficult to judge efficacy of treatment in single patients. What-
ever treatment is given, regular assessments should be carried out as needed, based 
upon the clinical response and adverse effects, to see if treatment can be reduced or 
discontinued, if the patient is in remission.9 Patients who initially respond and subse-
quently become unresponsive to therapy should be checked again for the appearance 
of another disorder, such as paraproteinemia.20 When treating and evaluating patients 
with CIDP, it is important to realise that infections and febrile conditions may worsen 
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symptoms. Although, anecdotally, CIDP patients have been described who showed a 
spectacular improvement after sepsis.21
In autoimmune diseases (e.g. rheumatoid arthritis) and immune-mediated disorders 
(e.g. multiple sclerosis) new therapeutic drugs are tested and evaluated relatively 
quickly. Although not proven, CIDP probably is an autoimmune disorder; therefore, 
immunosuppressive or immunomodulating agents are expected to be beneficial. 
Transferring experimental therapeutics from animal models to humans has not been 
always successful.22 Over the years, small non-randomised studies have reported pos-
sible beneficial effects of various immunosuppressive agents in CIDP. Since these were 
all small non-controlled studies a Cochrane review concluded that there was insufficient 
evidence to decide whether these immunosuppressive drugs were beneficial in CIDP 
(Table 1).23-26 It is difficult to prove beneficial effects of these newer treatments because 
(i) they are generally administered to small groups of patients who are refractory to all 
other treatments; (ii) they are often tried in combination with other treatments; and (iii) 
because CIDP is such a rare disorder, it is difficult to recruit large numbers of patients for 
clinical trials. In prescribing these immunosuppressive agents, one should be aware of 
the possibility that some of these might even cause demyelinating disease.27
Levels of evidence and dosage regimens for various treatments are listed in Table 
2.9, 22, 28-30 Since some patients are non-responsive, or become refractory or intolerant to 
the conventional treatments, newer therapeutic options are potentially important in the 
treatment of CIDP and randomised-trials are urgently needed.
Table 1. Cochrane reviews in the treatment of chronic inflammatory demyelinating polyradiculoneu-
ropathy
Study Treatment efficacy
Speed of
action
Potential 
long-term 
adverse 
effects Availability Costs
Eftimov et al. 24 Intravenous
immunoglobulin
Proven Fast Minor Good High
Mehndiratta and Hughes25 Corticosteroids Proven Moderate Severe Very good Low
Mehndiratta et al. 26 Plasma exchange Proven Fast Minor Variable High
Hughes et al.23 Cytotoxic drugs
and interferons
Unknown Variable Severe/
variable
Good/
Variable
Moderate/
Variable
73
Therapeutic options for CIDP
Ch
ap
te
r 3
.1
CurrenT PrOVen effeCTIVe TreATmenTS
Intravenous immunoglobulin (IVIg)
Several placebo-controlled trials have shown that IVIg is an effective treatment for 
CIDP.10-13 In one of these trials, IVIg was effective in 50 previously untreated CIDP pa-
tients.12 Another randomised, double-blind, crossover trial showed a positive effect of 
IVIg in three of seven CIDP patients. This trial was prematurely stopped after the benefits 
of IVIg were proven in another trial and continuing was considered unethical.11, 31
One randomised, double-blind, placebo-controlled study could not demonstrate a 
beneficial effect of IVIg in 28 CIDP patients.32
A Cochrane review confirmed the efficacy of IVIg and concluded that there is evidence 
that IVIg improves disability for at least 2-6 weeks compared with placebo.24
Table 2. Drug regimens for the treatment of chronic inflammatory demyelinating polyradiculoneu-
ropathy
Treatment evidence levela regimen
Proven efficacy in rCTs
Intravenous immunoglobulin 1a Induction: 2 g/kg, divided over 2-5 d
Maintenance: 0.4-1 g/kg every 2-6 wk
Plasma exchange 1a Induction: 3-5 PE sessions (2-2.5 L/session)
Maintenance: 1 PE session every 1-3 wk
Prednisolone 1b Induction: 60 mg/d or 1-1.5 mg/kg
Maintenance: slowly tapering over mo to y
unproven efficacy in rCTs
Intravenous methylprednisolone III Induction: 500 mg/d for 5 d, or 1 g/d for 3 d
Maintenance: once a mo, slowly tapering
Azathioprine III 1.5-3 mg/kg/d
Cyclosporin III 2.5-5.0 mg/kg/d divided into 2 doses
Mycophenolate mofetil III 1.0-2.0 g/d divided into 2 doses
Cyclophosphamide III Pulsed 1g/m2 IV over 1.5 h each mo, 3-6 mo
Methotrexate III 7.5-15 mg once a wk
Interferon-a III 3 MIU 3 x/wk SC
Interferon-b III 6 MIU 3 x/wk SC
Rituximab IV 375 mg/m2 IV once a wk for 4 wk
Tacrolimus IV 0.1-0.3 mg/kg/d divided into 2 doses
Etanercept IV 25 mg SCtwice a wk
Alemtuzumab IV 30 mg/d IV 5 d
a Levels of evidence: Ia = meta-analysis of more than one RCT of good quality; Ib = RCT of good quality; II = 
controlled study without randomisation or randomised study with low patient numbers;
III= uncontrolled study; IV = one or more case reports.
MIU = million international units; RCT = randomised controlled trial; SC = subcutaneous.
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Recently, the largest randomised, placebo-controlled trial in CIDP patients has proven 
the benefits of IVIg.13 This randomised, double-blind, placebo-controlled, response-
conditional, crossover trial conducted in 117 patients also showed the first evidence for 
long-term efficacy and safety of IVIg in CIDP patients.13 In the IVIg group, 54% improved 
in adjusted inflammatory neuropathy cause and treatment (INCAT) disability score33 
compared with 21% out of the placebo group. Results were confirmed during the cross-
over period. During the extension phase, patients who received IVIg had a longer time to 
relapse than patients who were treated with placebo. The frequency of adverse events 
and the incidence of serious adverse events on the long-term did not differ generally 
from placebo.13
If CIDP patients do improve after IVIg, clinical improvement can be expected within 
1-2 weeks after starting treatment.9 The maximum effect may last from several weeks to 
months.34 The exact mechanism of action of IVIg is unknown. IVIg has various immuno-
modulating effects such as neutralisation of autoantibodies, inhibition of complement, 
modulating phagocytosis through blockage of Fc receptors.18 In general, IVIg is well 
tolerated, and has only mild infusion-related adverse effects such as chills, headache 
and myalgias, which are probably caused by complement activation.18 However, some 
rare serious adverse events can occur, such as anaphylaxis, thrombo-embolic events 
or renal failure. Therefore, in patients known with cardiac failure or kidney failure, IVIg 
should be used with caution.18
The disadvantage of IVIg is its high cost and need for intravenous infusions. It is time 
consuming to administer and most patients require the treatment for a long period. 
Since it has few adverse effects, it is frequently considered as an initial treatment.9
The initial dosage of IVIg is usually 0.4 g IVIg/kg body weight for 5 days. It is unknown 
whether a higher infusion dosage (1 g/kg body weight for 2 days) is more effective. The 
best treatment schedule, dose and frequency in CIDP are still unknown and randomised 
trials comparing several dosage schedules are needed.35, 36
A flowchart for treatment of CIDP with IVIg is given in Figure 1.9 Also, it is unknown 
whether different brands of immunoglobulin are similar in efficacy. We are currently 
conducting a randomised controlled trial comparing two different immunoglobulins in 
CIDP patients receiving maintenance IVIg treatment.
Plasma exchange (Pe)
Two trials have shown that PE is an effective treatment for CIDP.14, 15
In the first double-blind sham-controlled trial, 5 of 15 patients who received PE 
experienced greater improvements on the neurological disability scale from baseline 
than the 14 patients who received sham exchange. These results were reproduced 
during an open-label phase. This study showed that PE can be beneficial in some CIDP 
patients. In the patients who responded to the treatment, the effect began to fade 10-
75
Therapeutic options for CIDP
Ch
ap
te
r 3
.1
IVIg 2g/kg (2-5 days) 
Evaluate efficacy 
Improvement1 
Deterioration 
No improvement 
Improvement continues 
IVIg 0.4-1.2g/kg (1-3 days) 
Improvement1 Improvement continues 
Deterioration 
IVIg 0.4-1.2g/kg (1-3 days) 
Improvement1 Improvement continues 
Deterioration 
Start maintenance treatment 
IVIg 0.4g/kg once every 2-4 weeks 
When stable for > 2 months 
attempt dosage reduction  
Stop 
Stop 
Stop 
Stop 
figure 1. Intravenous immunoglobulin (IVIg) treatment in chronic inflammatory demyelinating 
polyradiculoneuropathy
1Clinical assessment 1-2 weeks after onset of IVIg therapy.
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14 days after treatment. Limitations of this trial are its short duration of 3 weeks and 
possible interactions with other immunosuppressive drugs.14 In another double-blind, 
sham-controlled, cross-over study, 12 of 15 patients who completed the trial improved 
substantially with PE. These patients were all newly diagnosed with CIDP, either chronic 
relapsing or progressive, and did not receive other immunosuppressive drugs. Eight of 
the 12 responders relapsed after stopping PE, and prednisolone therapy was needed to 
maintain long-term remission. The three patients who did not respond to PE responded 
to prednisolone. The authors concluded that PE is a very effective therapy in CIDP, but 
adjuvant immunosuppressive drug treatment is often needed in the long term. Three 
patients in this trial withdrew; one because of problems with venous access, one had a 
stroke and another patient quit to receive open treatment elsewhere.15 On the basis of 
these two trials, a Cochrane review concluded that PE provides short-term benefits in 
about two-thirds of patients with CIDP.26
PE is normally started with a frequency of five exchanges per 2-week period. When the 
patient improves, a maintenance regimen (e.g. once every 1-3 weeks) can be adopted. 
PE is probably effective because it removes pathogenic antibodies and other substances 
like cytokines directly from the circulation. Whether this is the exact mechanism of PE is 
presently unknown.37 PE is an invasive procedure that is not always available. Further-
more, it is time-consuming, requires hospitalisation and is often needed for a prolonged 
period. Severe cardiac disease or coagulopathy are relative contraindications for PE. The 
most reported adverse effects are hypotension, fluid overload, electrolyte imbalances, 
infection, bleeding or thrombosis at the venous access site. Myocardial infarction is a 
rare adverse effect. Adverse events relating to, for example, difficulty with venous ac-
cess, use of citrate and haemodynamic changes occur in 3-17% of patients.26 Although 
most patients respond within several days after starting, rapid deterioration may occur 
after therapy is stopped.26
Prednisolone
Only one randomised controlled trial considering the treatment of CIDP with predniso-
lone has been conducted to date.16 In this study, 35 patients were randomised between 
prednisolone, starting with 120 mg/day and tapering over 12 weeks, and no treatment. 
The conclusion from this study was that corticosteroids significantly reduced impairment 
and improved nerve conduction measurements.16 However, it should be noted that it 
was an open-label study without concealed allocation. A Cochrane review concluded 
that this trial provided weak evidence that oral steroids reduce impairment in CIDP.25
Several case series support the general opinion that corticosteroids are beneficial.1 
Ten CIDP patients were given pulsed high-dose dexamethasone, three of these dis-
continued treatment -one as a result of adverse effects and two due to neurological 
deterioration. Of the two patients who deteriorated, one had a pure motor form of CIDP 
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and the other showed no response to IVIg or PE. All seven patients who completed the 
treatment improved in functional health status.38
The results from a randomised trial comparing pulse-dosed dexamethasone with 
prednisolone are eagerly awaited.39
About 65% of CIDP patients seem to respond after corticosteroid treatment.7 The 
generally accepted dosage for prednisolone is 60 mg/day or 1.5 mg/kg body weight on 
alternate days as induction, with maintenance therapy slowly tapering over months to 
years.
For an as yet unknown reason, patients with pure motor CIDP may deteriorate after 
corticosteroids; therefore, IVIg is advised in this group.38, 40
Corticosteroids have various effects on cellular immunity such as reducing the num-
ber of lymphocytes, decreasing the levels of cytokines and inhibition of macrophages. 
Corticosteroids have been used for a long time, are widely available and are not time-
consuming. Long-term adverse effects such as hypertension, hyperglycaemia, osteopo-
rosis, infections, gastrointestinal ulcers, obesity, cataracts and psychiatric disturbances 
are very common. Corticosteroids are inexpensive, but adverse effects can be severe. 
Another disadvantage of corticosteroids is a time-lag of several weeks that can occur 
between the start of treatment and clinical improvement. Also, corticosteroid treatment 
is often needed for a long period ranging from 6 weeks to several years.
Comparing IVIg, Pe and steroids
The choice of the best agent to use to treat patients with CIDP is difficult. One single-
blind, crossover trial compared PE with IVIg.41 Twenty CIDP patients were randomly 
assigned to either PE (twice a week for 3 weeks then once a week for 3 weeks) or IVIg 
(0.4 g/kg once a week for 3 weeks then 0.2 g/kg once a week for the next 3 weeks). 
This treatment regimen was chosen because it had an approximately similar cost and 
was thought to be effective. No significant difference between the two treatments was 
found.41 Some limitations of this trial are its unusual regimen of IVIg, and lack of an 
intention-to-treat analysis and inadequate allocation concealment.42
A double-blind crossover trial compared IVIg (2 g/kg) with a 6-week course of oral 
prednisolone.33 There was no significant difference in the proportion of patients with a 
significant improvement. The authors state that there was slightly more improvement 
in the IVIg group, although this did not reach significance.33 Also, this trial had the fol-
lowing shortcomings: (i) the trial was prematurely ended due to reaching the expiration 
date of the trial medication; (ii) the trial was not powered to detect equivalence; (iii) and 
the regimen of prednisolone was relatively short; and (iiii) the reduction in dosage was 
different from what is standard in general practice.33, 42
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In a cost-utility analysis, IVIg was far more expensive than prednisolone, but IVIg treat-
ment resulted in greater improvements in health-related quality of life and associated 
utility.43
All three treatments are likely to be similar in efficacy, although they differ consider-
ably in availability, cost and adverse effect profiles. Since they show about similar ef-
ficacy, it is difficult to suggest a first choice. The pros and cons should be compared on 
an individual basis. A consensus guideline recommends starting treatment of CIDP with 
IVIg or corticosteroids.1 If both these treatments are ineffective, PE is recommended.1
Combining IVIg, Pe and corticosteroids
Combination therapy may increase the duration of response, increase efficacy or reduce 
the need for standard therapy.36 One CIDP patient who did not respond satisfactory to 
IVIg or PE, and who could not tolerate high-dose prednisolone, responded to a syn-
chronised combination of all three treatments.44 A CIDP patient who did not respond 
to high-dose IVIg responded well to moderate-dose IVIg after a short course of PE.45 
Two CIDP patients, who were unresponsive to the conventional treatments, improved 
immediately after a repeated combination of PE and IVIg.46
POTenTIAl TreATmenTS
Subcutaneous immunoglobulin
In patients with a primary immunodeficiency syndrome, immunoglobulins have been 
given via a subcutaneous portable pump. It seems that subcutaneous immunoglobulin 
(SCIg) treatment leads to more stable plasma levels and reduced adverse effects.47 Fur-
thermore, it can reduce the costs significantly and it is easy to handle since no venous 
access is needed, thus improving autonomy. Two CIDP patients, responsive to IVIg, have 
been described in whom SCIg led to a stabilisation of the disease course.48 In both these 
patients, it was well tolerated and costs were reduced by 50%.48 Preliminary results of an 
open label prospective study by Magy49 of SCIg in CIDP patients are positive.49
A disadvantage of SCIg can be the restricted volume per infusion, which may result in 
the need for regular infusions.48
Intravenous methylprednisolone
An open-label, retrospective study of intravenous methylprednisolone (IVMP) reported 
improved muscle strength comparable with that of IVIg and oral prednisone.50 In this 
study, 16 patients were treated with long-term intermittent IVMP, although not in ac-
cordance with a standardised treatment regimen or evaluation regimen. Weight gain 
and Cushingoid features were reported to occur less often after IVMP than oral pred-
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nisolone.50 Currently, a randomised controlled trial comparing IVIg and IVMP is being 
conducted by Nobile-Orazio in CIDP patients.51
Azathioprine
Azathioprine is an anti-inflammatory drug that causes inhibition of proliferating im-
munocompetent cells.22 Although reliable data on its efficacy in CIDP are lacking, 
azathioprine is often prescribed because it can reduce the dosage of corticosteroids 
required.9, 23
An open-label, randomised controlled trial of 27 patients that compared azathioprine 
in combination with prednisone with prednisone alone showed no significant difference 
between treatments.52 Criticisms of this trial are its small size, lack of power to detect any 
but large treatment effects and the use of a low dosage. Furthermore, the treatment pe-
riod of 9 months may have been too short to draw conclusions about its efficacy.23 Four 
of five CIDP patients showed a sustained improvement after azathioprine and in the 
fifth patient it replaced corticosteroid therapy.53 Other case series have reported positive 
effects of azathioprine.54-57 In addition to there being case series describing positive ef-
fects, patients have also been described showing no response to azathioprine.58
It can take up to several months before azathioprine reaches maximal effect. The most 
reported adverse effects are leucopenia, thrombocytopenia, anaemia, myelosuppres-
sion and pancreatitis.28
Cyclosporin
Cyclosporin is a calcineurin inhibitor that inhibits the production of cytokines and is 
mainly used in organ transplant patients. The most serious adverse effects of cyclospo-
rin are dose-dependant nephrotoxicity and hypertension; therefore, renal impairment 
is a contraindication.
In a retrospective study, 19 CIDP patients, non-responsive to other treatments, were 
treated with cyclosporin.59 The mean disability status (measured on a 5-point scale) de-
clined from 3.8±0.7 to 1.8± 1.1 (p < 0.001) in the progressive group, and in the relapsing 
group the mean annual incidence of relapse declined from 1.0± 0.5 to 0.2± 0.4 (p < 0.05) 
after treatment with cyclosporin. In two patients, cessation of therapy was necessary 
because of reversible nephrotoxicity.59 Another case study reported an improvement in 
clinical symptoms in seven patients.60
In eight CIDP patients who were treated with cyclosporin, three improved or were 
able to stop prednisone; for the other five, it had no effect.61 In eight other patients with 
CIDP, of whom five had associated paraproteinaemia, three patients were reported to 
have an excellent response, two with complete remission.62 In the other patients, it was 
possible to reduce the corticosteroid dose and frequency of PE.62
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Various other small case series have described the treatment of CIDP with cyclospo-
rin.63, 64 Cyclosporin is more toxic, but it may have a more rapid mode of action and is less 
allergenic than azathioprine.61 One organ-transplant patient has been described who 
developed CIDP while on prednisolone and cyclosporin.27
mycophenolate mofetil
Mycophenolate mofetil (MMF) is a fast acting immunosuppressive agent that has been 
widely and successfully used in preventing the rejection of organ transplants. Further-
more, it is used in immune-mediated diseases such as rheumatoid arthritis and Crohn’s 
disease.65
MMF inhibits the proliferation of T and B lymphocytes. In general, MMF is well toler-
ated and relatively safe to use, causing only mild bone marrow suppression. It can be 
effective alone or act as an adjuvant by reducing the dosage of corticosteroids required 
and/or the frequency of IVIg infusions.66 A small study that retrospectively reviewed the 
efficacy of MMF in CIDP patients concluded only a modest benefit in 20% of patients, 
allowing reduction of corticosteroid or IVIg therapy.67 In two CIDP patients treated with 
MMF, IVIg dosage could be reduced by 50%.68 Three other CIDP patients are described, of 
whom one responded to MMF treatment; no details are given about the response of the 
other two.65 Another case series showed an improvement in strength and sensation in 
two CIDP patients.69 In four patients with treatment-resistant CIDP, there was no clinical 
significant benefit and in none of the patients the dosage of other immunosuppressive 
drugs could be reduced.70 In one of these patients, adverse effects were severe enough 
to stop the medication.70
The most reported adverse effects are diarrhoea, leucopenia, thrombocytopenia, 
neutropenia, lymphoma, gastrointestinal bleeding and headache.28, 65, 67
Cyclophosphamide
Cyclophosphamide eradicates T and B lymphocytes.71 The largest series described 15 
CIDP patients treated with intravenous pulse cyclophosphamide.72 Twelve of these 
showed marked improvement and 11 had a complete response. Three patients showed 
no improvement and three worsened. Six had minor adverse effects and none showed 
serious adverse effects.72 Another study described four CIDP patients having incomplete 
responses to immunotherapy, but improvement in functional status and muscle strength 
after high-dose cyclophosphamide (200 mg/kg over 4 days).71 Neutropenic infections 
and transient renal insufficiency as well as other mild adverse effects were reported.71
Another report described continuous positive effects of cyclophosphamide in four 
CIDP patients during the follow-up time, as well as positive effects in another patient 
and an improvement in quality of life in all five.73 Three of five other CIDP patients 
improved in muscle strength after high-dose cyclophosphamide.74 Two of these also 
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improved in nerve conduction and were able to reduce their immunomodulatory 
treatment.74 Another CIDP patient showed a good response to treatment with PE and 
cyclophosphamide.75
The most reported adverse effects are haemorrhagic cystitis, stomatitis, leucopenia, 
thrombocytopenia, malignancy and cardiomyopathy. 28 Therefore, cyclophosphamide 
should only be tried in patients with severe disease who are unresponsive to other less 
toxic drugs.
methotrexate
Methotrexate is a well known effective treatment for various autoimmune disorders. It is 
a folate-inhibiting drug and, in general, is an immunosuppressive agent with relatively 
low toxicity.
Retrospectively, the efficacy of methotrexate was evaluated in ten patients with 
CIDP who were unresponsive to conventional treatments.76 Seven patients showed an 
improvement in strength, measured as increasing at least two points in the Medical 
Research Council (MRC) sum score, whereas three patients worsened. Only two patients 
showed an improvement in disability and both of these were also being treated with 
corticosteroids.76
Very recently, the results have been published of a randomised controlled trial show-
ing no significant benefit of methotrexate in CIDP, although a treatment effect could not 
be excluded because of limitations in the trial design and a high response rate in the 
placebo group.77
Interferons
Interferon (IFN) reduces relapse frequency in multiple sclerosis, a demyelinating disease 
of the central nervous system. Interferons are immunomodulatory drugs that influence 
cytokine expression.
Nine of 15 CIDP patients that were treated with IFNa-2a, improved in mean MRC and 
sensory scores.78 In five of these, the clinical response was sustained without any further 
progression or relapse.78 One patient, unresponsive to corticosteroids and IVIg, and 
partially responsive to PE, improved substantially after treatment with interferona-2a.79 
A deterioration occurred after treatment was stopped followed by an improvement after 
reintroduction.79 A dramatic long-term response to interferona in a bedridden CIDP 
patient, unresponsive to conventional treatments, has also been described.80 Other case 
reports described a positive effect of IFNa in CIDP.81
In a double-blind, randomised, controlled, cross-over trial that prospectively followed 
ten CIDP patients, no significant difference was found between IFNb-1a and placebo.82 In 
a prospective, open-label study, 7 of 20 CIDP patients showed a significant improvement 
from baseline.83 Other case reports have described positive effects of IFNb in refractory 
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CIDP patients.84-86 An open-label study in therapy-resistant CIDP patients could not dem-
onstrate a beneficial effect of IFNb-1a, but did show a statistically significant effect when 
IVIg was combined with IFNb-1a.87 Recently, the results of a randomised controlled trial 
have been presented showing that IFNb-1a does not result in any significant IVIg dose 
reduction in IVIg-dependant CIDP patients.88
Further complicating the decision of whether to treat some CIDP patients with these 
agents are reports of patients who have developed CIDP while being treated with inter-
ferons for other disorders such as multiple sclerosis and chronic hepatitis C.89-91 In con-
trast, a CIDP patient with hepatitis C showed improvement after treatment with IFNa.92 
It is unknown which patients may improve and which ones may deteriorate during 
these treatments. The most reported adverse effects are flu-like symptoms, leucopenia, 
thrombocytopenia and psychiatric disturbances. 23, 28, 78
rituximab
Rituximab is a monoclonal antibody directed against CD20. Several reports indicated a 
positive response to rituximab in patients with IgM antibody-associated polyneuropa-
thy or CIDP.93-96
A CIDP patient who developed Evans syndrome (haemolytic anaemia/thrombocy-
topenia) was unresponsive to corticosteroids, IVIg, azathioprine and cyclophospha-
mide; this patient was reported to respond well to rituximab.97 Another CIDP patient, 
unresponsive to conventional treatments with high titers of anti-sulfated glucoronyl 
paragloboside IgM antibody without M-protein in serum, responded to rituximab.98 
A prospective pilot study investigated rituximab in six patients with IVIg-dependant 
relapsing immune polyneuropathy.99 Rituximab did not result in a reduction in the IVIg 
dosage in the majority of these patients. Of these six patients, two had a CIDP; in both 
these patients IVIg dosage could not be reduced.99 Another two CIDP patients with IgM 
monoclonal gammopathy without myelin associated glycoprotein antibodies showed a 
good response to rituximab.100 Rituximab is an expensive treatment. The most reported 
adverse effects of rituximab are hypotension, leucopenia, neutropenia, thrombocytope-
nia, bronchospasm and renal failure.28, 93
Tacrolimus
Tacrolimus is a well-known immunosuppressant that is often used in organ transplanta-
tion and for the treatment of autoimmune disorders. It has been described that 5% of 
patients who receive tacrolimus develop central nervous system toxicity.101
One CIDP patient treated with tacrolimus concurrently with prednisolone and PE 
improved in muscle strength, although this might have been due to the concurrent 
treatments.102
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Of approximately 1000 patients who received an organ transplant, three patients 
developed a severe sensorimotor neuropathy shortly after initiation of tacrolimus.101 
Neuropathies in these patients responded to IVIg or PE suggesting an immune-mediated 
cause.101
Patients who developed CIDP while being treated with tacrolimus have been re-
ported.27, 103
etanercept
Etanercept is a tumour necrosis factor-a antagonist that has been successfully used in 
rheumatoid arthritis. In ten patients with CIDP resistant to other treatments, the efficacy 
of etanercept was retrospectively evaluated.104 Three of these patients showed improve-
ment and three possibly improved.104 When prescribing etanercept, it should be noted 
that in some patients it might possibly induce demyelinative diseases such as multiple 
sclerosis, optic neuritis and myelitis.105
Alemtuzumab
Alemtuzumab is a monoclonal antibody that has been used in leukaemia and multiple 
sclerosis. It is a monoclonal antibody directed against the CD52 antigen, resulting in 
the prevention of complement-mediated lysis. Infusion-related adverse effects such as 
hypotension, fever, shortness of breath and rash are common.30 Other important ad-
verse effects are autoimmune thyreoditis and idiopathic thrombocytopenic purpura.30 
A CIDP patient, unresponsive to conventional treatments, was reported to respond well 
to alemtuzumab.30
eculizumab
Complement plays an important role in many inflammatory and autoimmune diseas-
es.106 Complement is important in recognising and eliminating apoptotic and necrotic 
cells, and facilitates the elimination of circulating immuuncomplexes.106 In patients with 
demyelinating polyneuropathy, the complement pathway may be activated.
Since IVIg inhibits complement binding and has been shown to be effective in CIDP, 
other complement inhibitors might also effective in CIDP.18 In 2007, the first complement-
specific drug, namely eculizumab, was approved.106 Eculizumab is a humanised mono-
clonal antibody that blocks the formation of complement protein (C5) and membrane 
attack complex. In a murine model, it prevented anti-ganglioside antibody-mediated 
neuropathy resembling GBS.106 The recommended intravenous dosage of eculizumab in 
paroxysmal nocturnal hemoglobinuria is 600 mg/week for 4 weeks, followed by a 900 
mg once at week 5, followed by 900 mg every 2 weeks as a maintenance dose.107
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Sirolimus
Sirolimus is used in organ transplantation and has a different mode of action than tacro-
limus.108 Sirolimus does not inhibit calcineurin and is not associated with nephrotoxicity. 
In 202 organ-transplant patients who were treated with sirolimus from 2001 to 2004, 
no evidence of neurotoxicity was found.108 Therefore, it was postulated that sirolimus 
could be considered as a substitute immunosuppressant in patients with cyclosporine 
or tacrolimus neurotoxicity.108 We could not find any reports from CIDP patients being 
treated with sirolimus. Liver or kidney transplant patients are treated with an initial load-
ing dose of sirolimus 6 mg and thereafter with doses ranging from 1-10 mg/day, with 
target serum levels of 8-15 ng/mL.108 This drug needs to be administered with caution 
because a patient has been described who developed a posterior reversible encepha-
lopathy after sirolimus treatment.109 Very recently, a case has been reported of a patient 
who developed CIDP after treatment with sirolimus.110
Stem cell transplantation
Stem cell transplantation is the most extreme form of immunosuppression.
A CIDP patient who improved after autologous stem cell transplantation has been 
described.111 In the 10 years before the stem cell transplantation, he had no spontane-
ous remissions and he developed serious adverse effects to immunosuppressive drugs. 
After the autologous stem cell transplantation, he was free of relapses needing only 
prednisone 5 mg/day.111 Unfortunately, 5 years after the stem cell transplantation, he 
developed a relapse, but was successfully treated with IVIg.112 He needed lower doses of 
IVIg and prednisone than before the stem cell transplantation and the drugs were better 
tolerated.112
Another therapy-resistant CIDP patient was treated with non-myeloablative autolo-
gous stem cell transplantation.113 This patient had no exacerbations during the follow-
up time of 22 months.113 A CIDP patient, unresponsive to therapy, has been described 
who developed aplastic anaemia after azathioprine therapy.114 This patient received al-
logeneic haematopoietic stem cell transplantation and showed a full recovery, without 
any relapse for at least 6.5 years of follow-up.114
Controversially, some patients have developed CIDP as part of a graft-versus-host dis-
ease following bone marrow transplantation.115, 116 Other patients have been described 
who had exacerbations of CIDP after bone marrow transplantation.117 The course was 
progressive despite therapy and both patients died.117 CIDP has been reported to oc-
cur 3-4 weeks after autologous peripheral blood stem-cell transplantation in multiple 
myeloma.118
Stem cell transplantation should be only considered as a last treatment option in pa-
tients who are unresponsive to various other treatments or who develop severe adverse 
effects.
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COnCluSIOn
IVIg, PE and prednisolone are all treatments proven to be beneficial in the treatment of 
CIDP in randomised controlled trials. Although their efficacy seems to be similar, they 
differ considerably in cost, availability and adverse effects. In individual patients, these 
factors should be taken into account when deciding which drug to initiate treatment 
with. If the first treatment has no effect, one of the other conventional treatments should 
be tried. Various other immunosuppressive drugs have potential positive effects in CIDP; 
however, none have been proven to be beneficial in randomised controlled trials. When 
prescribing one of these immunosuppressive drugs, it is important to realise that these 
agents may cause serious adverse effects, and some might even worsen or cause a poly-
neuropathy. These drugs should only be administered to patients who do not respond, 
become refractory or intolerant of any of the three conventional treatments for CIDP.
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ABSTrACT
Background: Different preparations of intravenous immunoglobulin (IVIg) are consid-
ered to have comparable clinical efficacy, but this has never been formally investigated. 
Some patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) 
report that some IVIg brands are more effective than others. A liquid IVIg preparation is 
more user friendly, and potentially can be infused at a faster rate.
Objectives: The primary objective was to compare the efficacy of two different IVIg 
brands in CIDP. The secondary objective was to compare their safety.
methods: This was an investigator-initiated multi-centre randomised controlled 
double-blind trial. Twenty-seven patients with active but stable CIDP treated with 
their individual stable IVIg (Gammagard S/D) maintenance dose and interval were ran-
domised to receive four infusions of freeze-dried 5% IVIg (Gammagard S/D) or the new 
liquid 10% IVIg (Kiovig). The overall disability sum score (ODSS) was used as the primary 
outcome-scale. The equivalence margin was defined as a difference of ≤1 point in mean 
ΔODSS between treatment groups. Main secondary outcome scales were the MRC sum 
score and the Vigorimeter.
results: Repeated measurements analysis of variance, adjusted for baseline ODSS, 
showed a clinically insignificant treatment difference of 0.004 (95% CI –0.4 to 0.4). We 
also found no significant differences in any of the other outcome measures. Besides a 
lower occurrence of cold shivers in patients randomised to Kiovig (p=0.03) no significant 
differences were found in the occurrence of adverse events.
Conclusions: This trial demonstrated equal clinical efficacy between a freeze-dried and 
a liquid IVIg preparation for maintenance treatment of CIDP.
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InTrODuCTIOn
Clinical trials have proven the efficacy of intravenous immunoglobulin (IVIg) for the 
treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).1-4 
The efficacy of intermittent IVIg in CIDP has been shown to last for a period of at least 
24 weeks.4 However, most patients need IVIg treatment for several years.5 In many CIDP 
patients, various brands of IVIg are used over the years, often depending on what is 
available in the hospital pharmacy.6 Although some authors recommend that switch-
ing between IVIg brands should only occur under careful professional supervision, in 
practice this is usually done without any specific safety measures.7 IVIg is increasingly 
being used for various neurological conditions.7 Various IVIg brands are generally as-
sumed to be equivalent,8, 9 but some patients report some brands as more efficacious 
than others.7, 10 When CIDP patients show no favourable response to IVIg it is not known 
whether treatment with an alternative brand might be beneficial. IVIg brands differ in 
their composition and production processes which might affect their efficacy and toler-
ability.8, 10-11 Whether this reflects differences in efficacy or safety in immune-mediated 
neuropathies has never been investigated and, therefore, trials comparing different 
preparations are recommended.12 The freeze-dried lyophilised brand Gammagard S/D 
has been used in randomised controlled trials in autoimmune polyneuropathies.13, 14 The 
manufacturing process of the new liquid IVIg preparation Kiovig employs a Cohn-Oncley 
cold alcohol fractionation procedure to isolate the IgG fraction which is further purified 
using chromatography to yield a solution containing ≥ 98% IgG instead of ≥ 90% IgG 
in Gammagard S/D.15 Kiovig contains a different distribution of IgG subclasses and no 
added glucose, sodium or preservatives. It is more concentrated and can be infused at a 
faster rate with a reduced volume load.11
We compared the efficacy and safety of these two products in a controlled double-
blind trial. A group of active but stable CIDP patients treated with a stable maintenance 
dosage of the 5% freeze-dried IVIg preparation were randomised to the same product or 
to an equivalent dosage of a more concentrated 10% liquid IVIg preparation.
meTHODS
This investigator-initiated trial was conducted at three university-affiliated neuromus-
cular disease centres in the Netherlands and was approved by the Medical Ethical 
Committees of these centres and the competent authority. This study was conducted 
in compliance with the E6 International Conference on Harmonization (ICH) guideline 
for Good Clinical Practice16 and following local regulations. Monitoring was conducted 
by an Association of Clinical Research Professionals (ACRP) accredited monitor. A data 
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monitoring committee regularly assessed the progress of the trial and the safety data. 
Written informed consent was obtained from all patients. This CIC trial (comparing IVIg 
in CIDP) is registered in the International Standard Randomised Controlled Trial number 
register as ISRCTN52121370.
Subjects
Inclusion criteria were:
1. Diagnosis of CIDP made by a consultant neurologist and fulfilling the American 
Academy of Neurology clinical research criteria.17
2. Age ≥ 18 years.
3. Initial chronically progressive, stepwise progressive or recurrent weakness of all ex-
tremities, developing over at least 2 months, with reduced or absent tendon reflexes.
4. Observed and documented clear improvement of muscle function after the first use 
of Gammagard S/D.
5. Active CIDP defined by an overall disability sum score (ODSS)18 grade ≥ 2 and a Medi-
cal Research Council (MRC) grade ≤ 4 in at least one of the muscles assessed in the 
MRC sum score19 before start of the trial or following a reduction of IVIg dose at some 
time within the last 12 months before start of the trial.
6. Ongoing intermittent treatment with IVIg (Gammagard S/D) leading to a stable 
condition. The individual dose must have been stable (within a 25% range of the 
total dose) for at least 8 weeks and unchanged within the last 4 weeks before start of 
the trial. 
7. Electromyography findings compatible with CIDP at least once during their ill-
ness.20, 21
Exclusion criteria were:
1. Known hereditary neuropathy or severe concomitant diseases such as HIV infection, 
Lyme disease, chronic active hepatitis, congestive heart failure, systemic lupus ery-
thematosus, drug or toxin induced neuropathy, vasculitis, and malignancies.
2. IgM paraprotein with anti-myelin-associated glycoprotein (MAG) antibodies.
3. Multifocal motor neuropathy (MMN), fulfilling the European Federation of Neuro-
logical Societies /Peripheral Nerve Society criteria.22
4. Atypical CIDP with pure sensory or persistent unifocal impairment or significant 
central nervous system involvement.
5. Treatment with another IVIg brand than Gammagard S/D during the previous 8 
weeks.
6. Participation in a controlled trial of a medicinal product within the last 12 weeks.
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Study design
The trial consisted of 10 infusions in three phases. First, an open label phase with one 
Gammagard S/D infusion, second a double-blind phase with four blinded infusions and 
third an open-label phase with five Kiovig infusions (Figure 1). Patients were treated 
in the hospital day-care centre or at home according to where they were treated prior 
to trial entry. Immediately before infusions 1 and 2 (baseline), 4 and 6 (blind phase), 8 
and 10 (open label phase) a neurological examination, including the MRC sum score 
(6 muscles) and INCAT sensory sum score (ISS), was carried out by the assessor (KK). 
Before every infusion, the ODSS as well as the muscle grip strength (vigorimeter) were 
recorded (Figure 1). 23 During every infusion and 1 week thereafter the patient was asked 
to record adverse events (AEs). One week after each infusion the patient completed the 
following questionnaires: Fatigue severity scale (FSS24), Short Form (36) Health Survey, 
Dutch language acute version 1 (SF-3625), and the Rotterdam handicap scale (RHS26).
Study drug
Patients were randomised to receive four infusions of 5% (50 g/l) freeze-dried IVIg (Gam-
magard S/D, Baxter AG, Vienna, Austria) or the new 10% (100 g/l) liquid IVIg (Kiovig, 
Baxter AG, Vienna, Austria). All included patients had been treated successfully with 
maintenance IVIg before start of the trial (mean 5 yrs, range 5 months to 13 yrs). For both 
brands, the IVIg dosage and frequency for each patient was kept the same as their treat-
ment regimen prior to trial entry and remained constant throughout the whole trial. One 
central trial pharmacist was responsible for the reconstitution (if necessary), packaging, 
labelling and distribution of the trial medication during the double-blind phase.
figure 1. Trial outline
ODSS = overall disability sum score; MRC = medical research council; ISS = INCAT sensory sum score; FSS = 
fatigue severity scale; RHS = Rotterdam handicap scale; SF-36 = Short Form (36) health survey.
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randomisation and blinding
We used a computer-generated randomisation list produced by a statistician (WH). A 
block randomisation was made for each centre. Patients were checked for eligibility and 
enrolled by the principal investigator (PD) in agreement with the main investigators 
of the three centres. The assessor allocated the next available number on entry after 
consent was given. Allocation concealment was ensured via sequentially numbered, 
opaque sealed envelopes distributed by the statistician to the principal investigator. 
After randomisation, the prescription was faxed by the principal investigator to the 
pharmacy. Patients, the assessor (KK) and the blinded neurologist who assessed the 
SAEs were all blind to the drug allocations. We did not dilute the 10% (Kiovig) solution 
to a 5% solution, as we had no data regarding its stability. Due to the different volumes 
of the preparations, the nurses who were experienced in administering the IVIg could 
not be blinded for the drug assignment as they had to adjust the infusion speed to 
ensure the integrity of the blinding for patients. All patients were treated according to 
their individual established IVIg dosage prior to study entry. The infusion bag and the 
drip chamber were enclosed in a covering bag and a coloured infusion line was used so 
neither the assessor nor the patient was able to discern which brand was infused. The 
IVIg was infused at a standard safe infusion rate. To check whether blinding was main-
tained, both patients and the assessor were asked after the blind phase and at the end 
of the trial to guess which drug they thought had been administered in the blind phase.
Allocation was revealed after all patients had completed the study and data entry had 
been declared complete.
efficacy
The primary objective was to study the efficacy of Kiovig compared to Gammagard S/D 
in the treatment of CIDP; the ODSS was used as the primary outcome measure. Before the 
trial started, we predefined in the protocol that a difference in the mean ODSS change 
from baseline between the two groups of ≤ 1 point was considered as equivalence. The 
two ODSS measurements, assessed immediately before infusion one (Gammagard) and 
two (first blinded infusion), were averaged and the mean value was taken as a baseline 
measurement. Changes in the vigorimeter values and the MRC sum score were used as 
secondary outcome measures as were all other measures.
Safety
The secondary objective was to compare the safety of both products. A questionnaire 
regarding AEs was completed by the patients during every infusion and again 1 week 
later. A neurologist blinded to the allocation of trial medication (EB, EC, AK) evaluated 
AEs by telephone at regular intervals.
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Statistical analysis
The sample size calculation based on historical data showed a SD of 0.84 for ∆ODSS 
(over a stable period of 2 months).18 To exclude differences of > 1 point in ∆ODSS, 11 
patients were required in each treatment group (a =0.05, power 80%). The mean of 
ODSS changes from baseline for each of the four blinded infusions (infusions 3, 4, 5, 
6) was compared using repeated measurements analysis of variance (ANOVA). As an 
operational criterion for equivalence, the 95% CI for the difference in the mean ODSS 
should not cross the values -1 and +1.
For all other outcome measures, the change from baseline was calculated by taking 
the mean of the scores during the double-blind phase and comparison was done with 
analysis of covariance (ANCOVA) with baseline value as covariate. Data were analysed 
according to the intention-to-treat principle.
All AEs were recorded. The statistical analysis for the objectives of the study was based 
upon data from the double-blind phase. The open-label Kiovig phase was primarily used 
to gain more safety information. The occurrences of AEs were compared using c2 or 
Fisher exact test. Analysis was performed using SPSS V.15.0 and SAS V.8.1.
reSulTS
From December 2007 to September 2008, 75 CIDP patients were screened for eligibility; 
48 were excluded mainly because they were not treated with IVIg on a regular basis or 
had no signs of active disease (Figure 2). Other reasons for non-eligibility were treat-
ment in a different hospital than the neuromuscular centre where the diagnosis was 
established or treatment with another brand of IVIg (two patients). In total, 27 patients 
were randomised; 25 completed the full trial period, including the open label phase. The 
first patient was included in December 2007 and the last patient follow-up was in April 
2009. All patients had at least moderate disability in arms or legs at baseline or following 
IVIg reduction during the 12 months before the start of the trial. To further substantiate 
that the patients enrolled in this trial had active disease still requiring intermittent IVIg 
treatment, we determined the occurrence of recent worsening in more detail. Twenty-
three of the patients had had at the minimum a worsening of symptoms in the 6 months 
before the start of the trial. Two patients had a deterioration 8 months before start of the 
trial. Another patient had a documented deterioration 11 months before entry and one 
patient had end-of-dose complaints before and during the trial.
All but one patient received the total amount of four blinded infusions. This patient 
decided to stop the blind treatment after one infusion due to an AE (fatigue). This patient 
was observed while being treated unblinded with Gammagard S/D during the rest of 
the double-blind phase and included in the analysis according to the intention-to-treat 
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principle. One patient decided not to continue with the open-label phase, regardless of 
what was given in the double-blind phase. Baseline and demographic characteristics 
were similar in the two groups (Table 1).
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(n = 39) 
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figure 2. The COnSOrT flowchart
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Treatment efficacy
The treatments were not significantly different in efficacy in the primary outcome mea-
sure (difference 0.004 (Gammagard minus Kiovig), 95% CI –0.4 to 0.4), using repeated 
measurements ANOVA, and this effect did not differ significantly between the four 
measurements in the blinded phase (p = 0.19). The ODSS showed a similar distribution 
between both groups (Figure 3). Using ANCOVA, there were no clinically relevant differ-
ences between the two treatments in all outcome measures (Table 2). In the patient who 
received trial medication only once during the blinded phase, the ODSS score after this 
treatment was exactly the same as after the non-trial medication. One patient required 
another IVIg dosage in the open label phase due to a minor deterioration.
Treatment tolerance
Both IVIg brands were well tolerated. There were no significant differences between the 
two treatments in the number of commonly reported AEs except for the lower occurrence 
of cold shivers in patients randomised to Kiovig (Table 3). Altogether, 4 out of 14 patients 
in the Kiovig treatment group versus 1 out of 13 patients in the Gammagard S/D group 
(p=0.33) reported their AEs to be ‘severe’ in the questionnaires. The number of patients 
who reported AEs to the blinded neurologist was similar in the two groups (8/14 in the 
Kiovig vs. 7/13 in the Gammagard S/D group, p=0.86). Two patients, one in each treatment 
group, had a serious AE (requiring inpatient hospital stay), which was unrelated to the trial 
drug (elective surgery unrelated to CIDP). One patient had a mild allergic reaction to one 
of the blinded Kiovig infusions only needing treatment with an oral antihistamine. In the 
open label Kiovig phase 14/27 patients reported AEs to the blinded neurologist. Half of 
these patients were treated in the blinded phase with Gammagard S/D, the other half with 
Kiovig. No serious adverse events occurred in this open-label phase.
Table 1. Baseline demographic and clinical characteristics
Characteristic
Gammagard S/D
(n = 13)
Kiovig
(n = 14)
Age (y) 54.0 (12.0) 54.6 (13.8)
Men 8 (62%) 12 (86%)
IVIg dosage (g/week) 12.5 (8-30) 14.6 (10-38)
IVIg interval (days) 18.8 (5.3) 15.5 (4.1)
Body weight (kg) 78.5 (13.2) 85.6 (12.5)
ODSS score* (range 0-12) 3.0 (0-7) 3.7 (1-5)
MRC sum score* (range 0-60) 53.6 (4.4) 54.6 (3.4)
Vigorimeter* (range 0-160 kpa) 89.3 (46.2) 86.8 (31.0)
Data are number (%), mean (SD), or median (range). Higher overall disability sum score (ODSS) values in-
dicate more limitations. Higher Medical Research Council (MRC) sum score values and vigorimeter scores 
indicate greater strength.
* Mean value of the two measurements before randomisation at baseline.
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Blinding
After the blinded and open label phase, both patients and the assessor were asked 
which treatment they thought had been administered during the blind phase to check 
if blinding had been successful. In 25 cases (93%) the assessor had no idea about the 
treatment that was given. In two cases the assessor thought correctly that the 10% 
preparation was given; once because the infusion speed was accidentally somewhat 
faster than regular, and in another case because the patient felt severely fatigued after 
the infusion. Thirteen patients had no idea what treatment they received in the blinded 
phase. Seven patients answered the treatment allocation question correctly and seven 
patients were incorrect.
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Table 2. Primary and secondary efficacy outcomes
Difference
(Gammagard minus Kiovig) 95% CI p Value
Primary outcome
ODSS 0.004 -0.4 to 0.4 0.98
Secondary outcomes
MRC sum score -0.58 -1.9 to 0.7 0.37
Vigorimeter 0.54 -4.0 to 5.0 0.81
ISS 0.59 -0.7 to 1.8 0.33
FSS 0.18 -1.9 to 0.6 0.33
RHS 0.74 -0.2 to 1.6 0.12
SF-36
Physical functioning -2.1 -4.5 to 0.28 0.08
Role-physical 1.8 -3.6 to 7.2 0.50
Bodily pain -2.8 -6.6 to 6.1 0.93
General health -1.9 -4.8 to 1.0 0.19
Mental component summary 1.5 -2.4 to 5.4 0.43
Data shown are differences from analysis of covariance with adjustment for baseline values with 95% CI 
and p value.
ODSS = overall disability sum score (range 0-12); a higher value indicates more limitations;
MRC = medical research council (range 0-60); a higher value indicates better muscle strength; Vigorimeter 
(range 0-160); a higher value indicates better muscle strength;
ISS = INCAT sensory sum score (range 0-20); a higher score indicates more sensory deficits;
FSS = fatigue severity scale (range 0-7); a higher score indicates more fatigue;
RHS = Rotterdam handicap scale (range 9-36); a higher score indicates less handicap;
SF-36 = Short Form (36) health survey (all separate items range 0-100); a higher scores indicate better 
health or less bodily pain.
Table 3. number of patients who reported common adverse events during the blinded phase
Adverse events
(blinded phase)
Gammagard S/D
(n = 13)
Kiovig
(n = 14)
p Value
Fatigue 10 (77%) 10 (71%) 1.0
Muscle and joint ache 8 (62%) 9 (64%) 1.0
Headache 8 (62%) 6 (43%) 0.33
Itching 5 (38%) 6 (43%) 0.82
Backache 3 (23%) 6 (43%) 0.42
Dizziness 5 (38%) 4 (29%) 0.70
Warm feeling 3 (23%) 5 (36%) 0.68
Skin rash 3 (23%) 5 (36%) 0.68
Pain at infusion area 3 (23%) 4 (29%) 1.0
Cold shivers 6 (46%) 1 (7%) 0.03
Data are number (%) and compared using c2 test or Fisher exact test.
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DISCuSSSIOn
In this study we compared the efficacy of a freeze-dried IVIg (Gammagard S/D) with a liq-
uid preparation (Kiovig) for the treatment of CIDP. We found no significant difference in 
clinical efficacy as the 95% CI for the difference of mean ODSS was within the interval -1 
to +1. Equivalence in this study was primarily based on the ability to carry out everyday 
functions measured using a disability scale (ODSS) validated in Guillain-Barré syndrome 
(GBS) and CIDP.18 No significant differences were found between the two preparations 
for all other outcome measures, including impairment scales regarding muscle strength 
and sensory symptoms, and scales measuring handicap, fatigue and quality of life.
An in vitro model of immune neuropathy found a comparable efficacy of eight dif-
ferent IVIg products.6 A different response to various IVIg brands has been described in 
a randomised trial in primary immune deficiency.27 In Kawasaki disease, retrospective 
studies reported similar as well as different responses to various brands.28, 29 An open 
study reported no clinical differences between Gammagard and Kiovig in MMN.30 As far 
as we know, no RCT has been published that evaluated differences between IVIg brands 
in neurological disorders.
The two preparations had similar AEs and there were no problems with the transition 
from one preparation to the other. Cold shivers were less common in patients treated 
with the liquid brand, which might be caused by less aggregates and excipients in 
Kiovig.15 Aseptic meningitis or neutropenia as AEs after IVIg are reported to be unrelated 
to the proprietary formulation.9, 31 A group of 30 healthy subjects showed no difference 
in tolerance to two different IVIg preparations including one liquid form.32 A retrospec-
tive study in Kawasaki disease reported more infusion-related rigors in one IVIg brand 
than in another.29
Since one IVIg preparation was more concentrated (10%), it was not possible to blind 
the nurses who administered the trial drug because the IVIg dosage as well as the dura-
tion of administering had to be equal for both preparations. Therefore, the nurses were 
trained thoroughly in maintaining the blind. By asking the patients to report which 
drug they thought they had received we could show that blinding had been successful. 
Randomisation was successful as clinical characteristics were well-balanced between 
the treatment groups.
To ensure that the CIDP patients were still IVIg dependant they had to have had at 
least moderate disability in arms or legs at baseline or following IVIg reduction during 
the previous 12 months. Most patients additionally had had at least some documented 
worsening of their CIDP within the 3-6 months before start of the study and some also 
had minor fluctuations in their clinical course after they had completed the trial. To make 
sure no IVIg refractory patients were included, only patients who initially improved after 
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IVIg, being in a stable condition using a stable maintenance dose of IVIg and who were 
considered to need IVIg treatment were included.
Previous international trials regarding the efficacy of IVIg in CIDP used treatment 
periods of ≤6 weeks.2, 20 Therefore, the double blind treatment period of four infusions, 
administered over a time period of 6-16 weeks (mean 10 weeks) due to the different 
inter-individual intervals, seems reasonable as the half-life time of IVIg is about 3 weeks. 
Since we only compared two different IVIg brands manufactured by the same pharma-
ceutical company with each other, we can only draw conclusions about the equivalence 
of these two products. Logistically, it was not feasible to compare more available brands. 
However, our results suggest that the clinical effects of a new liquid IVIg product are 
similar to a non-liquid product that has been used for several decades.13, 14
In specific situations certain brands are recommended, such as IVIg preparations that 
contain less IgA in patients with a low IgA level and preparations containing less sucrose 
in patients with kidney disease. Liquid IVIg preparations do not need reconstitution 
prior to use and can potentially reduce the infusion time, but this was not investigated 
in this study.
Although some patients may prefer certain IVIg brands, this trial suggests that this is 
unlikely to be caused by differences in clinical efficacy or tolerance between a freeze-
dried and a liquid product. As we showed no significant clinical differences between 
these two IVIg brands in their efficacy to treat CIDP it seems reasonable to assume that 
this will also apply for other diseases treated with IVIg.
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ABSTrACT
Objective: There is no consensus which treatment should be used preferentially in 
individual patients with chronic inflammatory demyelinating polyneuropathy (CIDP). 
Patients unlikely to respond to IV immunoglobulin (IVIg) could be prescribed corticoste-
roids first to avoid high cost and a delayed treatment response. We investigated which 
factors determined a response to IVIg.
methods: Treatment-naïve patients with CIDP initially treated with at least one full 
course of IVIg (2 g/kg) at one of two neuromuscular disease centers were included. 
Patients fulfilled the European Federation of Neurological Societies/Peripheral Nerve 
Society clinical criteria for CIDP. Significant improvement following IVIg was defined 
as an improvement (≥1 grade) on the modified Rankin scale. Difference in weakness 
between arms and legs was defined as ≥ 2 grades on the Medical Research Council scale 
between ankle dorsiflexion and wrist extension. Clinical predictors with a p-value <0.15 
in univariate analysis were analysed in multivariate logistic regression.
results: Of a total of 281 patients, 214 patients (76%) improved. In univariate analysis, 
the presence of pain, other autoimmune disease, difference in weakness between arms 
and legs, and a myelin-associated glycoprotein negative IgM monoclonal gammopathy 
of undetermined significance were associated with no response to IVIg. In multivariate 
analysis no pain (p = 0.018) and no difference in weakness between arms and legs (p = 
0.048) were independently associated with IVIg response. Of IVIg non-responders, 66% 
improved with plasma exchange and 58% with corticosteroids.
Conclusion: IVIg is a very effective first-line treatment. Patients with CIDP presenting 
with pain or a difference in weakness between arms and legs are less likely to respond 
to IVIg.
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InTrODuCTIOn
In randomised controlled trials, intravenous immunoglobulin (IVIg), plasma exchange 
(PE) and corticosteroids have been shown to be beneficial in the treatment of chronic 
inflammatory demyelinating polyneuropathy (CIDP).1-7 The long-term benefits and 
safety of IVIg in CIDP has been demonstrated in a large randomised placebo-controlled 
trial in CIDP.4 Some patients improve more after one of the effective treatments than 
after another and some can even fail to show a response to one or more of these proven 
effective treatments.8-11
There is no consensus on which is the best treatment for individual cases of CIDP.12 
In order to give the most appropriate treatment in the earliest phase of the disease it 
would be helpful to identify patients who are more likely to respond to one particular 
treatment.8,10 Corticosteroids and IVIg differ in terms of cost, speed of action and adverse 
events.13,14 Although expensive, IVIg is often considered a treatment of first choice be-
cause of its rapid onset of action compared to the usually slower response to steroids, 
and because it has a better long-term adverse event profile.9,15-18 Sometimes only one 
course of IVIg is sufficient to induce a sustained remission.12 Corticosteroids are usually 
prescribed for a lengthy period and require a slow tapering over several months, and 
thus may be accompanied by serious side effects.15,19 During that extended period it is 
likely that some patients may still be treated with corticosteroids although they may 
already have reached remission.17 For a yet unknown reason, not all patients improve 
after IVIg and a delay in starting effective treatment could result in secondary axonal 
damage that is potentially resistant to treatment.9 To avoid high cost and to minimise 
the probability of secondary axonal damage due to the prescription of an ineffective 
treatment, standard dose steroids or high-dose pulse corticosteroids could be given as 
a first-line treatment to patients unlikely to respond to IVIg if it can be proven that they 
are better off with corticosteroids.19-20 PE is generally considered after the patients fail to 
respond to IVIg and steroid treatment. PE is relatively inconvenient as special equipment 
is needed, good venous access is required and there is a risk of adverse events. We have 
investigated which clinical as well as neurophysiological factors might be associated 
with a good response to IVIg in a previous single-centre cohort of 52 patients with CIDP.1
The aim of this study was to investigate in a larger group of treatment-naïve patients 
with CIDP which clinical factors are associated with a good response to IVIg, to be able 
to optimise and personalise treatment at onset.
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Patients
In this retrospective study we combined data from medical records of patients with CIDP 
from two large university hospitals (Erasmus MC, University Medical Centre Rotterdam, 
the Netherlands and London Health Sciences Centre London Ontario, Canada). Patients 
were diagnosed as CIDP and followed over time by a consultant neurologist (AFH, PAvD, 
MV, SLV) experienced in neuromuscular diseases, and treated with IVIg between 1980 
and 2011 (N = 152 Erasmus MC; N = 129 London Health Sciences Centre). All patients 
fulfilled the European Federation of Neurological Societies/Peripheral Nerve Society 
clinical diagnostic criteria for typical or atypical (still considered CIDP but with differ-
ent features) CIDP.15 Twenty-five of these patients have been described previously.1 Not 
all these patients were included in the current study mainly because they were not all 
treatment-naïve or they were diagnosed differently over time. Patients with recurrent 
Guillain-Barré syndrome (GBS) or GBS patients with treatment-related fluctuations were 
excluded.21 Patients with multifocal motor neuropathy (MMN) as well as patients with 
any other chronic acquired or hereditary neuropathy were excluded. Patients with an 
IgG or IgM monoclonal gammopathy of undetermined significance (MGUS) were only 
included when they had a clinical course fully consistent with CIDP. Patients with an IgM 
MGUS who had antibodies against myelin-associated glycoprotein were excluded.
Treatment and response
All patients were treated with IVIg as a first treatment modality and completed at least 
one full course of IVIg (2 g/kg over 2-5 days). Before IVIg was available some of the 
patients initially received fresh frozen plasma (FFP).1,22 Because these patients (N = 15) 
were treated with IVIg thereafter and showed the same response to FFP as to IVIg it was 
unlikely that this would have any effect on the results, therefore, they were included 
in the current study. The 281 patients were followed with a mean duration of 5.2 years 
(median 3.8 years, range 20 days-28 years).
Clinically important improvement following treatment was defined as an improve-
ment (decrease) of ≥ 1 grade on the modified Rankin scale (range 0-5).23 When it was 
unclear whether a patient responded significantly, a second course of IVIg was given. 
When patients required maintenance IVIg treatment, regular attempts to reduce the 
dosage were performed to check whether patients were in remission or were still IVIg 
dependent.
To investigate the response rate to corticosteroids or PE in patients who failed to 
respond to IVIg, we only analysed data from patients treated with sufficiently large dos-
ages of steroids as monotherapy (e.g. prednisolone ≥ 60 grams a day for at least 6 weeks) 
or patients who received at least five PE sessions as monotherapy.
113
Predicting IVIg response in CIDP
Ch
ap
te
r 3
.3
Definitions of patient characteristics
Subacute CIDP was defined as an onset phase of 4-8 weeks. All patients with a subacute 
onset included in this study subsequently had a chronic progressive or relapsing course 
requiring long-term (IVIg) treatment. Asymmetrical weakness was defined as a differ-
ence ≥ 2 grades on the Medical Research Council (MRC) scale in at least one muscle pair 
(shoulder abduction, elbow flexion, wrist extension, hip flexion, knee extension, ankle 
dorsiflexion). A difference in weakness between arms and legs was defined as a differ-
ence of ≥ 2 grades on the MRC scale between ankle dorsiflexion and wrist extension. 
The level of the modified Rankin scale at nadir was defined as the worst score prior to 
or after start of treatment. Pure motor CIDP was defined as CIDP without sensory signs 
and abnormalities in sensory nerve conduction studies. Pure sensory CIDP was defined 
as pure sensory symptoms and signs at presentation, nerve conduction studies in these 
patients, however, could show some minor abnormalities in motor nerve studies and 
muscle weakness could appear subsequently during follow-up. A clinical remission was 
defined as a modified Rankin score 0-1 after discontinuation of treatment. Children were 
defined as <18 years old when IVIg was started. Medical records and letters were re-
viewed for the occurrence of (other) autoimmune disorders. Since patients were treated 
by the same consultant neurologist (AFH, PAvD, MV, SLV) from one of the two university 
hospitals, we could screen the medical records for the occurrence of pain and whether 
patients were treated with analgaesics. When the presence of pain was not reported 
and when analgaesics were not used we assumed that pain was not present. We did 
not analyse EMG findings because these examinations were not always performed in a 
standardised fashion in this two-centre study.12, 24-25
Statistical analysis
The literature was screened for important known factors that might be associated with 
a response to IVIg. These factors that were present in our data as well as other variables 
that in our opinion seemed relevant to IVIg response were analysed. To compare relative 
differences between IVIg responders and non-responders c2 test, Fisher’s exact test, or 
Mann-Whitney U test were used. For the categorical variables polyneuropathy type and 
weakness distribution the c2 test for trend was used, which gives the overall p value. 
Predictors that had a p value of < 0.15 in univariate analysis were selected to be analysed 
in multivariate logistic regression. This level of 0.15 was chosen to improve the power 
to identify important predictors.26 Multivariate logistic regression was used to identify 
which factors were associated with a good response to IVIg. Analysis was performed 
using SPSS V.20.0. A two-sided p value < 0.05 was regarded significant. The Hosmer-
Lemeshow test was used to check for goodness-of-fit.
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Patient characteristics
A total of 281 treatment-naïve patients with CIDP initially treated with at least one full 
course of IVIg (2 g/kg) were included. Main clinical characteristics of these patients are 
shown in Table 1. Thirty-five patients (13%) were known to have a concurrent autoim-
mune or immune-mediated disorder (Table 2).
Table 1. Clinical characteristics of IVIg responders and non-responders
Total (n = 281)
responsive to IVIg
p ValueYes (n = 214) No (n = 67)
Patient characteristics
Male 179 (64%) 133 (62%) 46 (69%) 0.33
Children 13 (5%) 10 (5%) 3 (5%) 0.95
Progression of weakness* 267 (95%) 205 (96%) 62 (93%) 0.33
Other autoimmune disease^ 35 (13%) 22 (10%) 13 (19%) 0.048
Pain^ 77 (27%) 50 (23%) 27 (40%) 0.007
Subacute onset 29 (10%) 25 (12%) 4 (6%) 0.18
Polyneuropathy type
Pure motor 37 (13%) 28 (13%) 9 (13%)
Pure sensory 29 (10%) 22 (10%) 7 (10%)
Sensory-motor 215 (77%) 164 (77%) 51 (76%) 0.93#
Areflexia legs 235 (84%) 175 (83%) 66 (90%) 0.17
Areflexia arms 209 (75%) 155 (73%) 54 (81%) 0.22
Weakness symmetrical 251 (94%) 190 (94%) 61 (94%) 0.94
Weakness distribution
Legs = arms 170 (62%) 140 (68%) 30 (46%)
Legs > arms 89 (33%) 56 (27%) 33 (50%) 0.002#
Legs < arms 14 (5%) 11 (5%) 3 (5%)
IVIg treatment
Time symptoms to first treatment, mo 4 (1-11) 3 (1-10) 4 (2-13) 0.75
Age start treatment, y 52 (39-62) 49 (39-61) 53 (42-65) 0.66
laboratory
IgG MGUS 14 (5%) 13 (7%) 1 (2%) 0.131
IgM MGUS (anti-MAG negative) 7 (3%) 3 (2%) 4 (6%) 0.036
Data are numbers (%) and compared using c2 test, Fisher’s exact test or c2 test for trend, or median (IQR) 
and compared using Mann-Whitney U test.
* In the months prior to IVIg start.
^ These variables were assumed to be absent when they were not reported in medical files.
# Overall p-value.
IVIg = intravenous immunoglobulin;
MGUS = monoclonal gammopathy of undetermined significance;
MAG = myelin-associated glycoprotein.
115
Predicting IVIg response in CIDP
Ch
ap
te
r 3
.3
Treatment response
The response rate to IVIg was 76% (214/281). The response to IVIg was not significantly 
different in children than in adults (76% vs. 77%, p = 0.95). Most patients who failed to 
improve with IVIg received subsequent treatment: 66% improved with PE and 58% with 
corticosteroids (Figure 1). Of the IVIg non-responders who were treated with at least 
one other treatment modality, 79% responded either after PE, corticosteroids or both. 
Only three patients did not respond to any of the three treatments. In 11 out of 37 pure 
motor CIDP patients, steroids were given with a response rate of 46% (5/11). From 86 
treatment-naïve patients who were IVIg responsive and reached a documented clinical 
remission, 14 (16%) needed only one IVIg course.
Clinical characteristics associated with IVIg response
The age of the patients when IVIg was started, or the time from symptom onset to IVIg 
start, were not associated with treatment response (Table 1). Furthermore, the presence 
of a pure motor or sensory CIDP subtype was also unrelated to the response to IVIg. In 
univariate analysis no difference in weakness between arms and legs, no other autoim-
mune disease, no MGUS and the absence of pain were all positively associated with IVIg 
response. In multivariate analysis, no difference in weakness between arms and legs, 
and the absence of pain were both independently associated with IVIg response (Table 
3). In multivariate analysis, the presence of another autoimmune disease or MGUS were 
not statistically significant associated with IVIg response when adjusted for the other 
Table 2. Presence of other autoimmune disease (n = 35)
Autoimmune disease number of patients
Rheumatoid arthritis 6
Thyroid gland disorder 5
Insulin-dependent diabetes mellitus (IDDM) 5
Inflammatory bowel disease 3
Interstitial nephritis 4
Systemic lupus erythematosus 2
Sjögren’s syndrome 1
Systemic sclerosis 1
Psoriasis 1
Asthma 1
Immune thrombocytopenic purpura 1
Crohn’s disease + IDDM + thyroid gland disorder 1
Multiple sclerosis + thyroid gland disorder 1
IDDM + thyroid gland disorder 1
Ulcerative colitis + thyroid gland disorder 1
Bechterew + psoriasis 1
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variables. This model fitted the data well based on the Hosmer-Lemeshow statistic (p 
= 0.68). The presence of pain or a difference in weakness between arms and legs were 
not statistically significant associated with a treatment response to corticosteroids. An 
overview of factors that have been reported to be associated with a response to IVIg in 
CIDP in the literature is given in Table 4.
Adverse events
In 10 patients IVIg was discontinued due to adverse events. Although these were rea-
sons to stop treatment, most were relatively minor, such as headache. Three of these 
patients had severe adverse events; one developed a Stevens-Johnson syndrome and 
two acquired haemolytic anaemia. None developed severe life-threatening adverse 
events such as an anaphylactic shock.
1st treatment 
2nd treatment
3rd treatment
+ response 214 pts, 76% - response 67 pts, 24% 
+ response 20 pts, 58% - response 14 pts, 42% + response 16 pts, 66% - response 8 pts, 34% 
+ response 3 pts, 75% - response 1 pt, 25% + response 6 pts, 75% - response 2 pts, 25% 
Steroids 34 pts PE 24 pts 
PE 4 pts Steroids 8 pts 
IVIg 281 pts 
figure 1. Treatment response in chronic inflammatory demyelinating polyradiculoneuropathy pa-
tients initially treated with intravenous immunoglobulin
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Table 3. multivariate logistic regression of a good response to IVIg (n = 256)
Or 95% CI p Value
Pain
No (ref.) 1.0 0.018
Yes 0.46 0.24 to 0.88
Weakness distribution
Arms = legs (ref.) 1.0 0.048#
Legs > arms 0.46 0.24 to 0.85
Legs < arms 0.72 0.18 to 2.93
Other autoimmune disease
No (ref.) 1.0 0.10
Yes 0.50 0.23 to 1.13
IgG mGuS
No (ref.) 1.0 0.22
Yes 3.73 0.46 to 30.09
Igm mGuS (anti-mAG negative)
No (ref.) 1.0 0.06
Yes 0.21 0.04 to 1.04
# Overall p value.
IVIg = intravenous immunoglobulin; MGUS = monoclonal gammopathy of undetermined significance.; 
MAG = myelin-associated glycoprotein.
Table 4. factors associated with a response to IVIg in CIDP: a review of the literature
Author year number of
patients
number of 
treatment-
naïve 
patients
response
rate to
IVIg (%)
Associated with a good response to 
IVIg
van Doorn, et al. 1 1991 52 not stated 62 Disease duration < 1 y
Progression of weakness
Absence of discrepancy between 
weakness of arms and legs
Areflexia arms
Slowed NCV of the motor median nerve
Choudhary, et al. 11 1995 22 not stated 64 Female gender
Hahn, et al.2 1996 30 not stated 63 Acute relapse
Disease duration < 1 y
Iijima, et al. 9 2005 312 283 64 Female gender
Shorter disease duration
Fast progression of symptoms
No axonal dysfunction
Tackenberg, et al. 18 2007 76 76 82 Monophasic or relapsing-remitting form
> twofold CSF protein increase
Iijima, et al. 42 2009 100 100 72 TAG-1 gene polymorphism
Querol, et al. 43 2014 53 not stated 74 No anti-NF155 antibodies
CIDP = chronic inflammatory demyelinating polyradiculoneuropathy; CSF = cerebrospinal fluid; IVIg = in-
travenous immunoglobulin; NCV = nerve conduction velocity; TAG-1 = transient axonal glycoprotein-1.
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DISCuSSIOn
The high response rate to IVIg of 76% in our large cohort was similar to what has been 
reported before.3,27-28 We used the modified Rankin scale to assess treatment response. 
This scale is easy to use and the cut-off point of ≥ 1 point has often been used for clini-
cally relevant improvement in CIDP.9-11,18,24,29 A disadvantage of this scale is, however, that 
it is probably too insensitive to show small but clinically meaningful functional improve-
ments. Nonetheless, the percentage of patients who improved is still high and exceeds 
the improvement rate found in the largest RCT conducted in patients with CIDP.4 The 
Peripheral Neuropathy outcome measures Standardisation (PeriNomS) study recently 
investigated which assessment scale is the most appropriate to use in future studies in 
inflammatory neuropathies.30 Because we were mainly interested in large clinical mean-
ingful differences in this retrospective study, we still consider that using the modified 
Rankin scale gives relevant information.
Clinical characteristics associated with IVIg responsiveness have been investigated in 
a larger group (N = 312) of IVIg treated patients with CIDP with a 64% response-rate.9 
However, only 283 of these patients were treatment-naïve (a similar number as our co-
hort), which may explain the somewhat lower response-rate.9 Our current study showed 
that the absence of a discrepancy in upper and lower limb weakness is associated with 
IVIg responsiveness, which has been found previously in a small cohort of patients.1 Pain 
has been reported to be prominent in 42% of CIDP patients, but has not been described 
as a risk factor for IVIg non-responsiveness before and should receive more attention in 
future studies.29
Thirteen per cent of the patients in our study were known to have a concurrent auto-
immune disorder in addition to CIDP, a similar percentage has recently been reported 
in the literature in patients with MMN and in a survey on GBS and CIDP.31,32 The overall 
prevalence of autoimmune disorders reported in the general population is 5%, suggest-
ing that patients with CIDP have an increased risk of autoimmune disease and CIDP 
might be the result of an aberrant immune response.31
A higher response rate in children compared to adults, as has been suggested previ-
ously, was not found in our cohort.33 Furthermore, age, sex and disease duration were 
not associated with IVIg responsiveness in our cohort.1,9,11 Axonal dysfunction of periph-
eral nerves has been reported to be associated with a failure of IVIg response.9 Whether 
nerve conduction studies are useful in the prediction of treatment response in CIDP 
remains unclear.27,34-35
In a recent study of 86 non-treatment-naïve patients with CIDP treated with IVIg, the 
only variable that was associated with reaching remission (asymptomatic without treat-
ment) at long term was a better response during the first 6 months.36 Unfortunately, 
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some patients in this study had been treated simultaneously with other immunosup-
pressive agents besides IVIg.36
Our study confirms that the (long term) adverse events of IVIg are minor and rarely a 
reason to discontinue treatment.9,37 A recent trial over a treatment period of 6 months 
found that IVIg treatment was less frequently discontinued than intravenous methyl-
prednisolone for reasons such as inefficacy, adverse events or intolerance.20
Our study indicates a higher response rate to steroids or PE prescribed as a second 
or even third treatment modality in patients unresponsive to IVIg than reported previ-
ously.29 Therefore, treatment with corticosteroids or PE should be offered to patients 
with CIDP who do not respond satisfactorily to IVIg, knowing that there is still a good 
chance of improvement even with a third treatment modality.15 Why some patients only 
respond to a particular treatment remains unknown and requires further investigation. 
Although 15% of patients with CIDP are reported to be unresponsive to all three treat-
ment modalities, we could only identify three patients (1%) who were unresponsive to 
all three treatments in our study.15 It has been reported that patients with CIDP who 
were unresponsive to steroid treatment often appeared to have been given an alternate 
diagnosis during follow-up.38 Clinical data from the three patients in our cohort that 
were unresponsive to all three treatments were reviewed thoroughly in order to check 
whether we could find any evidence for an alternative diagnosis during the long-term 
follow-up. However, no diagnosis other than CIDP could be established. All had clinical 
features of CIDP and a raised CSF protein level, and either clear demyelinating abnor-
malities on EMG, sural nerve biopsy findings compatible with CIDP, or a spontaneous 
remission during follow-up that strongly indicates CIDP.
We investigated a large group of patients with CIDP who were treated with IVIg as a 
first treatment modality and were followed for a long period of time. It is possible that 
some patients with CIDP who were thought to have had a therapeutically induced remis-
sion had, in fact, a spontaneous remission, making it more difficult to judge treatment 
efficacy and to identify predictors associated with an IVIg response. Therefore, a large 
patient cohort, such as ours, is needed to identify important variables associated with 
treatment effect.28,39 An important limitation of this study is its retrospective and open 
nature. Thereby, some items were not assessed systematically, such as the presence or 
absence of other autoimmune diseases or pain, and this could have lowered our chance 
of finding factors that are associated with a treatment response. A major limitation is the 
fact that the presence, severity and type of pain was not investigated in a standardised 
manner using existing scales. Sixteen per cent of our patients needed only one IVIg 
course to reach a clinical remission which is in line with the 15-30% reported in the 
literature.15 Although no significant difference in remission rate was found in patients 
with CIDP treated with pulsed high-dose dexamethasone compared to prednisolone, 
intravenous methylprednisolone seemed to induce more long-term remissions than 
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IVIg.19-20 Most of the IVIg non-responders from our cohort received more than one 
IVIg course. A study suggested that at least two IVIg courses over a period of 6 weeks 
may sometimes be required to identify an initial improvement.39 Many patients from 
that cohort were different from ours as there was often a long delay between onset of 
symptoms and initiation of IVIg treatment, all patients received a second IVIg dosage 
after 3 weeks, and many already had fixed axonal deficits.39 In our cohort, the diagnosis 
of CIDP was always established by a senior neurologist experienced in neuromuscular 
diseases possibly explaining the shorter treatment delay and the higher response rate 
to IVIg.39 Since we already observed a relatively high treatment response it is unlikely 
that we missed a substantial number of patients who would have only responded after 
two or more IVIg courses. Recent data suggest considering an even longer treatment 
period with IVIg of more than 6 weeks before declaring a patient non-responsive.40 Yet if 
one observes only a limited improvement with IVIg, one needs to explore the possibility 
of fixed neurological deficits caused by axonal degeneration as these in general do not 
improve with any treatment.
The ability to predict which patients are more likely to respond to IVIg will help physi-
cians to choose the optimal initial treatment. This may prevent unnecessary delay of 
effective therapy, reduce cost and limit or avoid side effects. Early optimal and person-
alised treatment is not only needed to improve disability but is important to prevent 
permanent disability from on-going demyelination and secondary axonal loss.39,41 As we 
showed, IVIg is a very effective treatment for CIDP and the short-term and long-term side 
effects are generally minor; but it is expensive and unfortunately most patients need 
long-term IVIg treatment. For patients with CIDP who do not suffer from pain or show a 
clear difference in weakness between arms and legs, IVIg is a good first treatment choice 
given its efficacy, fast speed of action and low side effect profile. By contrast, patients 
with CIDP with prominent pain or a clear difference in weakness between arms and legs 
are less likely to respond to IVIg. In view of the high cost of IVIg, to prevent unnecessary 
delay in improvement and because high-dose pulse steroid treatment might induce 
remission more often,20 it should be further investigated whether these patients are 
better off being initially treated with corticosteroids.
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ABSTrACT
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) patients treated 
with intravenous immunoglobulin (IVIg) usually start with a standard dosage of 2 g/
kg body weight. Only a minority of patients have a sustained improvement, and most 
require ongoing maintenance treatment. Preferred IVIg regimens, however, vary consid-
erably between doctors and at present it is unknown which is optimal. As there are also 
large differences in IVIg dosage and interval requirements between patients, optimal 
IVIg maintenance treatment of CIDP is even more complex. The lack of evidence-based 
guidelines on how IVIg maintenance treatment should be administered may potentially 
lead to under- or overtreatment of this expensive therapy. We provide an overview of 
published practical IVIg maintenance treatment regimens, IVIg maintenance schedules 
used in randomised controlled trials and one based upon our own long-term experience 
on how this treatment could be given in CIDP.
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InTrODuCTIOn
In 1980, 13 children with idiopathic thrombocytopenia were treated successfully with 
2 g/kg of IV immunoglobulin (IVIg).1 In 1985, the first report was published on a group 
of patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) 
that were being treated with infusions of fresh-frozen plasma and later with IVIg in 
the Erasmus MC.2 Improvements in these patients were seen within 8 days after start 
of treatment with IVIg.2 The first randomised controlled trial (RCT) showing that IVIg is 
effective compared to placebo came from a small cross-over trial in seven CIDP patients 
who previously improved after IVIg.3 The largest RCT showing that IVIg is effective in 
CIDP is the IVIg for the treatment of CIDP (ICE) trial.4 Next to IVIg, both corticosteroids 
and plasma exchange are proven to be effective in CIDP.5-7 We, as well as others, found 
that about 15% of CIDP patients only need one or two courses of IVIg to achieve a sus-
tained improvement, but most need treatment for many years.8, 9 Since the first reports, 
CIDP patients have been treated with IVIg for over 30 years now.2, 3 Its efficacy on a 
somewhat longer term has also been confirmed in the ICE trial.4 Considering its long-
term use and its reported success rate of around 54-76% it is remarkable that hardly 
any prospective studies have been published on how maintenance treatment with IVIg 
should be given.4, 10-12 An optimal treatment regimen is needed not only to improve and 
maintain muscle strength, but also to prevent permanent disability due to ongoing de-
myelination and secondary axonal loss.13 Furthermore, optimal use of IVIg is important 
to avoid overtreatment.14 This paper provides an overview on published information 
about IVIg maintenance treatment in CIDP and our experience at the Erasmus MC with 
IVIg maintenance treatment in CIDP over the years.
TreATmenT Of CIDP WITH IVIG
Current practice of IVIg maintenance treatment in CIDP
The half-life of IVIg ranges from 18-33 days, and most of the variation can probably be 
explained by individual differences in the speed of diffusion to the extravascular space 
and concentration-dependent catabolism.15, 16 The efficacy of IVIg can be determined 
quickly after infusion, most often within 1-2 weeks after start of treatment.3, 9 In some 
patients, however, more than one treatment course over a period of 6 weeks (2 g/kg 
followed by 1g/kg after 3 weeks) may be required to identify clear objective clinical 
improvement.17 In our experience, one full course of IVIg (2 g/kg, divided over 5 days) 
is usually sufficient to determine whether IVIg is effective in typical CIDP patients.9, 10, 18 
In case of doubt, a course of IVIg can be repeated to be sure that this treatment results 
in an improvement or not. Empirical evidence has shown that attempts to lengthen the 
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treatment interval between IVIg infusions in CIDP patients are unsuccessful most of the 
time. 18, 19 The dosage and frequency of maintenance IVIg treatment in CIDP varies per 
patient, usually ranging from 0.4 to 1.2 g/kg once every 2-6 weeks.20, 21 This variation 
is likely to be caused by differences in IVIg catabolism between patients but may also 
be due to variations in disease activity.22 A similar large variation in IVIg dosage level 
requirement and frequency has been reported in multifocal motor neuropathy (MMN) 
and primary immunodeficiencies. 23, 24 Therefore, the optimum dosage and frequency of 
maintenance IVIg must be individually established for every CIDP patient.8, 11, 13, 19 How 
this can best be achieved is currently unclear and is done by trial and error. 15, 25
Traditionally, the initial IVIg loading dose and to some extent maintenance treatment 
is based on an arbitrary and simplistic “dose per kg body weight” principle. Several stud-
ies have shown evidence that this principle is inappropriate.19, 26 Individually established 
effective dosages per infusion do not correlate with body weight or body mass index 
challenging the current practice of weight-dependant dosage adaptations.19, 22, 26, 27 It 
has been suggested that ideal or actual (calculated/adjusted) body weight should be 
used instead of (measured) body weight.26 The amount of muscle strength, disability or 
sensory disturbances does not seem to determine the dosage of IVIg required.19, 22, 28 In 
clinical practice, however, dosages and intervals are individualised usually based upon 
clinical response and practical reasons.29 Randomised controlled trials comparing differ-
ent dosage schedules are still urgently needed.12, 15, 30-34
A small study regarding IVIg maintenance treatment in CIDP reported a large vari-
ability in “lowest” effective dose, although no formal dose reduction schedules were 
used and in almost half of the patients’ dose reductions were performed due to the 
subjective impressions of patients themselves instead of using objective assessment 
scale parameters.19 An example of a practical treatment regimen to optimise the use of 
IVIg in CIDP has recently been published.11 In this schedule, one standard course of IVIg 
(2 g/kg) is given and the response is assessed 3 and 6 weeks thereafter.11 If the patients’ 
situation has not “normalised” six weeks after the initial course, another standard course 
will be given.11 Again the response will be assessed after 3 weeks and the period of 
time in which deterioration develops thereafter will be used to set the individual dosing 
interval.11 Patients are stabilised with two standard IVIg courses according to their es-
tablished dosing interval.11 The dose is then reduced with 20% per course until a relapse 
occurs.11 Patients are then maintained at the dose prior to the relapse.11 Although this 
approach has not been the subject of an RCT, it is a straight forward and efficient way to 
provide a guideline in how to personalise IVIg treatment in CIDP. The mean dosing inter-
val was 4 weeks with a broad range of 0.5-10 weeks. Although, considering the half-life 
of IVIg, it is hard to understand that in some patients this algorithm will set an interval 
of 10 weeks. This study further underlines that IVIg treatment should be individualised.11 
It is remarkable that the mean dosage was quite high (1.4 g/kg) explaining why in most 
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patients this IVIg dosage had to be infused over more than 1 day.11 In the Erasmus MC, 
we initially treat CIDP patients with a loading dose of IVIg of 2 g/kg (usually over 5 days) 
and when a patient improves and subsequently deteriorates, another IVIg dosage of 
0.4-2 g/kg over 1-5 days is given depending on the severity of disability and speed of 
deterioration. When a patient does not respond at all after at least 2 dosages of 2 g/kg 
of IVIg it is concluded that the patient is an IVIg non-responder and either corticoste-
roids or plasma exchange should be given. When a patient improves and subsequently 
deteriorates at least two times after each course of IVIg, we usually start maintenance 
IVIg treatment with a dosage of 0.4 g/kg every 3-4 weeks before we increase the dose 
until a maximal response is obtained. It is known that patients with CIDP may show 
some day-to-day variation in clinical performance in between IVIg infusions.12, 35 The 
GRIPPER study (ClinicalTrials.gov NCT02414490) is currently investigating wear-off or 
other treatment-related fluctuations by measuring daily grip strength in CIDP patients 
on IVIg.36 When clear end-of-dose effects are observed, we usually shorten the infusion 
frequency, especially when the IVIg dosage is already relatively high, for example, >40 g 
IVIg per infusion.12 If a clear fluctuation occurs adding an extra dose in between the nor-
mal infusions could be considered. When a relatively severe level of weakness remains 
despite improvement after IVIg, we usually give a higher dose of IVIg.21, 22 This approach 
allows us to administer infusions of maximum 1 g/kg on a single day, avoiding infusion 
over two consecutive days. An alternative approach would be to start with a high dose 
of IVIg and then try to lower the dosage to find the lowest effective dose.19, 37 The strat-
egy to find the lowest effective dose in MMN patients resulted in under-treatment and 
therefore finding the highest effective dose with the shortest interval might be a better 
approach.12, 38 In the ICE-study a standard, and relatively high, IVIg maintenance dose of 
1 g/kg every 3 weeks was used for CIDP patients during a period of 24 weeks in the first 
phase and another 24 weeks in the extension phase.4
Figure 1 gives an overview of three different ways to administer IVIg maintenance 
treatment in CIDP: the algorithm of Lunn, et al.11, the ICE trial treatment schedule4, and 
the way we usually treat CIDP patients in the Erasmus MC.
It is important that improvement after start of IVIg as well as IVIg dependency is 
proven objectively using proper assessment scales.39 IVIg dependency should be proven 
on a regular basis, for example, at least once every 6 months via dose reduction to avoid 
overtreatment.14 It is unlikely that the response to treatment of IVIg is dependent on 
the brand of IVIg used, but side effects may vary between different brands.28, 40, 41 Table 1 
gives a short guideline regarding IVIg treatment in CIDP.
Some concerns have arisen whether IVIg leads to treatment dependency.42, 43 Three 
factors appear to support the idea that IVIg treatment does not create treatment de-
pendency. First, some patients require only one or two IVIg courses to recover. Second, 
remission occurs in a substantial proportion of patients after treatment with IVIg over 
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several years. Third, patients do not need a continuous increase in dosage with pro-
longed treatment with IVIg.10, 44 Investigation if IVIg treatment leads to treatment depen-
dency is difficult because reasons why CIDP patients go into remission and predictors of 
remission are unfortunately still unknown. 24 In our experience the median time on IVIg 
treatment before it successfully can be stopped is about five years.
High peaks or high troughs?
Immunoglobulin G (IgG) is the major component of IVIg and is probably responsible 
for most of the immunomodulating effects.45 In Guillain-Barré syndrome (GBS), we have 
reported that a higher increase in serum IgG 2 weeks after IVIg treatment was associated 
with a better outcome.46 This study suggested that an increase in IgG above a certain 
threshold level is needed to gain a substantial effect of IVIg in GBS.46 It is also reported 
that the serum IgG level needs to increase above a certain threshold level in CIDP pa-
tients treated with IVIg in order to be effective.47
It is currently not known how to reach optimal immunomodulation in CIDP; whether 
keeping the plasma level of IgG high for prolonged periods is better than spiking the 
immune system intermittently with high doses of IVIg.48 It is known that the catabolism 
of IgG is proportional to its serum concentration. 49, 50 When the plasma IgG concen-
Table 1. Guideline for IVIg treatment in CIDP
Initial IVIg loading dose Standard: 2 g/kg (2-5 days)
Number of days depending on age and body weight. 
Consider lower IVIg dosages in case of impaired renal 
function
No improvement after first IVIg course Check diagnosis
Repeat 2 g/kg (2-5 days)
No improvement after second IVIg course Check diagnosis
Start corticosteroids, in case of pure motor CIDP give 
plasma exchange
Improvement followed by deterioration
(first time)
Repeat IVIg treatment usually 0.4-2 g/kg, depending on 
severity and rate of deterioration
Improvement followed by deterioration (second 
time)
Start maintenance treatment:
either fixed (1g/kg once every 3 weeks) or individualised*
Suboptimal improvement Increase the dose (or shorten the interval)
Clear end-of-dose effects Shorten the interval
Deterioration during period of relative stable 
course of disease
Consider giving an “extra dose of IVIg” (e.g. 0.4 g/kg) in 
between the usual interval
Stable for 6 months Check IVIg dependency#
CIDP, chronic inflammatory demyelinating polyradiculoneuropathy; IVIg, intravenous immunoglobulin;
*Using either the “start low and increase till maximum effect” or the “start high and decrease till minimum 
effective dose” approach, usually 0.4-1.0 g/kg once every 2-6 weeks.
#By lowering the dose (or lengthen the interval).
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tration reaches 200% of its normal value, the half-life of IgG decreases from 21 to 12 
days.51 A high peak dose may therefore result in greater catabolism of IgG which might 
be avoided by giving smaller doses more often. 52 Very high peak levels, however, may 
not be needed in either the induction or maintenance treatment of CIDP or MMN.19, 53-55 
Shortening the interval between IVIg infusions in CIDP results in a higher IgG trough level 
which appears to correspond to clinical efficacy.50, 56 Subcutaneous immunoglobulin 
therapy (SCIg) has been shown to be effective as maintenance treatment of CIDP.57 It is 
administered at lower dosages and at more frequent intervals compared to IVIg, result-
ing in higher trough and more stable serum IgG levels.50, 58, 59 The most frequently used 
dosage when switching from IVIG to SCIg is 1:1, although some studies suggest that a 
higher dosage is needed.53 In general dosages of up to 50 g per week are tolerated, using 
2-3 weekly injections.53 Two trials comparing SCIg to IVIg in CIDP or MMN suggested 
a somewhat better effect of SCIg on muscle strength than IVIg which might be the 
result of the more stable IgG levels due to the more frequent infusions.59-61 A recent trial 
comparing the efficacy of IVIg to SCIg in treatment-naïve CIDP patients reported similar 
effects on muscle strength, with an earlier maximum effect after IVIg treatment.62 The 
disease duration of CIDP before enrolment although was much longer in the IVIg treated 
group.62 Results of this study suggest that a loading dose of IVIg might not be needed 
to initiate a therapeutic response.62 It is nowadays a question whether more patients 
should be shifted from IVIg to SCIg for health-economic reasons or convenience.53
In primary immunodeficiencies, serum IgG levels are used to optimise the dosage 
and interval of the IVIg maintenance treatment.63 At present it is unknown if serum IgG 
levels can also be used as a reliable biomarker in CIDP. The most likely purpose of IVIg 
maintenance treatment in CIDP is to maintain a constant serum IgG level above a certain 
threshold in order to control the inflammatory process and to reach a stable clinical 
situation.22, 47, 64 Relapses are reported to correspond with a drop in serum IgG level.47 It 
has been speculated that both patients with CIDP or immunodeficiencies being treated 
with regular immunoglobulin treatment prefer regimens with shorter IVIg intervals due 
to the fact that they often experience wear-off effects before their next dose.29 Consider-
ing its half-life it is not surprising that the effect of IVIg is not always maintained over a 
3-4 week interval.35, 61 A recent study on patients who were referred to a neuromuscular 
clinic with the diagnosis of refractory CIDP showed that the most frequent interven-
tion required for a response to IVIg was increasing the frequency of IVIg maintenance 
treatment from once every 4 weeks to once every 2 weeks.65 Another report regarding 
patients who were considered to be IVIg unresponsive were in fact patients who showed 
a very short response to IVIg and were in need of IVIg maintenance treatment with a 
very short treatment interval.47 This indicates that some CIDP patients misclassified as 
non-responders to IVIg might in fact be undertreated.
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How to optimise or individualise IVIg treatment?
Currently there are no biomarkers to predict disease activity and to avoid over- as well as 
under-treatment in CIDP. Serum IgG levels may be helpful in finding the best dose and 
interval. Clinically stable patients with CIDP on fixed IVIg maintenance treatment reach 
a certain steady-state IgG level, which confirms the fact that patients do not need higher 
(or lower) dosages over time in long-term IVIg treatment.22 Ideally, one would be able 
to predict individual pharmacokinetics of IVIg based on simple clinical characteristics of 
patients in order to optimise and individualise IVIg treatment.
Two studies have shown how daily self-monitoring of muscle strength can be very 
useful in establishing the optimal dose and interval in individual patients.35, 66 A good 
instrument for this is the Martin-Vigorimeter which measures handgrip strength.67 
It is a simple assessment tool providing indicators that tended to parallel or precede 
initial improvement in inflammatory neuropathy cause and treatment disability score 
in a placebo-controlled trial that confirmed the efficacy of IVIg.17 Stronger grip strength 
has been reported to translate into better functionality for patients.68 The Vigorimeter 
is recommended for use in studies in inflammatory neuropathy based on its reliability, 
responsiveness, validity and patient satisfaction.69
A small study suggested that serum IgG concentrations correlate with the clinical 
condition in CIDP patients on IVIg maintenance treatment.47 Patients seem to have their 
own individual threshold level and a decrease in serum IgG level beneath this threshold 
led to clinical fluctuations.47 Monitoring of serum IgG level as well as clinical scores were 
used to guide IVIg dosage and frequency in four CIDP patients.47 The effect of differ-
ent IVIg dosages during maintenance treatment of CIDP will be investigated in a new 
international RCT (ProCID study) that is currently recruiting patients (ClinicalTrials.gov 
NCT02638207). Whether more frequent, but lower IVIg dosing leads to more stable IgG 
levels with higher trough levels and better clinical efficacy is currently being investi-
gated in The Netherlands in a dose-response RCT in CIDP (DRIP study). This trial has been 
registered in the Dutch Trial register as NTR3705.
COnCluSIOnS
There is limited evidence how to determine the optimal IVIg maintenance treatment 
regimen for a CIDP patient. The current weight-based dosing is probably inappropri-
ate. IVIg dosages and intervals vary substantially between individuals and to give 
the optimal dosage and interval, treatment should be personalised. How this can be 
achieved best is currently unknown. To obtain the maximum effect of IVIg, it is unknown 
whether high peak levels of IgG are needed, whether IgG levels should reach a certain 
threshold above which an effect appears, or if more constant serum IgG levels are pre-
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ferred. Potential biomarkers to achieve optimal maintenance treatment are: serum IgG 
levels and/or pharmacokinetics analysis, yet to be determined specific autoantibodies, 
genetic polymorphisms influencing IVIg pharmacokinetics, or simple and easy to use 
muscle strength dynamometry. The results of new trials or the testing and validation of 
proposed dosing algorithms will hopefully help to unravel the long-lasting discussions 
on IVIg dose and frequency requirements in CIDP.
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ABSTrACT
High peak levels of serum IgG may not be needed for maintenance treatment of 
chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) with intravenous 
immunoglobulin (IVIg). More frequent dosing of IVIg leads to more stable IgG levels 
and higher trough levels which may be related with improved clinical efficacy. More 
frequent lower dosing leads to lower peak levels and may induce less systemic side-
effects. The DRIP study is a double-blind randomised controlled cross-over intervention 
study. CIDP patients ≥ 18 years old, proven IVIg dependent and receiving an individually 
established but stable maintenance dose and interval of IVIg (Kiovig) can be included. 
One group (A) will be treated with their normal dosage and interval of IVIg and receive 
a placebo (albumin 0.5%) infusion in between their regular IVIg infusions, for a total of 
four infusions. The other group (B) will be treated with half their normal IVIg dosage 
(with the same volume of placebo to maintain the total volume) at half their interval 
(double their frequency) for four infusions. After a wash-out phase (2 infusions), patients 
will cross-over to the other treatment group. During the study the total dose of IVIg 
administered will remain unchanged as before start of the trial. The main objective is 
to investigate whether high frequent low dosage IVIg treatment is more effective than 
low frequent high dosage IVIg treatment as maintenance treatment for CIDP. Hand grip 
strength, as measured by the Martin Vigorimeter, will be used as the primary outcome 
measure. Secondary objective is to investigate whether high frequent low dosage of 
IVIg results in less adverse events compared to low frequent high dosage treatment. The 
DRIP study is currently ongoing and the protocol is presented.
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InTrODuCTIOn
Intravenous immunoglobulin (IVIg) is a proven effective treatment for chronic inflamma-
tory demyelinating polyradiculoneuropathy (CIDP).1 It is unknown whether high serum IgG 
peak levels are required to induce a clinical response and to reach and maintain a stable 
clinical condition in CIDP patients when treated with IVIg. The question how to treat CIDP 
patients most effectively with IVIg during the course of disease remains and randomised 
trials comparing different dosage schedules are needed.2-6 The pharmacokinetics of IgG 
differs when more frequent lower dosages are given in comparison to a less frequent 
higher IVIg dosage regimen. A lower dose more frequent IVIg regimen likely results in lower 
peak and higher trough levels of serum IgG, and may therefore be a preferable treatment 
schedule (Figure 1). 7 More frequent dosing leads to more stable IgG levels without very 
high peak levels which have been held responsible for the systemic side effects.7, 8 Whether 
more frequent, but lower IVIg dosing, leads to better clinical efficacy with less systemic 
side-effects, will be investigated in a dose-response RCT in CIDP (DRIP study). The results of 
the DRIP study may help to develop a more evidence based guideline regarding the optimal 
dose and frequency of maintenance IVIg treatment in CIDP. This trial has been registered in 
the Dutch Trial register as NTR3705. The background and outline of this study is described.
mATerIAl AnD meTHODS
Patients
CIDP patients responsive to IVIg who need regular IVIg treatment and who are in a stable 
condition with regular maintenance treatment of liquid 10% (100 g/l) IVIg (Kiovig, Baxter 
AG, Vienna, Austria) can be included. In all patients the diagnosis of CIDP or acute-onset 
CIDP (A-CIDP) has to be established by a consultant neurologist. The patients need to fulfil 
the European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) 
clinical diagnostic criteria for CIDP.9, 10 To indicate that each patient is still IVIg dependent 
and has active CIDP, he/she must have shown either an objective deterioration (decrease in 
muscle strength as measured with the Martin Vigorimeter and/or MRC sum score) follow-
ing reduction of IVIg dose or lengthening of the IVIg interval, or an objective improvement 
following an increase in IVIg dose or shortening of the IVIg interval at some time during 
the 9 months before randomisation. To be able to measure a meaningful improvement 
in the primary outcome measurement, patients are only eligible when their hand grip 
strength as measured by the Martin Vigorimeter was < the median value (kPa) for an age 
and sex matched healthy control.11 Patients with an infusion interval < 14 days will be 
excluded because we consider an infusion frequency of more than once a week (during 
the trial) not feasible for patients. The in- and exclusion criteria are displayed in Table 1.
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Table 1. In- and exclusion criteria DrIP study
Inclusion criteria exclusion criteria
1.  Diagnosis of CIDP or acute-onset CIDP made by a 
consultant neurologist, fulfilling EFNS/PNS clinical 
diagnostic criteria. 9, 10
1.  Known IgA deficiency or known allergic 
reaction to IVIg.
2.  Age ≥ 18 years. 2.  Hand grip strength (Martin- Vigorimeter 11) 
≥ the median value (kPa) for an age and sex 
matched healthy control. 11
3.  Significant improvement following the first use of 
IVIg. (decrease ≥ 1 modified Rankin scale) 26
3.  Maintenance dose < 15g of IVIg every 
infusion or an infusion interval < 14 days.
4.  IVIg dependency. 
(objective* deterioration following IVIg reduction or 
improvement following an increase in IVIg < 9 months 
before randomisation)
4.  Known hereditary neuropathy or severe 
concomitant diseases (HIV, Lyme, hepatitis, 
heart failure, SLE, drug or toxin induced 
neuropathy, vasculitis, malignancy)
5.  Ongoing intermittent treatment with 10% liquid IVIg 
(Kiovig) for at least 2 infusions. The dose must have 
been not changed within the 8 weeks prior to the 
study.
5.  Multifocal motor neuropathy. 
(fulfilling EFNS/PNS criteria) 27
6.  EMG findings compatible with CIDP showing 
peripheral nerve demyelination at least once during 
their illness. #
6. IgM paraprotein with anti- MAG antibodies.
7.  Signed informed consent. 7.  Atypical CIDP. 
(pure sensory, persistent unifocal, CNS 
involvement)
8.  Participation in a controlled trial of an 
investigational medicinal product ≤ 12 weeks 
prior.
9.  Severe known abnormalities in liver, kidney 
function or serum glucose level.
10.  Treatment with > 20mg 
prednisone a day.
11.  Treatment with other immunosuppressive 
drugs if the dosage has been changed within 
8 weeks prior to start of the study.
CIDP, chronic inflammatory demyelinating polyradiculoneuropathy; CNS, central nervous system; EFNS/
PNS; European Federation of Neurological Societies/Peripheral Nerve Society; EMG, electromyography; HIV, 
human immunodeficiency virus; INCAT, inflammatory neuropathy cause and treatment group; IVIg, intrave-
nous immunoglobulin; MAG, myelin-associated glycoprotein; MRC, medical research council; SLE, systemic 
lupus erythematosus.
* Martin Vigorimeter 11 or MRC sum score 28
# Preferentially fulfilling the electro diagnostic criteria proposed by the INCAT 29 or EFNS/PNS.9
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Treatment allocation and randomisation
Random assignments will be provided via a computer-generated list produced by the 
study statistician. A block randomisation will be made for each centre. The pharmacist 
will hold treatment codes for all the participants in the study. One investigator (KK) will 
allocate the next available number on entry after informed consent is given. Another un-
masked neurologist (EB) will randomise patients according to the computer-generated 
list. Allocation concealment will be ensured via sequentially numbered, opaque sealed 
envelopes. Allocation will be revealed after all patients have completed the trial and 
data entry has been declared complete.
Treatment and blinding
In the DRIP trial every patient will be treated at baseline (one infusion) according to their 
own individual established IVIg dosage and interval prior to start of the trial. During the 
double-blind phase (4 infusions) one group (A) will be treated with their normal dosage 
and interval of IVIg, followed by a placebo infusion between their regular infusions, so 
that they receive an infusion of either IVIg or placebo at half of the interval. The other 
group (B) will be treated with half of their normal dosage of IVIg (with placebo added 
to maintain the total volume) at half of the interval (Figure 2). Blinded study medication 
will always be divided over two infusion bags during the whole study so that IVIg as well 
as placebo will be given separately and the IVIg does not have to be diluted (in case of 
half the dose and interval) and in order to maintain the blind. Albumin 0.5% has been 
chosen as placebo because of its identical appearance to IVIg during visual inspection. 
Albumin has been used as a placebo in various IVIg trials including the largest IVIg treat-
ment trial in CIDP. 12
After a wash-out phase (2 infusions), patients will cross-over to the other treatment 
group (Figure 2). This study period seems reasonable because the half-life of IVIg is 18-
32 days3, 13 and the efficacy of IVIg can be determined within 1-2 weeks after start of 
treatment.14, 15 The total amount of IVIg given during the whole double-blind phase will 
remain the same in both groups.
A two-period, double-blind cross-over design was chosen because of its statistical ef-
ficiency. In this design, each patient acts as his/her own control, enabling a more precise 
estimate of the treatment effect. Due to the extended wash-out period (2 infusions) 
and the short half-life of IVIg a carry-over effect will be very unlikely. Patients will re-
ceive their treatment at home or at the hospital day-care according to where they were 
treated prior to trial entry. IVIg will be administrated at home or in the hospital day-care 
setting by a nurse who is trained in administering IVIg and the treatment of (S)AEs. The 
study period will be approximately 14-26 weeks, depending on infusion frequency prior 
to randomisation.
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Outcome measures
The primary objective of this study is to investigate whether high frequency low dosage 
IVIg treatment is more effective than low frequency high dosage as maintenance treat-
ment for CIDP. Secondary objectives are to investigate whether high frequency low dos-
age of IVIg results in less adverse events, as well as higher IgG trough levels compared 
to low frequency high dosage. Hand grip strength (Martin Vigorimeter) will be used 
as the primary outcome measure. The Martin Vigorimeter is a simple assessment tool 
measuring hand grip strength that tended to parallel or precede initial improvement 
in inflammatory neuropathy cause and treatment (INCAT) disability score in a placebo 
controlled trial that confirmed the efficacy of IVIg.16 Stronger grip strength has been 
reported to translate into better functionality for patients.17 Prior to every infusion, hand 
 
  Group A    Group B 
       
BASELINE  30g IVIg  Week 0  30g IVIg 
       
DOUBLE-BLIND PHASE 1 
 30g IVIg  Week 4  15g IVIg+Placebo* 
      
 Placebo  Week 6  15g IVIg+Placebo* 
      
 30g IVIg  Week 8  15g IVIg+Placebo* 
      
 Placebo  Week 10  15g IVIg+Placebo* 
       
WASHOUT 
 30g IVIg  Week 12  30g IVIg 
      
 30g IVIg  Week 16  30g IVIg 
       
DOUBLE-BLIND PHASE 2 
 15g IVIg+Placebo*  Week 20  30g IVIg 
      
 15g IVIg+Placebo*  Week 22  Placebo 
      
 15g IVIg+Placebo*  Week 24  30g IVIg 
      
 15g IVIg+Placebo*  Week 26  Placebo 
 
Example of the study outline for a patient treated with 30 grams of IVIg every 4 weeks. 
*Placebo is added to maintain the total volume.  
 
 
figure 2. Study outline
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grip strength will be measured (mean of three measurements of both hands) by the 
nurse administrating the IVIg under standard and stable conditions. To eliminate pos-
sible (minor) differences between Vigorimeters, patients will use the same Vigorimeter 
throughout the whole study. The mean of the two Vigorimeter measurements before 
the first infusion of each double blind phase will be taken as a baseline measurement. A 
difference of > 8 kPa in the mean of the four Vigorimeter changes from baseline in favor 
of the group treated with half the dosage and interval as compared with the other group 
will be considered a clinical relevant improvement. Patients additionally will complete 
questionnaires regarding disability (R-ODS) 18-20, fatigue (R-FSS) 21, 22, quality of life (SF-
36) 23, and side effects (side effects questionnaire) 2-5 days after every infusion. Blood 
samples will be drawn before and after every infusion to investigate serum IgG levels. 
Changes in the R-ODS, R-FSS, and SF-36 and the occurrence of side-effects will be used 
as secondary outcome measures.
Statistical analysis
Historical data, from a similar population of stable but IVIg dependent CIDP patients, 
showed a SD =7.65 kPa for the mean Vigorimeter change from baseline after 4 subse-
quent infusions (∆Vigorimeter).24 To demonstrate a clinically relevant difference in Vig-
orimeter measurements, at least 15 patients are required who complete both treatment 
arms (two-sided alpha 0.05, power ≥ 80%). A difference of > 8 kPa in the mean of the four 
Vigorimeter changes from baseline in favor of the group treated with half the dosage 
and interval as compared with the other treatment group will be considered a relevant 
clinical improvement.25 The value of 8 kPa is based on the minimum clinically important 
difference cut-off value of 8 kPa for grip strength (Vigorimeter) using the ½ SD tech-
nique.25 The mean Vigorimeter change from baseline will be compared between both 
treatments using ANOVA for cross-over studies. Repeated measurements ANOVA will 
be used to explore changes in Vigorimeter and serum IgG levels. Data will primarily be 
analysed according to the intention-to-treat principle. The percentage of patients with 
at least one serious adverse event will be compared using McNemar’s test. The most 
common reported side-effects will be described and the amount of patients reporting 
these in both groups will be compared.
COnCluSIOn
Currently it is unknown how IVIg maintenance treatment should be given in CIDP in 
order to be most effective and convenient. The DRIP study may give more insight into 
what constitutes a preferable dosage regimen for IVIg maintenance treatment of CIDP.
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ABSTrACT
Objective: Intravenous immunoglobulin (IVIg) is the first choice treatment for the 
Guillain-Barré syndrome (GBS). All patients initially receive the same arbitrary dose of 2 g 
per kg body weight. Not all patients, however, show a good recovery after this standard 
dose. IVIg clearance may depend on disease severity and vary between individuals, 
implying that this dose is suboptimal for some patients. In this study, we determined 
whether the pharmacokinetics of IVIg is related to outcome in GBS.
methods: We included 174 GBS patients who had previously participated in 2 ran-
domised clinical trials. At entry, all patients were unable to walk unaided and received 
a standard dose of IVIg. Total IgG levels in serum samples obtained immediately before 
and 2 weeks after the start of IVIg administration were determined by turbidimetry and 
related to clinical outcome at 6 months.
results: The increase in serum IgG (DIgG) 2 weeks after IVIg treatment varied consider-
ably between patients (mean 7.8 g/L; standard deviation 5.6 g/L). Patients with a low 
DIgG recovered significantly more slowly, and fewer reached the ability to walk unaided 
at 6 months (log-rank p<0.001). In multivariate analysis adjusted for other known prog-
nostic factors, a low DIgG was independently associated with poor outcome (p=0.022).
Interpretation: After a standard dose of IVIg treatment, GBS patients show a large varia-
tion in pharmacokinetics, which is related to clinical outcome. This may indicate that 
patients with a small increase in serum IgG level may benefit from a higher dosage or 
second course of IVIg.
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InTrODuCTIOn
Guillain-Barré syndrome (GBS) is a postinfectious polyradiculoneuropathy leading to a 
rapidly progressive flaccid paresis, followed by a slow and often incomplete recovery. 
Treatment of GBS is focused on the acute phase of the disease, when the activated im-
mune system damages the peripheral nerves. Plasma exchange (PE) and intravenous 
immunoglobulin (IVIg) are equally effective in GBS, but IVIg is more widely available 
and has less side-effects.1-3 IVIg is also an important treatment for patients with immune 
deficiencies and various other forms of autoimmune disease.4,5 IVIg has pleiotropic 
immune-modulating effects, including saturation of Fcg-receptors, neutralisation of auto-
antibodies and cytokines and inhibition of complement activation.6 Which, if any, of these 
immunological actions provide the therapeutic effect of IVIg in GBS is as yet unknown.
IgG is the major component of IVIg and probably responsible for most of the immune-
modulating effects.4 Pharmacokinetic studies on serum IgG levels after IVIg treatment 
have been conducted predominantly in patients with immune deficiencies. These stud-
ies suggest that IgG levels peak at 3 days after IVIg treatment and have a half-life of 18 
to 32 days.6 However, patients show a considerable variability in pharmacokinetics after 
treatment, which may influence the efficacy of IVIg.7 The variability in pharmacokinetics 
in patients with normal immunoglobulin levels, as in GBS, has been less well defined and 
the optimum therapeutic serum IgG concentration is unknown.7 The pharmacokinetics 
might partly explain the diversity in clinical course and outcome of GBS.
The therapeutic dose of IVIg for GBS was empirically set at 2g per kg body weight, 
based mainly on the clinical experience in patients with immune deficiencies.6 There is 
circumstantial evidence that this standard dosage of IVIg is too low for some patients 
with GBS. First, 10% of GBS patients treated with IVIg show early relapse after initial 
improvement or stabilisation, and these patients often improve after a second dose of 
IVIg.8 Second, some patients show no sign of improvement or further deteriorate in the 
first weeks after IVIg. Third, a case study suggested that a second course of IVIg might be 
beneficial in these patients,9 but this observation requires confirmation in a randomised 
controlled trial. More effective treatment for GBS is needed, considering the high mor-
tality of 5% and high morbidity with 25% of patients needing artificial ventilation and 
20% remaining severely disabled.10 A subgroup of patients with GBS that shows a more 
rapid clearance of IgG may have received a suboptimal dose of IVIg, and may benefit 
from a higher dosage or second course.
The aim of this study was to determine serum IgG levels in patients with GBS after 
standard IVIg treatment in relation to clinical course and outcome. GBS is an ideal dis-
ease for studying the pharmacokinetics of IVIg, because it is acute and monophasic, and 
all patients are treated with the same dose of IVIg. Pharmacokinetic information may be 
useful to optimise treatment in GBS and other autoimmune diseases responsive to IVIg.
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PATIenTS AnD meTHODS
Patients
The patients in this study had previously participated in 2 randomised controlled trials 
investigating the therapeutic effect of IVIg.11,12 The first trial compared the effect of IVIg 
with PE in 147 patients.11 The second trial studied the additional effect of methylpred-
nisolone (500mg per day for 5 days) when added to IVIg in 225 patients.12 All patients 
fulfilled the diagnostic criteria for GBS,13,14 were unable to walk 10m unaided, and 
received a standard IVIg dosage of 0.4g per kg body weight per day for 5 consecutive 
days within 2 weeks of onset of weakness. Furthermore, all patients received the same 
brand of IVIg (Gammagard or Gammagard S/D, Baxter Bioscience). These trials have 
been described in detail previously.11,12
To be included in the current study, sufficient amounts of serum taken pretreatment 
and 2 weeks after start of treatment had to be available to measure total IgG levels. 
Additionally, in some patients serum was available to determine total IgG levels at 
4 weeks, 3 months and 6 months after the start of treatment. Serum levels obtained 
after treatment with an additional or second IVIg course were excluded. Patients who 
had a previous episode of GBS or who developed chronic inflammatory demyelinating 
polyradiculoneuropathy (CIDP) were excluded. Approval of the local Medical Ethical 
Committee was obtained and all patients gave informed consent.
Data collection
All clinical and laboratory data were collected prospectively at standardised time points 
during a follow-up of 6 months.11,12 The Medical Research Counsel (MRC) sum score15 
and the GBS disability scale16 were used to indicate the level of severity of the disease. 
The MRC sum score ranges from zero (quadriplegic) to 60 (normal strength). The GBS 
disability scale ranges from zero (normal = no disability) to six (death). Good outcome 
was defined as a GBS disability scale of ≤ 2, indicating the ability to walk unaided, at a 
follow-up of 6 months. The 6-month endpoint was defined before the start of the cur-
rent study based on our previous prognostic study in GBS,17 although not recorded in 
writing. Body weight at the start of treatment and the dosage of IVIg were recorded.
Serum samples were stored at -80°C until use. Serum sodium and albumin levels were 
determined to check the quality of the samples after long-term storage. Total serum 
IgG levels were determined by routine automated turbidimetry on the Hitachi 917 
clinical chemistry analyser or the Modular P clinical chemistry analyser with the same 
Tina-quant IgG assay, according to the manufacturers’ instructions (Roche, Almere, The 
Netherlands). At total IgG levels of 9.0g/L and 21.5g/L, the between-run coefficients of 
variation were respectively 1.6% and 2.6%. The within-run coefficient of variation of the 
Tina-quant IgG assay was <1%.
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Statistical analysis
The variability of serum IgG levels between patients was expressed as a mean and 
standard deviation (SD). The coefficient of variation (CV) was defined as the ratio of the 
SD to the mean multiplied by 100 (%). Spearman correlation coefficient (rs) was used to 
analyse the correlation between serum IgG levels. A paired t test was used to compare 
the change in IgA and IgM after IVIg treatment.
Patients were divided into quartiles based on the increase in serum IgG (DIgG) at 2 
weeks after IVIg treatment from their pretreatment level. Clinical characteristics of these 
quartiles were compared using analysis of variance for linear trend or c2 test for trend. 
Time to reach the ability to walk unaided during the follow-up of 6 months for these 
quartiles was analysed using the Kaplan-Meier method and the log-rank test for trend. 
The effect of DIgG on the likelihood of walking unaided after 6 months, in relation to 
previously established prognostic factors including age, preceding diarrhoea, and GBS-
disability score, was determined by multivariate logistic regression. The Hosmer and 
Lemeshow test was used to check for goodness-of-fit of the model. SPSS for Windows 
(V.15.0, SPSS Inc., Chicago) was used for all statistical analyses. A 2-sided p value < 0.05 
was regarded as significant.
reSulTS
Of the 372 patients included in these 2 trials, 298 patients were treated with IVIg. Suf-
ficient quantities of serum to perform pharmacokinetic studies were available from 174 
patients. Of these patients, 57 had participated in the first trial (IVIg vs. PE) and 117 in the 
second trial (IVIg and placebo vs. IVIg and methylprednisolone). These 174 patients did 
not differ significantly from the excluded patients in age, sex, body weight, symptoms 
of a preceding infection (diarrhoea or upper respiratory tract), MRC sum score or GBS 
disability score at entry or at 6 months.
Total IgG levels were determined in serum samples obtained pretreatment and 2 
weeks after the start of treatment in all patients. In addition, in some of these patients 
total IgG levels were determined in samples obtained at 4 weeks (N = 91), 3 months (N 
= 86) and 6 months (N = 83) after the start of treatment. As expected, the serum IgG 
levels were higher in the samples obtained at 2 weeks and (to a lesser extent) at 4 weeks 
after IVIg administration as compared with the pretreatment level (Figure 1). There was a 
strong positive correlation between serum IgG levels obtained pretreatment, and those 
taken at 3 months (rs=0.73; p<0.001) and 6 months post-treatment (rs =0.73; p<0.001), 
indicating an individual constant baseline level of serum IgG.
The largest variability in IgG level was found in serum samples obtained 2 weeks after 
IVIg treatment (mean 18.8g/L; SD 5.8; CV 31%). The variability was less pronounced 4 
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weeks after IVIg (mean 14.0g/L; SD 3.1; CV 22%). There was no association between 
serum IgG levels at baseline or at 2 weeks and age, body weight or symptoms of a recent 
infection. The IgG level at 2 weeks correlated weakly with pretreatment level (rs=0.28; 
p<0.001) and the level at 4 weeks (rs=0.55; p<0.001), indicating that to some extent the 
IgG level 2 weeks after treatment can be attributed to the level at baseline. IgA and IgM 
levels were determined from 46 patients in serum obtained before and 2 weeks after 
treatment, showing no significant change in either level after IVIg. IgG levels in 59 serum 
samples from 42 patients were also determined at time of admission, before storage at 
-80°C, and this initial measurement showed a high correspondence with the IgG levels 
determined for the current study (rs=0.958; p<0.001).
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figure 1. Variability of serum immunoglobulin (Ig)G levels in Guillain-Barré syndrome patients be-
fore and at 4 time points after treatment with a standard high dose of intravenous immunoglobulin 
(2g per kg body weight)
Boxes indicate interquartile range (IQR), horizontal bars within boxes indicate medians, and whiskers indi-
cate range without outliers. Observations more than 1.5 times IQR from the box are indicated as open dots.
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To investigate the pharmacokinetics of IVIg, the change in serum IgG was calculated 
by subtracting the pretreatment level from the level at 2 weeks after IVIg treatment 
(DIgG). There was a large variability in DIgG 2 weeks after IVIg treatment (mean 7.8 g/L; 
SD 5.6). Patients were clustered into quartiles according to the DIgG levels (cutoff value 
for the 25th percentile was 3.99g/L, for the 50th percentile it was 7.30g/L, and for the 75th 
percentile it was 10.92 g/L). Comparing clinical characteristics and prognostic factors 
between these quartiles showed no significant difference in age, body weight or the 
presence of preceding infection (Table 1). Furthermore, there was no difference between 
these quartiles regarding IVIg dosage or the presence of additional methylprednisolone 
treatment.
Patients with a low DIgG 2 weeks after IVIg had a more severe course of disease, 
expressed as the GBS disability score and MRC sum score at entry and nadir (Table 1). 
In addition, the Kaplan-Meier curves of the quartiles of patients based on this DIgG 
showed a significant difference in the time required to reach the ability to walk unaided 
(GBS disability score of ≤ 2) (log-rank test for trend; p<0.001) (Figure 2). When adjusted 
for the GBS disability score at entry, the stratified log-rank test remained significant 
(p=0.004). Of the 27 patients who were not able to walk unaided after 6 months, 12 
(44%) were from the quartile with the lowest DIgG level, and 23 (85%) were from the 
lowest 2 quartiles. The time required to improve 1 grade on the GBS disability scale was 
also significantly longer in the quartile of patients with the lowest DIgG (log-rank test for 
trend; p=0.001).
The relation between IgG levels and outcome was determined in multivariate analysis. 
Previously identified prognostic factors in GBS that predict the chance to walk unaided 
at 6 months -age, preceding diarrhoea and GBS disability score- were included in the 
model.17 A forward stepwise approach was used. The IgG level pretreatment (p=0.74) or 
the IgG level at 2 weeks after treatment (p=0.32) were not significantly associated with 
the outcome; therefore, these variables were not included in the final model. The GBS 
disability score at entry was entered as a categorical variable (GBS disability score 3, 4 or 
5) in the multivariate analysis. After adjusting for age, preceding diarrhoea, and the GBS 
disability score at entry, the DIgG 2 weeks after IVIg treatment was still associated with 
the outcome in the final model (N=173; p=0.022). One patient was not included in this 
analysis, because there was no information available about the presence of preceding 
diarrhoea. Compared to the reference DIgG quartile 4, the odds ratio (OR) was 0.26 for 
quartile 1, 0.25 for quartile 2 and 3.90 for quartile 3. Comparing the combined quar-
tiles 1-2 with the combined quartiles 3-4 resulted in an OR of 0.148 (95% CI 0.05-0.48; 
p=0.001).
When adjusting for the Erasmus GBS outcome score (EGOS), a prognostic model based 
on a scoring system for age, preceding diarrhoea and GBS disability score at 2 weeks,17 
the DIgG was also associated with the outcome after 6 months (p= 0.020).
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Table 1. Baseline characteristics, clinical course, and outcome in quartiles of patients based on the 
increase in serum IgG levels (ΔIgG) two weeks after treatment with a standard high dose of intrave-
nous immunoglobulin
Quartiles based on ΔIgG at two weeks
p Value1 2 3 4
Serum DIgG (g/L) < 3.99 3.99-7.30 7.31-10.92 > 10.92
N 43 45 43 43
Serum IgG level (g/l)
Pretreatment 12.5 (3.8) 10.8 (2.4) 10.4 (2.6) 10.4 (3.0)
2 wk after treatment 13.5 (4.2) 16.6 (2.7) 19.4 (2.8) 25.7 (4.8)
Baseline characteristics
Demographic features
Age, y 52.1 (22.9) 49.2 (20.6) 51.8 (17.2) 45.4 (19.2) 0.20
Males 23 (54%) 29 (64%) 24 (56%) 23 (54%) 0.79
Body weight, kg 71.0 (19.7) 74.4 (15.1) 75.2 (13.9) 75.2 (16.1) 0.24
Preceding infections
Diarrhoea 9 (21%) 8 (18%) 11 (26%) 13 (31%) 0.19
Upper respiratory tract infection 17 (40%) 17 (38%) 13 (30%) `13 (31%) 0.31
Clinical severity at entry
GBS disability score 4.0 (0.44) 3.8 (0.56) 3.7 (0.58) 3.7 (0.56) 0.007
≥ 4 39 (91%) 34 (76%) 29 (67%) 28 (65%) 0.004
MRC sum score 35.8 (11.3) 39.0 (13.0) 42.7 (10.1) 43.7 (9.8) <0.001
≤40 25 (58%) 19 (42%) 14 (33%) 12 (28%) 0.003
Outcome characteristics
Clinical severity at nadir
GBS disability score 4.6 (0.7) 4.0 (0.7) 3.9 (0.7) 4.0 (0.5) <0.001
> 4 25 (58%) 10 (22%) 7 (16%) 5 (12%) <0.001
MRC sum score 23.0 (16.0) 32.9 (17.3) 37.9 (14.4) 39.1 (15.3) <0.001
≤ 40 36 (84%) 25 (56%) 20 (47%) 16 (37%) <0.001
mechanical ventilation
Frequency * 22 (52%) 9 (23%) 5 (12%) 5 (13%) <0.001
Outcome at 6 mo
GBS disability score > 2 12 (28%)# 11 (24%)† 1 (2%)‡ 3 (7%)• 0.001
Data are presented as means (standard deviation) and compared using analysis of variance for linear trend 
or as numbers (percentage) and compared using c2 test for trend. * at any time
# 95% CI=15%-44%, † 95% CI=13%-40%, ‡ 95% CI=0.1%-12%, • 95% CI= 1%-19%.
DIgG = increase in serum immunoglobulin G; IgG = immunoglobulin G; GBS = Guillain-Barré
syndrome; MRC = medical research council; CI = confidence interval.
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DISCuSSIOn
We determined the pharmacokinetics of IVIg treatment in patients with GBS in rela-
tion to the clinical course and outcome. Infusion with a standard regime of 2g per 
kg body weight resulted in a considerable variability in increase of serum IgG levels 
(DIgG) between patients. Two weeks after commencing treatment, the DIgG ranged 
from -5g/L to 26g/L, with <4 g/L in the lowest quartile of patients and >10 g/L in the 
highest quartile. The DIgG levels were determined in a representative group of 174 
GBS patients with regard to demographic characteristics, preceding infections, disease 
severity and outcome. The variation in DIgG in these patients was unrelated to sex, age, 
body weight, presence of symptoms of preceding infections, or additional treatment 
with methylprednisolone. IgG levels were defined by turbidimetry, which is a routine 
and highly accurate method for determining the levels of IgG in serum. Previous studies 
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figure 2. Proportion of patients who regained the ability to walk unaided in quartiles based on in-
crease in serum immunoglobulin (Ig)G 2 weeks after treatment with a standard high dose of intra-
venous immunoglobulin
The Kaplan-Meier curves show the cumulative fractions of patients walking unaided along time grouped 
according to the quartiles (1-4) of increase in serum IgG (DIgG).
Cutoff values DIgG for quartile 1: < 3.99 g/L (N=43), quartile 2: 3.99-7.30 g/L (N=45), quartile 3: 7.31-10.92 
g/L (N=43), and quartile 4: DIgG > 10.92 g/L (N=43). p Value is based on the log-rank test for trend.
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have shown that the IgG level in frozen serum samples is not influenced by long-term 
storage (up to 25 years).18 Various control studies were conducted in the current study to 
verify the quality of the tested serum samples and reproducibility of the tests. Based on 
these results, we concluded that there is a considerable variation between GBS patients 
in the pharmacokinetics of IVIg.
Previous studies in patients with other diseases have shown that after infusion with the 
standard high dose of IVIg, the serum IgG level increases 5-fold, declines within 72 hours 
to 50%, and returns to pretreatment levels after 21 to 28 days.6 The initial rapid decline 
in IgG levels is largely influenced by redistribution, whereas the slower catabolism in the 
next phase follows a first-order kinetic.6 The half-life of IVIg is approximately 18-32 days, 
which is similar to that of native serum IgG.6 In our study, a low DIgG was associated 
with more extensive disability and weakness at the start of treatment, as defined by the 
GBS disability score and MRC sum score. A higher disease activity, with more extensive 
immune activation and nerve damage, may result in a higher consumption of IgG. This 
subgroup may also be exposed to a higher rate of (intensive care unit--related) infections 
that may further increase the catabolism of IgG. Accordingly, in patients with sepsis and 
severe trauma needing artificial ventilation, the consumption of IgG is increased.19,20 A 
second factor in this study associated with a low DIgG was a high baseline level of serum 
IgG before treatment. Patients with a high serum IgG concentration are known to have 
a higher catabolism of IgG.21 When the plasma IgG concentration reaches 200% of its 
normal value, the half-life of IgG decreases from 21 to 12 days.22 It is possible that this 
dose-dependent clearance can be explained by saturation of the neonatal Fc receptor 
(FcRn), which protects IgG from degradation.23 The FcRn is present in many adult tissues, 
especially in vascular endothelial cells, suggesting that these cells are a major site of IgG 
catabolism. Variable numbers of tandem repeats promoter polymorphisms influence 
the expression of FcRn, leading to differences in IgG binding,24 and possibly contribute 
to the individual clearance rates of IVIg. Part of the therapeutic effect of IVIg may be 
attributed to the saturation of these receptors, which results in a higher clearance of 
auto-antibodies.25 The efficacy of IVIg in immune thrombocytopenia has been shown 
to be FcRn dependant.26 IVIg may also inhibit the production of auto-antibodies and cy-
tokines, although no general immunoregulatory feedback on IgG synthesis by IVIg has 
been demonstrated.27 The variability in IgG kinetics between individual GBS patients, as 
found in the current study, may be explained by the combination of disease severity and 
these host genetic factors involved in IgG turnover.
The current study suggests that GBS patients with a low DIgG have a more severe 
clinical course and poor outcome after a standard dose of IVIg, independent of other 
prognostic factors. A low DIgG 2 weeks after IVIg treatment was related to more severe 
clinical deficits at nadir, defined by the MRC sum score and GBS disability score, and a 
higher frequency of mechanical ventilation. In these patients, the time to reach a GBS 
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disability score of ≤ 2 and to improve 1 grade on the GBS disability score was prolonged. 
In addition, a low DIgG was associated with a higher chance to remain disabled at 6 
months after treatment. Multivariate analysis confirmed that the association between 
DIgG at 2 weeks and poor clinical outcome was independent of the disease sever-
ity before treatment and other main prognostic factors in GBS. When adjusted for the 
EGOS, which contains the GBS disability score at 2 weeks, the DIgG was still significantly 
associated with the chance of reaching independent walking after 6 months. This may 
indicate that the DIgG has an additional value in predicting outcome in GBS, although 
this should be confirmed in an independent prospective study. Very recently, IVIg-
related plasmacytosis 7 days after initiation of treatment was reported as a prognostic 
marker in GBS patients receiving IVIg treatment.28
The optimal dosage of IVIg for treatment of GBS is unknown. The current standard 
regime of 2g per kg body weight was set arbitrarily, and is not defined in dose-finding 
studies in subgroups of patients. If the immune modulating effects of IVIg are dose 
dependent, a low DIgG may result in suboptimal immune suppression, more extensive 
or prolonged damaging of peripheral nerves, and worse outcome. In a multicentre con-
trolled trial comparing two IVIg regimens, GBS patients treated with 2.4g per kg body 
weight in 6 days showed faster and better recovery than patients treated with 1.2g per 
kg body weight in 3 days.29 A small case study suggested that a second course of IVIg 
might be beneficial in GBS patients who show no sign of improvement or further dete-
riorate in the first weeks after IVIg.9 There is circumstantial evidence that the number of 
plasma exchanges in GBS should be adjusted to the initial severity of the disease.30 From 
clinical practice in the treatment of chronic forms of immune mediated neuropathy, it 
is known that patients who show an insufficient response may further improve after a 
higher dosage of IVIg. This may also indicate that in GBS patients treated with IVIg, a cer-
tain threshold of DIgG is needed for a substantial effect, or that a subgroup of patients 
may further improve after a higher dosage of IVIg. In the current study, decisions about 
further treatment could only be made based upon a IgG level determined at 2 weeks. It 
is possible that this delay is too long to improve outcome, although the time window in 
which (additional) IVIg treatment is still effective is unknown. It is known that PE may be 
effective in up to 30 days after admission.1,31 A controlled trial is needed to demonstrate 
the additional therapeutic benefit of a higher dosage or second course of IVIg in these 
patients.
IVIg is used in the treatment of a wide spectrum of immune disorders, including 
various autoimmune neuromuscular diseases.5 The pharmacokinetics of IVIg treatment 
have been evaluated in healthy controls and patients, showing a considerable intra- and 
interpopulation variability.7 Patients may be subject to more pronounced individual 
variation than normal persons if disease activity or disease-predisposing factors influ-
ence IgG catabolism. GBS is a model disease to determine the pharmacokinetics of 
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IVIg, because GBS is an acute monophasic disorder, usually affecting persons with an 
unremarkable immune history, who are treated with the same standard regime of IVIg. 
The current study suggests that the high variability of IVIg pharmacokinetics in patients 
with GBS is related to clinical course and outcome. Prospective studies are required to 
determine if monitoring of serum IgG levels can be used to optimise the use of IVIg 
treatment in GBS patients on an individual basis.
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ABSTrACT
Objective: To determine the variability of serum IgG in patients with chronic inflamma-
tory demyelinating polyradiculoneuropathy (CIDP).
methods: All 25 CIDP patients had active but stable disease and were treated with 
individually optimised fixed dose IVIg regimens. IgG was measured by turbidimetry and 
variability was defined as coefficient of variation (CV).
results: The intra-patient variability of the pre-treatment IgG levels, post-treatment lev-
els and increase in serum IgG shortly after IVIg (DIgG) was low (mean CV = 3%, 4%, 10%). 
The inter-patient variability between patients treated with the same dose and interval 
was low in pre-treatment, post-treatment and DIgG level (mean CV = 13%, 11%, 20%). 
The DIgG levels were associated with IVIg dosage (rs = 0.78, p<0.001).
Conclusion: Clinically stable CIDP patients show a steady-state in serum IgG after se-
rial IVIg infusions. The low intra- and inter-patient variability in IgG may indicate that 
constant levels are required to reach this stability.
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InTrODuCTIOn
Intravenous immunoglobulin (IVIg) has been proven effective for Guillain-Barré 
syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy 
(CIDP). The precise mechanisms of action are unknown, but the pleiotropic immune-
modulating effects of IgG are assumed to be responsible for the therapeutic effect.1 
The optimum dosage and frequency of IVIg to reach a clinically stable situation in CIDP 
during maintenance treatment differs between patients and varies between 0.4-1.2 g/
kg body weight every 2-6 weeks.2 Currently, the optimum regimen has not been defined 
and cannot be predicted and needs to be established empirically in clinical practice.2, 3 
The variation in the required dosage and frequency of administration might be partially 
explained by individual differences in catabolism of IVIg. The aim of this study was to 
determine the intra-patient and inter-patient variability of serum IgG levels in clinically 
stable but IVIg-dependent CIDP patients receiving fixed dose maintenance treatment 
of IVIg.
meTHODS
All patients fulfilled the American Academy of Neurology criteria for CIDP and par-
ticipated in a randomised controlled trial comparing freeze-dried IVIg (Gammagard S/D) 
with a liquid preparation (Kiovig).4, 5 All were treated in neuromuscular centers and the 
dosage and frequency of IVIg was determined by neurologists experienced in treating 
CIDP. Muscle weakness was defined by the Medical Research Council (MRC) sum score 
(range 0-60) and Vigorimeter, disability by the overall disability sum score (ODSS) and 
sensory dysfunction by the INCAT sensory sum score (ISS).5 Medical ethical approval and 
informed consent was obtained.5
Patients had active CIDP and worsening of symptoms following IVIg reduction within 
the year before the start of the trial, confirming IVIg dependency.5 All were treated 
according to their own individually optimised IVIg dosage and frequency prior to 
trial entry and these regimens remained constant throughout the trial. To establish 
the optimal regimen of IVIg, the dosage was increased to achieve the maximal clinical 
response and the infusion frequency was shortened when patients were experiencing 
end-of-dose symptoms and signs.6 Regular attempts to decrease the dose were made 
as recommended.6
Serum IgG concentration (g/L) was determined by turbidimetry. At total IgG levels of 
9.0 g/L and 21.5 g/L, the between-run coefficients of variation were respectively 1.6% 
and 2.6% and the within-run coefficient of variation was <1%.7 Prior to this study, we 
had established that peak serum IgG levels were reached 1 minute after infusion, and 
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remained stable for at least 30 minutes after infusion. In this study, IgG levels were 
determined in serum samples obtained immediately before and 5 minutes after every 
infusion. The peak increase in serum IgG after IVIg (DIgG) was defined as the IgG level 
after treatment minus the level just before treatment. The coefficient of variation (CV) 
was calculated as the ratio of the standard deviation to the mean multiplied by 100 (%). 
High variability in drugs is generally defined as a CV ≥ 30%.8
The DIgG of both preparations was compared using Wilcoxon matched-pairs signed-
rank test. Correlation was tested with Spearman correlation coefficient (rs). Analysis was 
performed using SPSS V.17.0. Two-sided p values <0.05 were regarded significant.
reSulTS
Twenty-seven patients were originally included in the trial. One patient was excluded 
from this study because of an unusual treatment regimen potentially influencing IgG 
levels (every other infusion a double dosage) and another because of premature termi-
nation of participation. All had been treated successfully with maintenance IVIg before 
starting the trial (mean 5 years, range 5 months to 13 years).
The DIgG after Gammagard infusion was smaller than after Kiovig (median 6.1 g/L (IQR 
5-9) vs. 6.8 g/L (6-9), p<0.001), which may in part be attributed to the lower IgG content 
in Gammagard (95%) compared to Kiovig (~100%). Because of these differences in IgG 
content and the higher number of Kiovig infusions throughout the trial we focused on 
the analysis of the IgG values after Kiovig infusions, although a similar low variability 
in IgG levels was observed after Gammagard. The lowest serum IgG level reached prior 
to infusion was 9.70 g/L (mean 15.0 g/L; median 15 g/L IQR 13-17) and the minimum 
DIgG level was 3.7 g/L (mean DIgG 7.8 g/L; median 7 g/L IQR 6-9). After serial infusions, 
intra-patient variability was low in pretreatment IgG levels (mean CV 3%, median 4 IQR 
3-5), post-treatment levels (mean CV 4%, median 4 IQR 3-4) and DIgG levels (mean CV 
10%, median 8 IQR 6-12) (Figure 1). Although somewhat larger than the intra-patient 
variability, the inter-patient variability was small in pre-treatment IgG levels (mean 
CV 13%, median 8 IQR 4-28), post-treatment IgG levels (mean CV 11%, median 5 IQR 
3-20) as well as DIgG levels (mean CV 20%, median 14 IQR 9-28) between those patients 
receiving the same dose and frequency of Kiovig (N = 17, Figure 1, Supplementary Table 
1). When we calculated the increase in serum IgG 2 weeks after IVIg in the 13 patients 
with a frequency of one infusion every 2 weeks the delta IgG was very low and close 
to zero (mean 0.09 g/L, median 0.07 g/L, range -0.61 till 0.7 g/L), whereas it was much 
larger in GBS (mean 7.8 g/L) due to the use of a larger dosage in GBS than used in the 
maintenance IVIg treatment in our CIDP cohort. The 2 week level was unsuitable for this 
cohort, and therefore, the peak IgG levels were determined shortly after infusion.
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The post-treatment IgG levels and DIgG levels were related to the IVIg dosage ad-
ministered per infusion (rs = 0.405, p<0.05; rs = 0.78, p<0.001), but not to the infusion 
frequency. The total dosage per infusion required to reach a stable clinical state and 
DIgG did not correlate with age, sex, body weight, lean body mass, muscle strength, 
disability or sensory dysfunction (Supplementary Table 2).5, 7
DISCuSSIOn
We showed that the serum IgG levels before and shortly after serial IVIg infusions were 
remarkably constant over time in patients with active but stable CIDP on constant main-
tenance treatment. This indicates that these patients have reached a steady state with a 
constant distribution rate and turnover of IgG without accumulation over time.
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figure 1. Serum ΔIgG levels in patients receiving maintenance intravenous immunoglobulin (IVIg) 
treatment (Kiovig, n=25)
DIgG = peak increase in serum IgG 5 min after IVIg infusion compared to pretreatment. Box and whisker 
plots show DIgG in 25 different patients, the box indicates 25th-75th percentiles; horizontal line indicates 
median value and the whiskers indicate minimum and maximum values. Patients are grouped by dosage. 
The colours of the boxes represent the infusion interval; patients receiving the same dosage and interval 
are displayed next to each other.
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The dosage and frequency of IVIg required to maintain a clinically stable condition 
differs between CIDP patients, which might be due to interindividual differences in IVIg 
metabolism. Although there is some inter-patient variability between CIDP patients 
treated with the same IVIg dose and frequency, the mean CV can still be considered low 
from a pharmacological perspective which leads us to a different conclusion than previ-
ously reported.9 A higher inter-patient variability in serum IgG levels 2 weeks after a stan-
dard course of IVIg has been observed in GBS (CV 31%) and primary immunodeficiency 
patients.7, 10 This variation may depend on the activity of the disease, immunological 
host factors, baseline IgG levels, IgG glycosylation and Fc-receptor polymorphisms.3, 11, 12 
The low inter-patient variability in serum IgG levels we found in CIDP may be explained 
by the different study design in which none of the CIDP patients were treatment naïve, 
and all were already known to be IVIg responsive and clinically stable after a previous 
adjusted regimen of maintenance IVIg treatment. Variation in half-life of IgG is greater 
among patients with abnormal baseline IgG levels due to its concentration-dependent 
catabolism. 13, 14 The mean CV in baseline serum IgG level was somewhat lower in the 
CIDP patients treated with the same dose and interval (CV 13% N = 17) than in GBS 
(mean CV 28% N=174) (Kuitwaard K, 2009, unpublished data) which might have con-
tributed to the low variability seen in CIDP.7 Furthermore, the CIDP patients were treated 
with a lower IVIg dosage than the 2 g/kg used in GBS patients.
In patients with primary immunodeficiency, a minimum level of serum IgG may be 
required to prevent infections.10 In GBS, an increase of serum IgG level (about 7.30 g/L) 
2 weeks after 2 g/kg IVIg may be required for a better recovery since the increase in the 
IgG level was independently associated with the ability to walk unaided at 6 months.7 
The results of the current study suggest that a minimum serum IgG level and a minimum 
increase in serum IgG may be required to induce a clinical response and to reach a stable 
clinical condition in CIDP. This laboratory finding may be in line with the clinical observa-
tion that more than one IVIg course may be required to show improvement in CIDP.15 
We did not include non-responsive or clinically unstable patients in this study; these 
patients may not have reached this minimum serum IgG level and may benefit from a 
higher IVIg dosage. Research in these patients is required to define if serum IgG levels 
can be used as a biomarker to monitor the effect of IVIg treatment.
No factors have been identified so far to predict the optimum regimen for mainte-
nance IVIg treatment in CIDP. 2, 3 Body weight and the degree of disability were not 
related to the required dose of IVIg, confirming previous reports.2 Factors other than 
body weight might determine the optimum dosage, and maintenance IVIg treatment 
can probably be started at a low dose and should only be increased if required by the 
clinical situation.2
The dose administered was the only factor related to the ΔIgG. The IVIg dosages or 
ΔIgG levels were not associated with body weight, lean body mass, or severity of disease. 
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In GBS, we demonstrated an association between disease severity and the increase in se-
rum IgG level at 2 weeks after standard IVIg treatment.7 This difference may be explained 
by the fact that in the current study, all patients were in a stable and good neurological 
condition being treated with optimised regimens.
We have shown that in active but stable CIDP, the inter-patient variability was larger 
than the intra-patient variability but still considered small. More studies are needed to 
determine whether unselected treatment-naïve CIDP patients do show a large variabil-
ity in serum IgG levels after IVIg and if monitoring of serum IgG levels can be used to 
optimise IVIg treatment regimens in CIDP. Until such time, the reason why CIDP patients 
require different dosages in their IVIg maintenance treatment remains uncertain.
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Supplementary Table 1. Intra- and inter-patient variability in IgG level per subgroup of patients treated 
with the same dose and interval of IVIg (Kiovig)
Patient 1 Patient 2 CV of IIV
Dose/interval (g/wks) 25/3 25/3
Pre-treatment IgG (g/L) 16.3 (16-17) 15.4 (15-16)
CV of IOV 3% 2% 4%
Post-treatment IgG (g/L) 22.0 (21-22) 21.1 (20-21)
CV of IOV 2% 3% 3%
ΔIgG (g/L) 5.5 (5-6) 5.2 (5-6)
CV of IOV 11% 8% 0.3%
Patient 3 Patient 4 Patient 5 Patient 6 CV of IIV
Dose/interval (g/wks) 25/2 25/2 25/2 25/2
Pre-treatment IgG (g/L) 15.2 (15-16) 13.6 (13-14) 15.7 (14-16) 16.8 (16-17)
CV of IOV 5% 7% 6% 3% 9%
Post-treatment IgG (g/L) 21.6 (21-24) 19.3 (19-20) 20.2 (19-21) 20.8 (20-21)
CV of IOV 7% 4% 4% 3% 6%
ΔIgG (g/L) 6.0 (6-8) 5.8 (6-6) 4.7 (4-5) 3.7 (3-4)
CV of IOV 25% 7% 6% 15% 26%
Patient 7 Patient 8 Patient 9 CV of IIV
Dose/interval (g/wks) 30/3 30/3 30/3
Pre-treatment IgG (g/L) 17.5 (17-18) 12.1 (12-13) 14.3 (14-15)
CV of IOV 4% 3% 2% 28%
Post-treatment IgG (g/L) 24.1 (24-24) 19.4 (19-20) 20.8 (20-21)
CV of IOV 2% 3% 6% 20%
ΔIgG (g/L) 6.6 (6-7) 6.8 (7-7) 6.4 (6-7)
CV of IOV 12% 7% 15% 9%
Patient 10 Patient 11 CV of IIV
Dose/interval (g/wks) 30/2 30/2
Pre-treatment IgG (g/L) 11.1 (11-12) 18.5 (18-19)
CV of IOV 5% 3% 35%
Post-treatment IgG (g/L) 17.4 (16-19) 30 (30-31)
CV of IOV 13% 2% 38%
ΔIgG (g/L) 6.3 (5-7) 11.8 (11-12)
CV of IOV 35% 5% 43%
Patient 12 Patient 13 CV of IIV
Dose/interval (g/wks) 35/3 35/3
Pre-treatment IgG (g/L) 13.5 (13-14) 13.0 (13-13)
CV of IOV 6% 3% 3%
Post-treatment IgG (g/L) 20.3 (20-21) 21.8 (21-22)
CV of IOV 4% 2% 5%
ΔIgG (g/L) 6.8 (6-7) 8.8 (8-9)
CV of IOV 8% 4% 18%
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Supplementary Table 1. Intra- and inter-patient variability in IgG level per subgroup of patients treated 
with the same dose and interval of IVIg (Kiovig) (continued)
Patient 14 Patient 15 CV of IIV
Dose/interval (g/wks) 35/2 35/2
Pre-treatment IgG (g/L) 16.3 (16-17) 14.6 (14-15)
CV of IOV 2% 3% 8%
Post-treatment IgG (g/L) 21.4 (21-22) 22.2 (22-23)
CV of IOV 3% 4% 3%
ΔIgG (g/L) 5.1 (5-6) 7.6 (7-8)
CV of IOV 9% 12% 28%
Patient 16 Patient 17 CV of IIV
Dose/interval (g/wks) 40/2 40/2
Pre-treatment IgG (g/L) 14.4 (14-15) 13.2 (13-14)
CV of IOV 4% 3% 7%
Post-treatment IgG (g/L) 20.8 (20-21) 21.4 (21-22)
CV of IOV 4% 4% 2%
ΔIgG (g/L) 6.4 (6-7) 8.2 (8-8)
CV of IOV 8% 12% 18%
DIgG = peak increase in serum IgG 5 minutes after IVIg infusion compared to pre-treatment. Data are pre-
sented as medians (IQR). CV = coefficient of variation (mean, %); IIV = inter-individual patient variability; IOV 
= inter-occasion or intra-patient variability.
Supplementary Table 2. Correlations of IVIg dose and DIgG and various patient characteristics
IVIg dosage (g) DIgG (g/L)
age rs = 0.054,
p = 0.80
rs = 0.004
p = 0.98
sex rs = -0.120
p = 0.57
rs = 0.253,
p = 0.22
Body weight rs = 0.248,
p = 0.23
rs = -0.099,
p = 0.64
Lean body mass rs = 0.093,
p = 0.66
rs = -0.297,
p = 0.15
MRC sum score rs = 0.090,
p = 0.67
rs = -0.128
p = 0.54
Vigorimeter rs = -0.026,
p = 0.90
rs = -0.18
p = 0.93
ISS rs = 0.222,
p = 0.29
rs = 0.336
p = 0.10
ODSS rs = 0.101,
p = 0.63
rs = 0.260
p = 0.21
Infusion frequency (days) rs = -0.006,
p = 0.98
rs = 0.019,
p = 0.93
rs = Spearman correlation coefficient; MRC = Medical Research Council; ISS = INCAT sensory sum score; ODSS 
= overall disability sum score
Chapter 4.2
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GBS and CIDP show many similarities but are usually considered separate disorders 
mainly based on differences in duration of onset, subsequent disease course and re-
sponse to treatment. There are other differences, like the occurrence of preceding infec-
tions or antiganglioside antibodies but many similarities also exist. In clinical practice 
the distinction between GBS or CIDP may not be straightforward and some patients do 
not fulfil the strict diagnostic criteria for GBS (duration of progression less than 4 weeks) 
or CIDP (duration of progression at least 8 weeks).1-3 First, there are patients with an 
onset phase of 4-8 weeks that have been described as subacute idiopathic demyelinat-
ing polyradiculoneuropathy (SIDP). 4 Second, some patients initially fulfil the criteria for 
GBS and are diagnosed as such, and then show secondary deteriorations after initial 
improvement or stabilisation with IVIg or PE treatment, or show further progression for 
a period exceeding 8 weeks without these treatment-related fluctuations (TRFs). These 
patients are eventually diagnosed with an acute-onset (A-CIDP). Third, although GBS is 
in general a monophasic disorder, some patients do have recurrences of acute weakness 
and should be diagnosed with recurrent GBS and treated accordingly. Fourth, some CIDP 
patients have a monophasic course, needing only one IVIg treatment course before they 
get into remission. Fifth, some cases have been reported in which individual patients 
had separate episodes of both GBS and CIDP. These clinical observations may suggest 
that GBS and CIDP share common host susceptibility factors and/or form a continuous 
spectrum of inflammatory polyradiculoneuropathies. An accurate diagnosis has major 
implications for both the monitoring and treatment of individual patients.
For GBS, IVIg is usually the first choice treatment since plasma-exchange (PE) requires 
good vascular access and specific facilities and may be difficult to perform when pa-
tients have autonomic disturbances, and because PE is less convenient treatment with 
PE is less likely to be completed.5 All patients treated with IVIg receive the same initial 
arbitrary dose of 2 g IVIg per kg body weight (usually divided over a five-day course). This 
dosage is based mainly on the clinical experience of treating patients with idiopathic 
thrombocytopenic purpura. Not all GBS patients, however, have a good recovery after 
this standard dose and some show an end-of-dose effect with deterioration after initial 
improvement, a so called TRF, which can be treated successfully with another course 
of IVIg. The severity of GBS as well as the outcome (after four weeks or six months) 
varies considerably between patients and therefore it is likely that this standard course 
of IVIg might not be optimal for all. Although the exact working mechanism of IVIg is 
still unknown, IgG is the major component of IVIg and probably responsible for most 
of the immune modulating effects. IVIg clearance and consumption may vary between 
individual patients with GBS, suggesting that some patients may show better recovery 
after a higher dosage or second IVIg course. In contrast to CIDP, corticosteroids (given 
either oral or IV) are not effective in GBS.6 There might be a limited short-term additional 
effect of IV methylprednisolone added to IVIg after correction for prognostic factors. 7
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For treatment of CIDP, IVIg, PE, and corticosteroids have all proven to be beneficial. 
Corticosteroids and IVIg differ in terms of cost, speed of action and adverse events. There 
is no consensus on which is the best treatment for individual patients of CIDP. In CIDP, 
IVIg treatment is started with the same arbitrary standard dosage of 2 g/kg as in GBS. 
Most patients with CIDP require maintenance treatment for a prolonged period of time, 
some even till up to more than 30 years. IVIg maintenance treatment regimens vary 
considerably between CIDP patients and between institutions. IVIg treatment schedules 
seem to be dependent on both disease activity but may also be related to individual 
differences in catabolism of IVIg. Fast IgG metabolisers may require a shorter infusion 
interval than slow metabolisers. How maintenance IVIg treatment should be given and 
how treatment should be individualised by defining the optimum dosage and interval is 
currently unknown and is usually done by trial and error and seems to be related to the 
preference of local neurologists or departmental guidelines.
In this thesis we investigated the diversity of GBS and CIDP with its overlapping forms 
as well as the variation in response to treatment, with a focus on the treatment with 
IVIg. Defining the variation in subtypes of inflammatory neuropathy patients as well 
as the diversity in treatment response is important in order to be able to individualise 
treatment regimens.
In this chapter the main results of these studies, as described in chapter 2-4, will be 
discussed in relation to the available literature. Based on these results, recommenda-
tions for clinical practice are provided and suggestions for further research will be given.
THe SPeCTrum Of GBS AnD CIDP
Recurrences of GBS have been reported in small case series to occur in about 2-5% 
of patients. 8,9 In chapter 2.2 we describe the largest group of recurrent GBS patients 
published so far. This was the first study comparing the characteristics of recurrent GBS 
with those of non-recurrent GBS patients. Since we identified 32 patients with recurrent 
GBS out of a total of 524 GBS patients, the crude estimated prevalence is around 6%. In 
these patients, the clinical symptoms in a first episode were often similar to the follow-
ing episodes (either GBS or MFS; pure motor or sensory-motor) but the severity of the 
symptoms and the nature of the preceding infections varied between episodes. There 
was a trend towards a shorter interval between episodes and a more severe deficit with 
each recurrence. A later study from the Gothenburg region confirmed that the frequency 
of recurrent GBS is 6%.10 This study that used our definition of recurrent GBS, found that 
there was a trend towards similar viral infections in recurrences.10 Some patients in our 
study had very specific recurrent symptoms during subsequent episodes, such as unilat-
eral cranial nerve palsy at the same site. Replicated laterality of cranial nerve dysfunction 
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has been described before in MFS.11,12 The results from our study suggest that some 
patients have a susceptibility to have an abnormal immune reaction to certain types of 
infection, resulting in a person-specific immune-mediated nerve injury. The finding of 
similar symptoms in individual recurrent GBS patients has been reproduced later in an 
Asian cohort.13 In our cohort, recurrences of GBS occurred more frequently in young pa-
tients (<30 years), in those with milder symptoms and in patients with the MFS variant. 
Age as a risk factor for a recurrent GBS was not described in the literature before. After 
the publication of our study another study group confirmed that the mean age in the 
recurrent GBS patients was significantly lower than in the non-recurrent ones (35 vs. 51 
years).10 Why a younger age predisposes for a recurrent course is unknown. It is possible 
that an immunological host factor is involved and that younger GBS patients in general 
have more time ahead to encounter infections that results in an immune-response to 
nerves causing a recurrence. Furthermore, in younger patients the immune system 
might be more active and vulnerable to develop a recurrence. In addition, patients with 
a specific genetic and or immunological predisposition to develop GBS might develop 
the disease at an earlier age. The mean age of patients with a relapsing course of CIDP 
has been reported to be lower compared with CIDP patients with a non-relapsing 
(monophasic or progressive) course (27 vs. 51 years).14 This further strengthens the idea 
that GBS, recurrent GBS, relapsing CIDP and other varieties of CIDP all form parts of the 
same spectrum of inflammatory neuropathies. Patients with the MFS subtype were also 
found to be more likely to have a recurrence than GBS patients in an Asian cohort.15
Interestingly, other autoimmune diseases were more common in recurrent GBS than in 
non-recurrent GBS patients although this did not reach the conventional level of statisti-
cal significance (p = 0.05). Despite its retrospective nature, our study provides important 
information that patient-specific genetic and/or immunological host factors likely play 
an important role in recurrent GBS and are probably more important in determining the 
clinical phenotype than external factors such as preceding infections.
The rare case descriptions of patients who had had separate episodes of both GBS 
and CIDP (Chapter 2.1 and 2.3) further suggests that GBS and CIDP may constitute 
a clinical continuum and that there are common host specific factors that influence 
the susceptibility for inflammatory polyneuropathies. After our publication, a Swedish 
publication described two recurrent GBS patients who developed a progressive clinical 
course similar to CIDP.10 The fact that these patients were published in a paper on recur-
rent GBS shows that differentiation between GBS and CIDP can be difficult and perhaps 
they should be considered as part of a continuum.
In Chapter 2.1 the results of a survey among 461 members of the Dutch society of 
neuromuscular disorders are described. A total of 245 GBS and 76 CIDP patients were 
included. Nineteen of these 245 (7%) GBS patients reported a recurrence and in 9 of 
these we could verify the recurrence by screening of medical letters (4%). Two patients 
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had separate episodes in which they both had GBS and CIDP. Other autoimmune dis-
eases were present in 9% of GBS patients (23/245) in this cohort which is higher than 
the prevalence of 5% reported in the general population. 16 Another study reported a 
higher frequency of other autoimmune diseases in multifocal motor neuropathy (MMN) 
another inflammatory neuropathy. 17 In a large Dutch and Canadian cohort of CIDP 
patients as described in Chapter 3.3, other autoimmune diseases were present in 13% 
of CIDP patients (35/281), and 5 of these 35 patients even had multiple autoimmune 
disorders.
GBS is an immune-mediated disease that can be triggered by preceding infections 
but potentially also by vaccinations. The possible association of inflammatory poly-
neuropathies with vaccination causes considerable uncertainties among patients and 
society. To help answer the question of whether patients with GBS or CIDP may be vac-
cinated, we studied the recurrence of GBS after receiving a vaccination. In our study, 
described in Chapter 2.1, none of the 106 GBS patients who received a flu vaccination 
(range 1-37 times, with a total of 775 vaccinations) in the years after they developed 
GBS reported a recurrence thereafter. Of the 24 patients who received a flu vaccination 
(range 1-17 times) after being diagnosed with CIDP, five reported an increase in symp-
toms after one or more vaccinations. The results of our study indicate that the risk of 
developing a recurrence of GBS after a flu vaccination is small, and that flu vaccinations 
seem relatively safe in patients who have had GBS or still have active CIDP. In 1976 the 
American vaccination programme against the swine flu virus, an influenza virus, was 
stopped prematurely due to an increase of cases developing GBS after vaccination.18 
In 2009 the world witnessed the emergence of another influenza virus of swine origin 
that was a serious public health threat. After the quick development and start of the 
vaccination campaign against the Mexican flu (H1N1) the question was raised whether 
GBS and CIDP patients could receive a vaccination safely.19 The results of our study and 
the fact that the chance of getting (recurrent) GBS after a vaccination is probably much 
smaller than the chance of getting (recurrent) GBS after a flu infection itself resulted 
in our recommendation, as well as that from others, that GBS or CIDP is no absolute 
contraindication for a flu vaccination.19-22 In GBS or CIDP patients with a reason for a 
flu vaccination, due to advanced age or comorbidity, the risk of getting GBS after flu 
infection is probably higher than the risk of the vaccination itself. This recommendation 
has been further supported by other studies.23-25 It is important to mention that GBS or 
CIDP patients who do not belong to this risk group, should not have vaccinations. When 
a CIDP patient receives a vaccination one should be aware that a temporary increase of 
symptoms may occur but this is usually minor and does not require extra treatment.20,22,26 
A flu vaccination is relatively contraindicated in patients who had GBS recently (past 6 
weeks) or in patients with a history of GBS in the six weeks after a flu vaccination. A large 
multinational study in Europe, including the Netherlands, did not observe an associa-
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tion between the influenza H1N1 vaccine and GBS, after adjustment for confounders. 
27 Although our survey (Chapter 2.1) provided useful information regarding the safety 
of vaccinations it has several methodological limitations due to its retrospective nature 
such as selection as well as recall bias. Strong aspects however are the large numbers of 
patients included (response rate of 70%) with an extended follow-up time and the fact 
that we confirmed the diagnosis of recurrence.
recurrences and vaccinations in patients within the spectrum of GBS and CIDP:
some key-points for clinical practice
1.  Recurrence of GBS is rare, with a recurrence rate of around 6%.
2.  Recurrences of GBS are more likely in patients under 30 years of age, in those with initial milder 
symptoms and in patients with MFS.
3.  CIDP patients can experience a temporary minor increase of symptoms after a flu vaccination.
4.  Seasonal flu vaccinations seem relatively safe in GBS or CIDP patients. GBS or CIDP itself is no reason to 
have a flu vaccination.
TreATmenT Of CIDP
IVIg, PE and corticosteroids are effective treatments for CIDP, but each treatment may 
be more or less effective in certain individuals or a subgroup of patients and may cause 
treatment specific side-effects.28 In Chapter 3.1 we give an overview of their efficacy, 
side effects, costs and availability in order to guide clinicians in their choice of treatment. 
An update of the Cochrane reviews is given in Table 1. The fact that the proof of evidence 
for IVIg is better than for corticosteroids even on the long-term, its faster speed of action 
and better (long-term) side-effect profile is probably the main reason that IVIg is often 
the first treatment choice in countries where IVIg is available and affordable. The main 
advantage of corticosteroids is its low price and ease of administration. A recent study 
has found that high-dose (pulsed) treatment with corticosteroids is likely to induce a 
more long-lasting effect than IVIg, since the time to relapse is longer after discontinu-
ing steroids than after IVIg. 29,30 On the other hand, IVIg was shown to be superior over 
high-dose corticosteroids because it was effective more often and better tolerated.29 
Our study, as described in Chapter 3.3, indicates that IVIg is a very effective treatment 
and that (long-term) adverse events are minor and hardly ever a reason to withdraw 
treatment. High-dose corticosteroids given as pulsed therapy may result in less side-
effects than daily oral steroids although this has not yet been proven.31 Not much is 
known about the risk of side-effects of corticosteroids in CIDP because most trials have 
an insufficient follow-up period to capture these on the long-term.32 PE has the advan-
tage of a fast speed of action, similar to IVIg. In a retrospective study, side-effects leading 
to therapy interruption, occurred more often after PE (19%), than in steroid (12.5%) or 
IVIg (4%) treatment.33 The disadvantage of PE is that PE is less convenient and special 
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equipment is needed for the procedure. Therefore, PE is usually given only when both 
IVIg and steroids have shown to be ineffective. There is no evidence so far from RCTs for 
the effectiveness of other immunomodulatory drugs in CIDP. 28,34,35 Patients diagnosed 
with CIDP, who do not improve after IVIg, corticosteroids or PE, should have their di-
agnosis reconsidered. 36 Patients who become unresponsive to treatment should be 
re-evaluated for the appearance of a monoclonal protein or other signs of malignancy.37
Since some CIDP patients reported that one brand of IVIg seemed more efficacious 
than another; we compared the efficacy of two immunoglobulin brands in a RCT (CIC 
study).41,42 The results of this trial are described in Chapter 3.2. This trial did not find any 
differences in efficacy between two different IVIg products (a liquid and a freeze-dried 
product). The limitations of this study are that it was an equivalence study and that for 
practical reasons only two products were compared (both manufactured by the same 
pharmaceutical company and likely from the same donor population). Our study was 
the first RCT to compare various IVIg brands in inflammatory neuropathies. After this 
publication, another study showed similar results. 43 Although different IVIg brands all 
contain similar amounts of IgG, they differ slightly in composition, purification and virus 
elimination process. 44 In patients with renal failure, preparations with a low sugar or 
sucrose content are recommended and patients with thromboembolic risk factors are 
likely better off being treated with preparations with a lower osmolality and protein 
level infused over a longer period of time.44 Currently another RCT is comparing two dif-
ferent IVIg preparations in CIDP. 28,45 Different IVIg brands did not seem to differ much in 
respect to IgG Fc–glycosylation as well.46 Since IVIg brands are similar in efficacy, trying a 
different brand of IVIg in patients who show no response to IVIg is unlikely to be useful. 
It may however be tried when patients experience more than usual side-effects related 
to IVIg treatment.
In Chapter 3.3 we describe a study that included 281 CIDP patients from two neuro-
muscular disease centres that all received IVIg as a first treatment. These patients were 
followed for a mean duration of 5 years (median 3.8 years, range 20 days-28 years). A 
clear and significant response to IVIg (improvement ≥ 1 grade on the mRankin scale) 
Table 1. Cochrane reviews in the treatment of CIDP
Study Treatment efficacy Speed of
action
Potential 
long-term 
adverse 
effects
Availability Costs
Eftimov38 IVIg Proven Fast Minor Good High
Hughes39 Corticosteroids Proven Moderate Severe Very good Low
Mehndiratta40 Plasma exchange Proven Fast Minor Variable High
Mahdi-Rogers35 Other immunomodulatory 
drugs
Unknown Variable Severe/
variable
Good/
variable
Moderate/
variable
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was achieved in 76% of patients. The higher response rate to IVIg in our study com-
pared to the ICE trial (response rate of 58%) is likely due to the fact that the diagnosis 
in our study was always established by a senior neurologist with long-term experience 
in the diagnosis and treatment of CIDP.47,48 Although most patients required long-term 
treatment, 16% of the treatment responders who achieved a documented clinical remis-
sion needed only one IVIg course, a similar percentage has been reported before.2 If 
these patients had been treated with corticosteroids as a first treatment they probably 
would have been on steroids for many months due to the need for slow tapering with 
steroids. In the largest clinical trial of IVIg in CIDP side effects were also an infrequent 
reason to stop treatment even over the long term.48,49 In our study, most of the IVIg non-
responders received an alternative subsequent treatment successfully; 66% improved 
after plasma exchange and 58% with corticosteroids. Of the IVIg non-responders who 
were treated with at least one other treatment modality, about three quarters improved 
after either PE, corticosteroids or both. The response rate to second as well as third 
treatment modalities (corticosteroids or PE) we found was higher compared to what 
has been reported in the literature.33,50 Although our study was non-blinded, it provided 
an important implication for clinical practice, as it seems very useful to try one or even 
two of the other three evidence based efficacious treatments before moving to other 
immunomodulatory treatments since efficacy of these treatments has not been proven 
in CIDP.35 Given the high success rate of IVIg, PE and corticosteroids, combining two 
treatments is rarely necessary and might cause an unnecessary risk of (more) side ef-
fects. In CIDP both corticosteroids and IVIg are in general efficacious, but some patients 
for unknown reasons do not respond to either one of the two treatments. In multivariate 
analysis, the presence of pain or a difference in level of weakness between arms and 
legs was associated with a lack of response to IVIg in our study. Whether these patients 
are better off when treated with corticosteroids still needs to be investigated. Some of 
the patients from our cohort have been included in a previous study from the Erasmus 
MC that already showed an association between no response to IVIg and a discrepancy 
between weakness of the arms and legs. 51 In patients with pure motor CIDP, IVIg is 
generally recommended as a first choice because corticosteroids can lead to a dramatic 
clinical deterioration, as we have experienced several times. 2,52 A post-hoc analysis of 
the PREDICT trial, comparing dexamethasone with prednisolone in CIDP, reported an 
association of less sensory electrophysiological abnormalities with early deterioration 
in CIDP patients treated with corticosteroids.53 In our cohort, 46% of pure motor CIDP 
patients however did show a significant improvement after steroids; therefore this treat-
ment should not be omitted in pure motor CIDP if IVIg is not efficacious.
In our cohort, there were only 3 patients who did not respond to any of the three 
proven effective treatments, all were screened again but no alternative diagnosis was 
found. The high response rate to the first as well as the second or third treatments mo-
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dalities in our study is likely due to the short interval (median 4 months) from symptom 
onset to start of treatment and the fact that patients were treated in neuromuscular 
centres with a long experience and expertise in diagnosing and treating CIDP by expe-
rienced doctors. This may be important because recent studies from the USA showed 
that the diagnosis of CIDP is often made incorrectly, especially by non-neuromuscular 
specialists, in patients with another cause of neuropathy or no neuropathy at all.54,55
Important limitations of our study (Chapter 3.3) are its retrospective nature and the 
fact that some items, such as pain or other autoimmune disease, were not assessed in a 
standardised manner. Subgroups of patients who only improved after a third treatment 
modality were relatively small, and therefore offer limited information. Currently it is 
not possible to predict whether an individual CIDP patient will improve after IVIg or 
steroids or whether a treatment failure is more likely. Animal models of CIDP are be-
ing developed and used to continue the search for biomarkers in order to be able to 
predict the response to IVIg.56 CIDP patients with antibodies of the IgG4 isotype against 
paranodal proteins contactin-1 (CNTN1) and neurofascin-155 (NF155) share specific 
clinical features and are less likely to respond to IVIg.57,58 59 Although specific autoanti-
bodies can be detected only in a small group of CIDP patients so far, they can be useful 
in guiding treatment choice. It has been suggested that rituximab might be useful in 
these patients with IgG4 antibodies. 60 Recently it has been reported that CIDP patients 
with contactin-associated protein1 (CASPR1) are less responsive to IVIg and they show 
severe neuropathic pain, since the presence of pain was associated with no response 
to IVIg in our cohort it will be interesting to check these patient for these antibodies.59 
Furthermore it is possible that the discrepancy in weakness between arms and legs that 
we found to be associated with no response to IVIg, can be explained by axonal changes 
due to certain antibodies.
Although IVIg, corticosteroids and plasma exchange are all proven efficacious in CIDP, 
many questions still remain. Maintenance treatment regimens vary largely between pa-
tients and the best strategy to adjust maintenance IVIg treatment in individual patients 
with CIDP is unknown. In Chapter 3.4 we give an overview of what is currently known 
regarding IVIg maintenance treatment and give guidance on how maintenance treat-
ment can be given in clinical practice. We are currently investigating in an RCT whether 
more frequent low IVIg dosing is more effective than low frequency high dosing as 
maintenance treatment in CIDP (DRIP study) which is briefly pointed out in Chapter 3.5.
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Treatment of CIDP: practical key-points
1.  Around three quarters of treatment-naïve CIDP patients is responsive to IVIg.
2.  In CIDP patients who do not respond to one or two courses of IVIg, trying a different brand of IVIg is 
unlikely to be useful.
3.  In IVIg non-responders, the response rate to steroids or PE is still quite high. Therefore, these treatments 
should both be tried first before trying other immunosuppressive drugs that have not been proven to be 
efficacious.
4.  Although there is a risk of deterioration, pure motor CIDP patients can show a good response to 
corticosteroids. This implies that when IVIg is not efficacious, treatment with corticosteroids should not 
be omitted.
5.  Patients without a difference in weakness between arms and legs and those without pain are more likely 
to improve after IVIg.
6.   From the patients who are IVIg responsive and who reach a clinical remission, about 15% only needs one 
course of IVIg.
7.  Most CIDP patients need IVIg for a long period of time, but side effects are hardly ever a reason to stop 
treatment, even on the long-term.
Serum IGG leVelS In IVIG-TreATeD GBS AnD CIDP
The working mechanism of IVIg in GBS and CIDP is still unknown and patients are 
treated with the same standard induction dose (2 g/kg in 2-5 days) for many years based 
on studies in idiopathic thrombocytopenia.61,62 Not all patients recover well after this 
standard dose, but studies comparing different IVIg dosages have not been done in 
GBS. It has been shown that the number of plasma exchanges could be adjusted to the 
severity of GBS, and that in CIDP the response (rate and magnitude) can be improved 
by either repeating or increasing the dosage.63, 64 In the treatment of CIDP it is known 
that at least two IVIg courses may be required before patients show an improvement. 
65 A small case series suggested that a second IVIg course might be beneficial in severe 
unresponsive GBS patients. 66 Although not formally investigated, re-treatment with IVIg 
is recommended in GBS patients who show a treatment-related fluctuation (TRF).67 68 
These findings indicate that patients with inflammatory neuropathy may not respond 
equally to a standard IVIg dosage and that some patients may benefit from a higher 
dosage or additional course of IVIg. The differences in treatment response may be re-
lated to a variation in the clearance or consumption of IVIg. In patients with primary 
immunodeficiency the pharmacokinetics of IVIg have been reported to show consider-
able variability, which may suggest that a similar variability is present in patients with 
inflammatory neuropathies.69
In Chapter 4.1 we describe a study that was conducted with 174 GBS patients, who 
had all participated in one of two previous RCTs and were treated with a standard course 
of IVIg (2 g/kg in 5 days). 7,70 We found considerable variation between GBS patients in 
the pharmacokinetics of a standard course of IVIg. Patients with a low increase in serum 
IgG two weeks after standard IVIg treatment (delta IgG level) had a more severe course 
of disease expressed as a higher GBS-disability score and a lower MRC sum score both 
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at entry and nadir. The time required to improve one grade on the disability scale was 
significantly longer in the patients with the lowest increase in serum IgG. A low increase 
in serum IgG two weeks after IVIg was associated with a worse outcome, independent 
of other prognostic factors. Our data suggest that a certain threshold of delta IgG (> 
7.30 g/L) is required for a substantial therapeutic effect in GBS. When adjusted for the 
Erasmus GBS Outcome scale (EGOS) prognostic model,71 the delta IgG level was still 
associated with the outcome at six months (Chapter 4.1). From these results, it can be 
concluded that a subgroup of GBS patients may likely benefit from a second course of 
IVIg. Whether some patients, for example those who metabolise IVIg faster, have a better 
outcome when treated with a second course of IVIg requires further investigation in 
a RCT. Based upon the results of our study, the second IVIg dose trial in GBS patients 
with a poor prognosis was started (SID-GBS trial), registered in the Dutch trial register 
as NTR2224.72 Although some GBS patients with a poor prognosis are already treated 
in clinical practice with another course of IVIg, results from a RCT are needed to prove 
whether this is justified.73
In our study, GBS patients with a higher pre-treatment serum IgG level had slightly 
more disability in the acute stage. A higher disease activity with more extensive immune 
activation and nerve damage may result in a higher consumption of IVIg. Patients with a 
higher serum IgG level are known to have a higher catabolism of IgG, probably caused by 
the saturation of the pool of neonatal Fc receptors that protects IgG from degradation. 
74-76 The expression level of the neonatal Fc receptor (FcRn) is influenced by the number 
of gene copies, but a recent study found no difference between this genetic polymor-
phism and the pharmacokinetics of IVIg or outcome in GBS. 77 It is interesting that the 
serum IgG level at a three and six month time period did show statistically significant 
differences between groups of GBS patients with different FcRn polymorphisms.77 
It is possible that the “baseline” serum IgG level, before the administration of IVIg, is 
influenced by the acute stage of the disease suggesting that serum IgG levels being 
measured much later are more representative for the individual “baseline” IgG level.77 
This means that a relationship between FcRn polymorphisms and serum IgG levels can-
not be ruled out. Serum IgG levels are associated with serum albumin levels which may 
be explained by the fact that both IgG and albumin are protected against degradation 
by the FcRn.78,79 Patients with a mutation in the b2-microglobulin chain of the FcRn 
have been reported to have a higher catabolism of IgG.80 The higher IgG baseline level 
that we found in our GBS study only had a small effect on the variation observed in 
delta IgG level, and in multivariate analysis the pre-treatment serum IgG level was not 
associated with the outcome. After the publication of our results, the MMN research 
group in Utrecht investigated the pharmacokinetics of IVIg in MMN.81 Serum samples 
were obtained at somewhat different time-points before and after a standard course of 
IVIg (2 g/kg) in 23 treatment-naïve MMN patients. 81 Similar to our results the authors 
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found a large variation in serum IgG level as well as in delta IgG between patients.81 
Furthermore baseline IgG levels were higher and the mean delta IgG level was lower in 
IVIg non-responders but due to the low patient numbers it is likely that this study could 
not provide sufficient power to detect significant differences. 81
The optimum dosage and frequency of maintenance IVIg treatment varies widely 
between CIDP patients. 82 This variation might be partially explained by individual dif-
ferences in IVIg catabolism and disease activity. In Chapter 4.2 we describe a study in 
which we investigated serum IgG levels in CIDP patients with active but stable disease 
obtained from a previous RCT comparing two different immunoglobulin preparations in 
CIDP (Chapter 3.2). All patients were IVIg responsive and had been treated according 
to their own individual established optimum regimen of IVIg. 2 Similar to what has been 
reported in the literature, the total dosage of IVIg per infusion required to reach a stable 
clinical situation did not correlate with body weight.82 83 This is of interest since at least 
the loading dose of IVIg is still based on body weight. Disability did not correlate with 
the IVIg dosage required, which is similar to what we observe in clinical practice where 
initially more severely affected CIDP patients do not seem to require a higher dosage 
than mildly affected patients of the same body weight. It has been reported previously 
that the dosage of IVIg required does not correlate with (initial) disability in CIDP. 82 
Although the inter-patient variability in increase in serum IgG immediately after IVIg 
was higher than the intra-patient variability in these CIDP patients (Chapter 4.2), both 
were considered low. Serum IgG levels remained relatively constant over time during 
subsequent courses of maintenance IVIg treatment in stable CIDP patients. More or less 
constant serum IgG levels (above a certain threshold) are probably needed to reach and 
maintain a clinical stable situation in CIDP. Different from our pharmacokinetic study in 
GBS (Chapter 4.1) is that all CIDP patients were known to be IVIg responders, and all 
were in a clinically stable situation receiving maintenance IVIg treatment according to 
individual established dosages and intervals. A limitation of this study is the relatively 
low number of patients that received exactly the same dosage and frequency of IVIg, 
reducing the amount of patients that could be compared. Two other studies published 
later on, found constant serum IgG levels during two courses of IVIg in CIDP. 79,83 Both 
these studies reported large inter-patient variability, although the study by Rajabally 
et al. does not report whether they only compared patients with the same dosage and 
interval. 79,83
High peak levels of serum IgG may not be needed for maintenance treatment of CIDP 
with IVIg. Whether more frequent dosing of IVIg leads to more stable IgG levels and 
higher trough levels corresponding with an improvement in efficacy and less side ef-
fects is currently being investigated in an RCT in a cohort of CIDP patients (DRIP study) 
(Chapter 3.5).84 It is reported that a decrease in serum IgG level seems to correspond 
with a higher level of clinical disability in MMN and CIDP. 79,85,86 Serum IgG levels have 
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been used to guide dosage and interval of IVIg in CIDP for the first time in a small study. 
86 If high peak levels are needed for the efficacy of immunoglobulins IVIg would be pre-
ferred above SCIg. if high peak levels are not needed and the efficacy is more dependent 
on stable serum labels as well as high trough levels, SCIg would be more favourable. 
The fact that a loading dose of IVIg (0.4 g/kg/day over 5 days) improved motor function 
to a similar degree as SCIg in treatment-naïve CIDP (0.4 g/kg every week) suggests that 
a loading dose is not always needed to initiate a therapeutic response. 87 In this study 
patients did show an earlier maximal improvement after treatment with IVIg compared 
to when treated with SCIg, which might be explained by the higher peak serum levels 
of IgG after the loading dose of IVIg. 87 Results of future trials are required to investigate 
whether monitoring of serum IgG levels can be used to improve the clinical efficacy of 
IVIg treatment in GBS or CIDP. Till then monitoring of serum IgG levels to adjust the IVIg 
dosage and interval cannot be recommended.
IgG levels in IVIg treated GBS and CIDP: practical key-points
1.  GBS patients show considerable variation in the pharmacokinetics of IgG (after IVIg treatment) which is 
associated with the outcome at six months.
2.  A low increase in serum IgG two weeks after start of IVIg is associated with a worse outcome in GBS, 
independent of other prognostic factors.
3.  A subgroup of GBS patients may benefit from a higher dosage or second course of IVIg.
4.  Body weight by itself does not seem to influence the IVIg dosage required for effective CIDP 
maintenance treatment.
5.  In CIDP patients on maintenance IVIg treatment more constant serum IgG levels above a certain 
threshold level are probably required to reach and maintain a stable clinical situation.
6.  Standard monitoring of serum IgG levels cannot be recommended until future trials provide more 
evidence that these levels are related to treatment response and outcome.
fuTure PerSPeCTIVeS
To further investigate the whole spectrum of inflammatory polyneuropathies, including 
the rare subtypes such as GBS-TRF, recurrent GBS and A-CIDP; large prospective cohort 
studies are very helpful. The prospective International GBS Outcome Study (IGOS) 
started in May 2012 and by May 2017 included more than 1500 participants from 19 
countries across 5 continents.88 The IGOS is a perfect platform to gain a large amount 
of data regarding these rare subtypes of GBS from different geographical parts all over 
the world.88 Large international studies such as IGOS will provide opportunities to study 
genetic susceptibility factors in the development of these inflammatory neuropathies 
possibly via techniques such as genome wide association studies or whole exome se-
quencing. Understanding why some patients develop recurrent GBS or chronic forms 
of inflammatory polyradiculoneuropathy might give more insight how to improve and 
personalise treatment.
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Over the past 10-15 years, a lot of new information has been gathered that shed more 
light on the pathogenesis of GBS. A recent study has shown that former GBS patients 
show a stronger response to pathogen-associated molecules compared to healthy 
controls. 89 The next step could be to investigate whether patients with recurrent GBS 
show even stronger responses to pathogen-associated molecules compared to patients 
with a monophasic GBS. It is important to realise that GBS is highly diverse with respect 
to clinical course and outcome. Some less severely affected patients show spontaneous 
and complete recovery even without treatment, while others remain severely handi-
capped despite repeated IVIg treatment. Further studies are needed to understand what 
mechanisms influence this clinical diversity and how treatment can be personalised in 
such a way that each patient receives the optimal treatment for their own personal 
situation. The IGOS aims to define biomarkers for disease activity and recovery and to 
develop prognostic models to predict the clinical course and outcome in individual pa-
tients with GBS.88 Partially based upon the results of our study, as described in Chapter 
4.1, showing that GBS patients with a higher increase in serum IgG level two weeks 
after IVIg showed a better outcome, the SID-GBS trial was started.72 In this SID-GBS trial, 
GBS patients treated with a standard dose of IVIg that have a poor prognosis at day 7 
defined by the modified EGOS prognostic model90 are randomised to receive either a 
placebo or a second course of IVIg. Results of this RCT are expected by the end of 2018. 
If this trial can prove that a second IVIg dose is more effective in patients with a poor 
prognosis and/or a lower increase in serum IgG after the first course, this will lead to an 
improvement in treatment and outcome in GBS and as such will be a first step towards 
more personalised medicine in GBS. In the SID-GBS trial serum IgG levels will also be 
determined from an earlier time point (one week after the start of treatment) which is 
different from the study we have published (Chapter 4.1). Although the time window 
in which additional IVIg treatment is effective is unknown, it is likely that an early start 
of a second IVIg course is better (“time is nerve”) to avoid axonal damage or (para)nodal 
disruption. In CIDP a quick start of effective treatment is associated with a higher chance 
to be able to stop treatment later on. 91
A prospective international observation study (I-SID GBS study, as part of the IGOS) 
is currently investigating whether a second course of IVIg (started within the first four 
weeks after onset of GBS) is more effective than treatment with one standard course 
of IVIg. The results of this observational study are likely to be published prior to the 
results of the Dutch RCT (SID-GBS trial). In large parts of the world, especially in low 
income countries, IVIg is not readily available or too expensive and GBS patients are left 
untreated or are treated with PE (or modified PE). The decrease in serum IgG level has 
been reported to differ between patients treated with (standard) PE.92 The French PE 
trial indicated that the number of plasma exchanges could be adjusted to the severity 
of GBS.64 These papers together with the results of our study (Chapter 4.1) showing 
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an association between the delta IgG and outcome of GBS after a standard IVIg course, 
make it worth investigating whether patients with a poor outcome after PE have a lower 
decrease in serum IgG after standard plasma exchange (e.g. 4 sessions) and therefore 
would potentially benefit from more sessions of PE.64 The IGOS study will provide more 
information on a very large scale regarding multiple topics studied in this thesis, includ-
ing longitudinal serum IgG levels after IVIg in relation to outcome. In the IGOS study, 
serum IgG levels are determined at multiple time-points to determine IVIg pharmaco-
kinetics. Additionally, DNA polymorphisms will be investigated to determine potential 
genetic susceptibility factors involved related to the response to treatment. These data 
likely will be available within the next few years.
It is unknown why some CIDP patients do not respond to IVIg. Future research should 
focus on finding explanations for this lack of response, but also on why some patients 
after being treated with IVIg successfully over many years at some point do not need 
treatment anymore. Why CIDP patients who do respond to IVIg require different dos-
ages and frequencies is currently unknown and requires further investigation. A large 
scale international study similar to the IGOS is currently being prepared for in CIDP 
(ICOS study). This study will provide a large amount of data regarding the occurrence 
of A-CIDP, the response to IVIg treatment, as well as IVIg pharmacokinetics. These large 
international studies (IGOS and ICOS) provide unique opportunities to study genetic 
polymorphisms and other potential biomarkers that may explain why some patients do 
not respond to IVIg, require a higher dosage or prolonged IVIg treatment. The recent 
discovery of new antibodies in a small group of CIDP patients has led to an advance in 
understanding of the diversity of CIDP and its subforms and differences in the response 
to therapy. It is expected that over the next years new antibodies will be discovered 
in subgroups of CIDP patients that can be related to the treatment response which 
may further support the development of personalised treatment. Some concern has 
arisen recently whether IVIg leads to treatment dependency in CIDP when compared 
to corticosteroid treatment.30 Some CIDP patients however only need one or two IVIg 
courses, and patients who have been treated with IVIg for years can still reach a remis-
sion without the need for further treatment. Treatment dependent patients were more 
often responsive to IVIg and resistant to corticosteroids compared to patients whose 
treatment could be withdrawn and were not treatment dependant. 91
Future studies in CIDP will hopefully give an answer whether treatment dependency is 
due to clinical features or to the therapy used. Since IVIg acts fast, and high-dose steroids 
potentially may induce more frequent remissions, the Optimal Induction Treatment 
In CIDP study (OPTIC trial) has been initiated. This study will investigate whether the 
addition of methylprednisolone to IVIg will lead to an earlier remission. Future studies 
investigating serum IgG levels in CIDP patients treated with IVIg are expected. It is of in-
terest to investigate serum IgG levels in treatment-naïve CIDP patients who receive their 
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first IVIg course and to compare responders versus non-responders in order to predict 
response and individualise therapy as early as possible. Currently we are investigating in 
a RCT (DRIP-study) whether high frequent low dosage IVIg treatment is more effective 
than low frequent high IVIg dosage as maintenance treatment for CIDP (Chapter 3.5). If 
our hypothesis is true that more stable IgG levels lead to a better efficacy, subcutaneous 
IgG (SCIg) might potentially be more effective than IVIg because it is usually given in 
smaller dosages more often over time. A recent small study found similar efficacy on the 
short-term after SCIg compared to IVIg in treatment-naïve CIDP patients, with an earlier 
improvement following IVIg treatment.87 Very recently a large placebo controlled trial 
was published showing that SCIg is effective as maintenance treatment in CIDP.93 In the 
future, more studies are needed to compare the efficacy and pharmacokinetics of SCIg 
versus IVIg.94,95 Since CIDP patients have been treated with IVIg for over 30 years it is 
remarkable that so many questions still remain regarding its working mechanism, what 
determines the response, and how IVIg treatment can be optimised.
fInAl remArKS
GBS and CIDP, connected by their overlap forms such as recurrent GBS, GBS-TRF, mono-
phasic CIDP and A-CIDP, should be considered parts of a spectrum of immune-mediated 
polyradiculoneuropathies instead of completely separate entities. Three facts appear to 
underline the importance of genetic and host-specific immune responses in GBS and 
CIDP; 1st only a small proportion of patients develop GBS after exposure to an identical 
infection, 2nd GBS and CIDP can co-occur in a single patient and 3rd GBS can reoccur at a 
higher rate than expected, showing similar symptoms after different infections.
Descriptions of specific individual cases can be relevant since these may give more 
insight into the clinical course and outcome of GBS and CIDP, especially in atypical 
patients who are often not covered in clinical trials. Since individual patients with GBS 
or CIDP can vary largely in clinical characteristics, severity, duration of progression, me-
tabolism, and outcome, it is unlikely that one standard treatment regimen will fit every 
patient. It is important to choose the best treatment option in each individual as soon as 
possible in order to prevent secondary axonal degeneration, side-effects and unneces-
sary costs. Treatment with a standard IVIg dosage based on body weight alone does not 
fulfil the needs of every patient. More personalised treatment based on an individual’s 
clinical subtype as well as genetic and metabolic factors instead of a one-size-fits-all 
approach can hopefully be applied in GBS and CIDP patients in the near future. Serum 
IgG levels may predict the clinical response to IVIg, but whether these levels can be used 
as biomarkers to improve IVIg treatment regimens needs to be determined in a RCT. 
Hopefully the results of the SID-GBS trial, that are expected by the end of 2018, will give 
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an answer as to whether a second IVIg course improves the outcome in patients with a 
poor prognosis. If it can be proven that monitoring of serum IgG levels can be used as 
a biomarker to optimise IVIg therapy this might also have an impact for other diseases 
that are currently treated with IVIg.
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SummAry
Both Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyneu-
ropathy (CIDP) are immune-mediated polyradiculoneuropathies.
In Chapter 1, the introduction, an overview is given of the diagnostic criteria for both 
GBS and CIDP including the differential diagnosis and treatment options.
Although GBS and CIDP have been considered as separate entities, there is some 
evidence that gives weight to the argument that they are part of a spectrum of inflam-
matory demyelinating polyneuropathies. Some CIDP patients have an acute onset, 
resembling GBS, and some patients diagnosed with GBS may relapse or experience 
treatment-related fluctuations 4-8 weeks after onset of GBS. The spectrum of GBS, CIDP 
and its subforms is investigated in the first part of this thesis (Chapter 2).
Although GBS generally is a monophasic disorder, recurrences do occur in an 
undefined subgroup of patients. In Chapter 2.1 we report whether we could identify 
which subgroup of patients is more likely to develop a recurrence of GBS, and whether 
preceding infections and neurological symptoms are similar in subsequent episodes. In 
this study we identified 32 patients with recurrent GBS, who had a total of 81 episodes, 
and then compared their clinical characteristics with 476 non-recurrent GBS patients. 
Recurrences occurred more frequently in younger patients (under the age of 30), in 
patients with milder symptoms (able to walk with or without support) and in patients 
with Miller Fisher syndrome. While neurological symptoms and signs were often similar, 
the nature of the preceding infection often varied which may indicate that genetic and 
immunologic host factors might play an important role in patients with recurrent GBS. 
In Chapter 2.2, four patients are described who all had separate episodes of both GBS 
and CIDP. These rare cases show that both GBS and CIDP can co-occur in a single patient 
in different episodes and should be diagnosed and treated accordingly. These case 
descriptions illustrate that GBS and CIDP probably could be seen as part of a continuum 
instead of separate entities. In Chapter 2.3 we describe the whole spectrum of GBS 
and CIDP and its subforms which were investigated via a survey among members of 
the Dutch society of neuromuscular disorders (Spierziekten Nederland) known with the 
diagnosis GBS or CIDP. Two hundred and forty-five GBS and seventy-six CIDP patients 
were included (response-rate of 70%). in nine patients we could confirm they had a re-
current GBS (4%), and two patients had experienced both GBS and CIDP. We also studied 
whether autoimmune diseases were more frequently reported in GBS or CIDP. We found 
that the GBS and CIDP patients included in our study had a slightly higher prevalence 
of other autoimmune diseases compared to the general population. We studied a large 
number of patients who may have had multiple vaccinations over time, in order to 
answer the question whether ex-GBS and CIDP patients can receive vaccinations safely 
or not. Since none of the 106 GBS patients who received a flu vaccination (range 1-37 
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times, total 775 vaccinations) reported a recurrence thereafter, seasonal flu vaccinations 
seem relatively safe in patients who have had GBS. Additionally we investigated the 
presence of residual symptoms such as pain, severe fatigue, and a reduced quality of 
life. It appeared that years after the diagnosis of GBS or CIDP, a large number of patients 
suffer from these sequellae.
The second part of this thesis (Chapter 3) is focused on the treatment of CIDP.
Chapter 3.1 contains a review paper on treatment options in CIDP. Intravenous im-
munoglobulin (IVIg), plasma exchange (PE) and corticosteroids have all been proven to 
be beneficial in randomised controlled trials (RCTs), albeit the proof for corticosteroids 
is less clear. Although these treatments are more or less similar in clinical efficacy, they 
differ in terms of cost, availability and adverse effects. These characteristics should be 
taken into account when deciding which treatment should be offered to a patient. If 
the first treatment has no effect, one of the other proven effective treatments should be 
tried before moving towards other immunosuppressive drugs that are not proven yet to 
be beneficial. An overview of these treatments, their mode of action, adverse effects and 
potential place in the spectrum of treatments for CIDP based on their level of evidence 
is given. Various IVIg preparations are generally assumed to be equivalent, although 
this has not been investigated. Some patients report that some IVIg brands seem more 
efficacious than others. In Chapter 3.2 the results of a RCT comparing two different 
immunoglobulins in the treatment of CIDP are described. No significant differences 
were found in clinical efficacy or the occurrence of adverse events between the two IVIg 
preparations. Although some patients might prefer a certain IVIg brand, the results of 
this trial suggest that the perceived difference in clinical efficacy is unlikely to be due 
to differences in the IVIg preparation used. For unknown reasons not all CIDP patients 
improve after IVIg. In Chapter 3.3 the results of a retrospective study are presented 
in which we investigated factors that may determine a clinical response to IVIg. IVIg 
seemed to be highly effective as a first-line treatment in CIDP, since 76% of patients 
improved significantly after treatment. The (long term) adverse events were minor and 
hardly ever a reason to discontinue treatment. Of the IVIg non-responders three quar-
ters of patients still responded to PE, corticosteroids or both. Thirteen percent of the 
CIDP patients were known to have a concurrent autoimmune disorder which is higher 
than in the general population. It was shown that pure motor CIDP patients can improve 
after corticosteroids. Therefore corticosteroid treatment should not be omitted in pure 
motor CIDP patients who are unresponsive to IVIg. CIDP patients with pronounced pain 
or a difference in weakness between arms and legs seem less likely to be IVIg responsive. 
Although most patients need IVIg for a long period of time, 16% only needs one IVIg 
course to reach clinical remission. The optimal treatment regimen of IVIg maintenance 
treatment in CIDP is currently unknown. There are large differences in IVIg dosage 
and interval requirements between individual CIDP patients. Chapter 3.4 provides an 
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overview of the different IVIg maintenance schedules currently used in the treatment 
of CIDP. Randomised trials comparing different dosage schedules of IVIg are needed. In 
Chapter 3.5 the protocol of a dose response trial of IVIg in CIDP is presented. This trial 
investigates whether high frequent low dosage IVIg treatment is more effective than 
low frequent high dosage IVIg treatment. This dose response trial is currently including 
patients and is expected to be finished by the end of 2018.
IgG is the main component of IVIg, and probably responsible for most of its immuno-
modulatory effect.
In Chapter 4 the focus is on serum IgG levels in IVIg treated GBS and CIDP patients. GBS 
patients all receive the same arbitrary dose of 2 g IVIg per kg body weight. However, not 
all patients show a good recovery after this standard dose. In Chapter 4.1 we describe 
a study in which we determined whether the pharmacokinetics of IVIg were related to 
outcome in GBS. Patients showed considerable variability in the increase in serum IgG 
level two weeks after start of a standard IVIg course (2 g/kg). Patients with a low increase 
in serum IgG had a more severe disease course, recovered slower and were less likely 
to reach the ability to walk unaided after 6 months. Even after adjustment for other 
known prognostic factors, a low increase in serum IgG was independently associated 
with a worse outcome. These results indicate that patients with a small increase in serum 
IgG level may benefit from a higher dosage or second course of IVIg. CIDP patients are 
often treated with IVIg, and receive the same arbitrary initial dose of 2 g/kg of IVIg as 
GBS patients. Most CIDP patients need long-term treatment and the optimum dosage 
and frequency of IVIg maintenance treatment varies largely between individual patients 
and might be partly explained by individual differences in IVIg catabolism. In Chapter 
4.2 the results of a study are presented in which we investigated serum IgG levels in 
clinically stable but IVIg dependent CIDP patients. All patients received an individually 
optimised fixed dosage IVIg maintenance treatment. The dosage of IVIg required to 
reach a stable clinical situation did not correlate with body weight. Clinically stable CIDP 
patients showed a steady-state in serum IgG after serial IVIg infusions. The low intra- and 
inter-patient variability in serum IgG may indicate that constant IgG levels are required 
to reach stability. More studies are required to further optimise the dosage and interval 
of IVIg maintenance treatment in CIDP.
Given that GBS can reoccur showing similar symptoms after different infections, and 
that GBS and CIDP can co-occur in a single patient indicates that host-specific immune 
responses are important in the spectrum of GBS and CIDP. Furthermore autoimmune 
diseases seem to be more prevalent in both GBS and CIDP. Patients are often treated 
with the same standard dose of IVIg, but some patients are less likely to respond due 
to differences in their clinical characteristics or IVIg catabolism. Whether these patients 
are better off if IVIg is given in a modified dosage or when they receive an alternative 
treatment needs to be investigated in clinical trials.
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SAmenVATTInG
Zowel het Guillain-Barré-syndroom (GBS) als de chronische inflammatoire demyelinise-
rende polyneuropathie (CIDP) zijn immuun-gemedieerde polyradiculoneuropathieën.
In Hoofdstuk 1, de inleiding, wordt een overzicht gegeven van de diagnostische cri-
teria voor zowel GBS als CIDP, inclusief de differentiële diagnose en behandelingsopties.
Hoewel GBS en CIDP als afzonderlijke entiteiten worden beschouwd, zijn er aanwij-
zingen dat zij deel uitmaken van een spectrum van inflammatoire demyeliniserende 
polyneuropathieën. Sommige CIDP-patiënten hebben een acuut begin, dat lijkt op GBS, 
en sommige patiënten gediagnostiseerd met GBS kunnen 4-8 weken na aanvang van 
het GBS een terugval vertonen of behandeling gerelateerde fluctuaties ervaren. Het 
spectrum van GBS, CIDP en zijn varianten wordt onderzocht in het eerste deel van dit 
proefschrift (Hoofdstuk 2).
Hoewel GBS in het algemeen een monofasische aandoening is, komen recidieven voor 
in een ongedefinieerde subgroep van patiënten. In Hoofdstuk 2.1 rapporteren we of we 
kunnen vaststellen welke subgroep van patiënten een grotere kans heeft op een recidief 
van het GBS en of neurologische symptomen en voorafgaande infecties vergelijkbaar 
zijn in opeenvolgende episodes. In deze studie identificeerden we 32 recidiverende 
GBS-patiënten, die in totaal 81 episoden doormaakten, en vergeleken hun klinische 
kenmerken met 476 niet-recidiverende GBS-patiënten. Recidieven kwamen vaker voor 
bij jongere patiënten (jonger dan 30 jaar), bij patiënten met mildere symptomen (in 
staat om met of zonder ondersteuning te lopen) en bij patiënten met het Miller Fisher-
syndroom. Hoewel neurologische symptomen en verschijnselen vaak vergelijkbaar 
waren, varieerde de aard van de voorgaande infectie regelmatig, wat erop kan duiden 
dat genetische en immunologische gastheerfactoren een belangrijke rol zouden kun-
nen spelen in recidiverend GBS. In Hoofdstuk 2.2 worden vier patiënten beschreven 
die allemaal afzonderlijke episodes van zowel GBS als CIDP doormaakte. Deze zeldzame 
gevallen laten zien dat zowel GBS als CIDP samen kunnen voorkomen in een enkele 
patiënt gedurende verschillende episodes en dienovereenkomstig moeten worden 
gediagnosticeerd en behandeld. Deze casusbeschrijvingen illustreren dat GBS en CIDP 
waarschijnlijk kunnen worden gezien als onderdeel van een continuüm in plaats van 
afzonderlijke entiteiten. In Hoofdstuk 2.3 beschrijven we het hele spectrum van GBS 
en CIDP en de varianten die zijn onderzocht via een enquête onder leden van de Ne-
derlandse vereniging van neuromusculaire aandoeningen (Spierziekten Nederland) met 
de diagnose GBS of CIDP. In totaal werden 245 GBS en 76 CIDP-patiënten geïncludeerd 
(respons van 70%). In negen patiënten (4%) konden we een recidiverend GBS aantonen 
en twee patiënten hadden zowel GBS als CIDP doorgemaakt. We hebben tevens onder-
zocht of auto-immuunziekten vaker voorkomen in GBS of CIDP. We ontdekten een iets 
hogere prevalentie van andere auto-immuunziekten onder de GBS- en CIDP-patiënten 
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van ons onderzoek in vergelijking met de algemene bevolking. Om de vraag te be-
antwoorden of ex-GBS en CIDP-patiënten veilig gevaccineerd kunnen worden of niet 
hebben we een groot aantal patiënten bestudeerd die mogelijk meerdere vaccinaties 
hebben gehad in de tijd. Omdat geen van de 106 GBS-patiënten die een griepvaccinatie 
kregen (variërend 1-37 keer, totaal 775 vaccinaties) daarna een recidief meldden, lijken 
seizoensgebonden griepvaccinaties relatief veilig bij patiënten die GBS hebben gehad. 
Daarnaast hebben we de aanwezigheid van restverschijnselen onderzocht, zoals pijn, 
ernstige vermoeidheid en een verminderde kwaliteit van leven. Het bleek dat jaren na 
de diagnose van GBS of CIDP een groot aantal patiënten restverschijnselen vertoont.
Het tweede deel van dit proefschrift (Hoofdstuk 3) is gericht op de behandeling van 
CIDP.
Hoofdstuk 3.1 bevat een overzichtsartikel over behandelingsopties in CIDP. Intra-
veneuze immunoglobuline (IVIg), plasmaferese (PE) en corticosteroïden zijn allemaal 
bewezen effectief in gerandomiseerde gecontroleerde onderzoeken (RCT’s), hoewel het 
bewijs voor corticosteroïden minder duidelijk is. Hoewel deze behandelingen min of 
meer vergelijkbaar zijn in klinische werkzaamheid, verschillen ze in kosten, beschikbaar-
heid en bijwerkingen. Met deze kenmerken moet rekening worden gehouden bij de be-
slissing welke behandeling men aan een patiënt aanbiedt. Indien de eerste behandeling 
geen effect heeft, moet een van de andere bewezen effectieve behandelingen worden 
geprobeerd alvorens over te gaan naar andere immunosuppressiva waarvan nog niet is 
bewezen dat ze werkzaam zijn. Een overzicht van deze behandelingen, hun werkings-
wijze, bijwerkingen en mogelijke plaats in het spectrum van behandelingen voor CIDP 
op basis van hun bewijskracht wordt gegeven. Verschillende IVIg-preparaten worden in 
het algemeen als gelijkwaardig beschouwd, hoewel dit niet goed is onderzocht. Sommi-
ge patiënten geven aan dat sommige IVIg-preparaten beter lijken te werken dan andere. 
In Hoofdstuk 3.2 worden de resultaten beschreven van een RCT die twee verschillende 
immunoglobulinen vergelijkt in de behandeling van CIDP. Er werden geen significante 
verschillen gevonden in klinische werkzaamheid of het optreden van bijwerkingen 
tussen de twee IVIg-preparaten. Hoewel sommige patiënten misschien een bepaald 
IVIg-merk prefereren, suggereren de resultaten van deze studie dat het waargenomen 
verschil in klinische werkzaamheid waarschijnlijk niet te wijten is aan verschillen in de 
gebruikte IVIg-preparaten. Om onbekende redenen verbeteren niet alle CIDP-patiënten 
na behandeling met IVIg. In Hoofdstuk 3.3 worden de resultaten van een retrospectief 
onderzoek gepresenteerd waarin we factoren hebben onderzocht die mogelijk de 
respons op IVIg bepalen. IVIg leek een zeer effectieve eerstelijnsbehandeling te zijn bij 
CIDP, aangezien 76% van de patiënten na de behandeling aanzienlijk verbeterde. De 
(lange termijn) bijwerkingen waren minimaal en zelden een reden om de behandeling 
te staken. Van de patiënten die niet op IVIg reageerden, vertoonden driekwart van de 
patiënten alsnog een reactie op PE, corticosteroïden of beide. Dertien procent van de 
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CIDP-patiënten had naast de CIDP een auto-immuunziekte, dit percentage is hoger dan 
dat in de algemene bevolking. Er werd aangetoond dat puur motore CIDP-patiënten 
kunnen verbeteren na corticosteroïden. Daarom moet behandeling met corticosteroï-
den niet worden overgeslagen in puur motore CIDP-patiënten die niet reageren op IVIg. 
CIDP-patiënten met uitgesproken pijn of een verschil in zwakte tussen armen en benen 
reageren minder goed op IVIg. Hoewel de meeste patiënten langere tijd IVIg behande-
ling nodig hebben, heeft 16% slechts één IVIg-kuur nodig om een klinische remissie te 
bereiken. Het optimale behandelingsregime van IVIg onderhoudsbehandeling in CIDP 
is momenteel onbekend. Er zijn grote verschillen in benodigde IVIg-dosering en interval 
tussen individuele CIDP-patiënten. Hoofdstuk 3.4 geeft een overzicht van de verschil-
lende IVIg-onderhoudsschema’s die momenteel worden gebruikt bij de behandeling 
van CIDP. Gerandomiseerde studies zijn nodig die verschillende doseringsschema’s 
van IVIg met elkaar vergelijken. In Hoofdstuk 3.5 wordt het protocol van een dosis-
respons-trial van IVIg in CIDP gepresenteerd. Deze studie onderzoekt of hoog frequent 
lage dosering IVIg-behandeling effectiever is dan laagfrequente IVIg-behandeling met 
hoge dosering. Deze dosis respons studie includeert momenteel patiënten en zal naar 
verwachting eind 2018 voltooid zijn.
IgG is de belangrijkste component van IVIg en waarschijnlijk verantwoordelijk voor 
het grootste deel van het immuun modulerende effect.
In Hoofdstuk 4 ligt de nadruk op serum IgG waardes bij IVIg-behandelde GBS- en 
CIDP-patiënten. GBS-patiënten ontvangen allemaal dezelfde willekeurige dosis van 2 
g IVIg per kg lichaamsgewicht. Niet alle patiënten vertonen echter een goed herstel 
na deze standaarddosis. In Hoofdstuk 4.1 beschrijven we een onderzoek waarin we 
bepaalden of de farmacokinetiek van IVIg gerelateerd was aan de uitkomst in GBS. 
Patiënten vertoonden aanzienlijke variabiliteit in de toename van serum IgG waarde 
twee weken na start van een standaard IVIg-kuur (2 g/kg). Patiënten met een geringe 
stijging van IgG in het serum hadden een ernstiger ziektebeloop, herstelden langzamer 
en hadden minder kans om na 6 maanden zelfstandig te kunnen lopen. Zelfs na cor-
rectie voor andere bekende prognostische factoren, was een lage toename van serum 
IgG onafhankelijk geassocieerd met een slechtere uitkomst. Deze resultaten geven aan 
dat patiënten met een geringe stijging van het serum IgG mogelijk gebaat zijn met een 
hogere dosering of een tweede kuur met IVIg. CIDP-patiënten worden vaak behandeld 
met IVIg en krijgen dezelfde willekeurige aanvangsdosis van 2 g/kg als GBS patiënten. 
De meeste CIDP-patiënten hebben langdurige behandeling nodig en de optimale do-
sering en frequentie van IVIg-onderhoudsbehandeling varieert sterk tussen individuele 
patiënten en kan waarschijnlijk deels worden verklaard door individuele verschillen 
in IVIg-katabolisme. In Hoofdstuk 4.2 worden de resultaten gepresenteerd van een 
onderzoek waarin we serum IgG waardes hebben onderzocht in klinisch stabiele maar 
IVIg-afhankelijke CIDP-patiënten. Alle patiënten kregen een individueel geoptimali-
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seerde IVIg-onderhoudsbehandeling volgens een stabiele dosering. De dosering van 
IVIg die nodig is om een  stabiele klinische situatie te bereiken, correleerde niet met 
het lichaamsgewicht. Klinisch stabiele CIDP-patiënten vertoonden stabiele serum IgG 
waardes na opeenvolgende IVIg-infusies. De lage intra- en interpatiënt variabiliteit in 
serum IgG kan erop wijzen dat constante waardes nodig zijn om een stabiele klinische 
situatie te bereiken. Meer studies zijn nodig om de dosering en het interval van IVIg-
onderhoudsbehandeling in CIDP verder te optimaliseren.
Aangezien GBS kan recidiveren en vergelijkbare symptomen kan vertonen na het 
doormaken van verschillende infecties, en GBS en CIDP samen kunnen voorkomen in 
één enkele patiënt geeft aan dat gastheer specifieke immuunreacties belangrijk zijn in 
het spectrum van GBS en CIDP. Tevens blijken auto-immuunziekten meer voor te komen 
in GBS en CIDP. Patiënten worden vaak behandeld met dezelfde standaarddosis IVIg, 
maar sommige patiënten reageren minder goed vanwege verschillen in hun klinische 
kenmerken of IVIg-katabolisme. Of deze patiënten gebaat zijn met IVIg in een aan-
gepaste dosering of een alternatieve behandeling, dient in klinische trials te worden 
onderzocht.
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DAnKWOOrD
Dit is misschien nog het moeilijkste gedeelte van dit proefschrift, aangezien dit het 
meest (en vaak het enige) gelezen gedeelte is… 
Dit proefschrift is enkel mogelijk door de lange geschiedenis van onderzoek naar 
en behandeling van GBS en CIDP door de GBS- en CIDP-onderzoeksgroep van het 
Erasmus MC. Allereerst wil ik alle patiënten bedanken voor hun continue inspanning 
en bereidheid tot deelname aan vaak meerdere onderzoeken en hun gastvrijheid bij de 
huisbezoeken waarbij ik bij velen een hapje mocht mee-eten. Tevens wil ik alle verpleeg-
kundigen van de dagbehandeling en van Eurocept Homecare bedanken voor hun inzet. 
Mijn promotor Prof. van Doorn wil ik bedanken voor de mogelijkheid om het onder-
zoek op te zetten en de kans om naast mijn werk in het Albert Schweitzer nog een 
dag in de week het onderzoek voort te zetten. Beste Pieter, ook al ben ik geen “typisch 
Pieter-meisje”, toch voel ik me altijd zeer prettig en gewaardeerd en geef je mij de ruimte 
mijzelf te zijn, met wat correcties waar nodig. Jij bent het ultieme voorbeeld dat hard 
werken en veel plezier wel samen kunnen gaan. Jouw positieve inslag (naast mijn wat 
meer negatieve kijk op de dingen), eerlijkheid, klinische blik en hart voor de patiënt 
waardeer ik zeer. Ik kan je altijd bellen over een patiënt, ook op de ski-piste. Jij geeft 
altijd alle credits aan anderen en stelt je onderzoekers altijd aan iedereen voor op con-
gressen en daarbuiten; dat vind ik mooi om te zien. Ik hoop dat we de samenwerking 
nog even kunnen voortzetten. 
Beste Bart, je hebt je de afgelopen jaren ontwikkeld tot professor en bent niet alleen 
de link naar het lab en de immunologie, maar nu ook de link naar de rest van de wereld 
met de IGOS- en ICOS-studies. Jouw kennis, kunde en de stapels geordende artikelen 
in jouw kamer verbazen mij keer op keer. De verwachtingen op het gebied van de 
internationale samenwerking zijn hoog gespannen, maar ik weet zeker dat je ze kan 
waarmaken. Haring en champagne: een prima combinatie. 
Professor Sillevis Smitt, beste Peter, wat leuk dat jij als mijn oud-opleider nu ook be-
trokken bent bij de beoordeling en verdediging van mijn proefschrift. Ludo van der Pol, 
hartelijk dank voor je bereidheid plaats te willen nemen in de kleine commissie. Profes-
sor van Gelder en professor Hintzen, Teun en Rogier, bedankt dat jullie willen plaatsne-
men in de commissie, ook al vrees ik jullie vragen op het gebied van de farmacologie en 
immunologie wel enigszins. 
Professor Vermeulen, het is een eer om de grondlegger van de IVIg-behandeling in 
CIDP in mijn commissie te hebben. Ook kwam ik erachter, na een mail die je stuurde naar 
aanleiding van een publicatie over de negatieve gevolgen van chiropractie, dat jij – net 
als ik – een fervent tegenhanger bent van de kwakzalverij. 
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Beste Esther, vele malen heb jij je telefonisch ingespannen voor de studie patiënten. 
Ik vind het erg leuk dat jij als Dordtse neuroloog uit het Erasmus MC wil plaatsnemen in 
mijn commissie. 
Wim Hop en Hester Lingsma, bedankt voor jullie statistische ondersteuning. Wim, 
ook al had je meestal eigenlijk geen tijd, altijd kon ik bij je aankloppen en vroeg je 
uiteindelijk ‘heb je een stickie bij je’? Fantastisch hoe jij uit de stapels papieren weer 
een boekje tevoorschijn wist te toveren met betrouwbaarheidsintervallen bij zeer kleine 
patiëntenaantallen, om zo de reviewers tevreden te stellen. 
Dear Angelika Hahn, it was a pleasure and honour to be able to work with you. You 
know your CIDP patients by heart and were always willing to go through all the patient 
files over and over again. You also gave me valuable advice about the things that really 
matter in life. 
De GBS-familie alias de “Friends of the Schwann cell”: Rinske van Koningsveld, Mar-
cel Garssen, Karin Geleijns, Mark Kuijf, Liselotte Ruts, Sonja van Nes, Judith Drenthen, 
Christa Walgaard, Carina Bunschoten, Willem-Jan (alias Gaylord) Fokkink, Joyce Roodbol, 
Bianca van den Berg, Chris Fokke, Christine Verboon, Alex Doets, Sonja Leonhard, Merel 
Broers en Marieke van Woerkom. Wij weten altijd het nuttige met het aangename te 
combineren; de PNS is met jullie altijd een groot feest. 
Jacqueline Habermehl, bedankt voor al je hulp en de altijd handige blik in de agenda 
van Pieter. 
Ruth Huizinga, Anne Tio en Wouter van Rijs, het GBS en CIDP onderzoek is niets zonder 
jullie. Jullie precisie, nauwkeurigheid en kennis van zaken zijn onontbeerlijk. 
Patricia Blomkwist, naast de patiëntendagen ben jij altijd bereid om in je vrije tijd een 
GBS-patiënt op de IC te bezoeken en de nodige steun te geven. 
De sfeer op de 22-ste wordt niet door de ruimte zelf maar enkel gevormd door de 
mensen met wie ik daar en in het ziekenhuis heb mogen werken. Gezien mijn nogal 
lange promotietraject zijn het er teveel om op te noemen. Toch kan ik het niet laten 
enkele namen te noemen: Heleen den Hertog, Maaike Dirks, Rinze Neuteboom, Marie-
Claire de Wit, Naghmeh Jafari, Immy Ketelslegers, Nadine van der Beek, Juna de Vries en 
Eric van Breda. 
Tessel Runia, Marieke van Oijen en Ellen Maathuis; bedankt voor de vele koffiemo-
menten en speeluitjes met de kinderen tijdens verlof en parttime dagen. 
Ladies van de Boekenclub; Gezina Sas, Lisette Maasland, Ilse Hoppenbrouwers, Heleen 
den Hertog, Janet de Beukelaar, Naghmeh Jafari, Annemarie Visser. Ook al is het boek 
vaak ver te zoeken, eten is een primaire levensbehoefte. 
Alle medewerkers van de afdeling KNF in het Erasmus MC wil ik bedanken voor hun 
steun tijdens de moeilijke periode na het verlies van Polle. Gelukkig kreeg ik de mogeli-
jkheid na mijn opleiding tot Neuroloog een tijdje als KNF-er te mogen werken in betere 
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tijden. Judith, dankzij jou ben ik wat wijzer geworden op het gebied van de KNF en is het 
uiteindelijk dan toch gelukt om een leuke baan te vinden. 
Al mijn collega’s in het Albert Schweitzer ben ik zeer erkentelijk voor de ruimte die er 
wordt gegeven om te kunnen doen wat je ligt en leuk vindt. Henk, bij jou kan je altijd 
terecht ook als er op het allerlaatste moment nog een nieuwe titel van het proefschrift 
moet komen. Janet, jouw inzet voor alles en iedereen én vriendschap kent geen grenzen. 
Anouk en Carine, wat heerlijk dat ik kan meegenieten van jullie kersverse moederschap. 
Constant, ik zal onze treinbiertjes missen als je in het Dordtse neerstrijkt. Jeroen, fijn om 
samen met jou de KNF naar een hoger niveau te tillen, hopelijk is daar nu weer wat meer 
ruimte voor na onze promoties. De KNF-laboranten, polidames en verpleegkundigen wil 
ik bedanken voor hun inzet en de prettige samenwerking. 
Mijn paranimfen: Christa Walgaard en Eva Wolf. Chris, binnenkort sta jij hier ook. Het 
wordt weer eens tijd dat we iemand een C/krista-sandwich geven! Eva wat leuk dat jij als 
middelbare school vriendin hier naast me staat, ik hoop natuurlijk dat jouw emigratie 
naar Nieuw Zeeland niet doorgaat.  
Alle andere vriendinnen van de middelbare school; Maaike Neuteboom, Kirsten Wel-
bergen, Nienke Beerends. Ewout van Galen, ook al spreken en zien we elkaar weinig, het 
is altijd als vanouds. 
Mijn buren Cleo en Sebas, Irene en Wouter, wil ik bedanken voor de gezelligheid 
en voor allerhande hand- en spandiensten waaronder het geregeld voeden van mijn 
kinderen. 
Moraan Gilad, als toekomstige schoonmoeder van Hinke, bedankt voor al je hulp als ik 
je nodig had en natuurlijk voor de gezelligheid. 
Paps en mams en Ilse, ook al hebben jullie geen flauw idee wat ik precies doe, dat 
maakt ook niet uit, op jullie steun kan ik altijd rekenen. En toch leuk, dat de naam Kuit-
waard in ieder geval op Pubmed is vertegenwoordigd. 
Lieve James, wie had dat gedacht; dat een ontmoeting in Thailand onze levens zou 
veranderen. Jij bent een grote steun bij de totstandkoming van dit proefschrift, altijd 
weer was je bereid mij uit de brand te helpen in het geval van “computer says no” of als 
er weer een figuur gemaakt danwel aangepast diende te worden. Je kunt de zin “CIDP 
is a chronic inflammatory polyradiculoneuropathy” waarschijnlijk niet meer aanhoren 
en er is eindeloos geduld voor nodig als het perfecte Engels weer teniet werd gedaan 
door een van de promotoren. Mijn ware levensgeluk deel ik met jou en onze heerlijke 
kinderen Hinke en Taeke. 
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Krista Kuitwaard was born on September 30th 1978 in Alkmaar, the Netherlands. She 
studied medicine at the Free University in Amsterdam. After obtaining her medical 
degree in 2003 she worked for a year at the Department of Neurology of the Medical 
Centre in Alkmaar (Noordwest Ziekenhuisgroep). Here, her interest in the Guillain-Barré 
syndrome (GBS) started which resulted in the publication of a case report of a GBS pa-
tient. Thereafter she worked as a resident in neurology at the Erasmus Medical Centre in 
Rotterdam and started her neurology training in 2005 (head: Prof. Dr. P.A.E. Sillevis Smitt). 
Parallel to this residency she started her PhD research under supervision of Prof. Dr. P.A. 
van Doorn and Prof. Dr. B.C. Jacobs. In 2009 she received the C.U. Ariëns Kappers prize 
from the Dutch Neurological Society (NVvN) for the best neurology-related publication: 
“Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syn-
drome”. After completing her neurology residency in 2013 she worked for 10 months as 
a neurologist and clinical neurophysiologist in the Erasmus Medical Centre. Since 2014 
she works as a neurologist in the Albert Schweitzer hospital in Dordrecht. Currently she 
is continuing CIDP research in the Erasmus Medical Centre for one day a week, by con-
ducting an IVIg dose finding trial in CIDP patients (DRIP study) and investigating genetic 
polymorphisms in CIDP patients treated with IVIg, for which she received the SPIN award 
for innovative ideas in the field of immunoglobulin research in neurology. She lives with 
her partner James Winter and their two children; Hinke and Taeke in Rotterdam.
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Summary of PhD training and teaching
Name PhD student: K. Kuitwaard
Erasmus MC Department: Neurology
PhD period: 2007-2018
Promotor(s): Prof. P.A. van Doorn & Prof. B.C. Jacobs
1. PhD training
year Workload
(eCTS)
General courses
- Principles of research in Medicine
- Introduction to data analysis
- Regression analysis
- Clinical trials
- Pharmaco-epidemiology
- Classical methods of data analysis
- Repeated measurements
- Good Clinical Practice
- Biomedical English and writing
- Recertification BROK
2007
2007
2007
2007
2007
2007
2007
2007
2008
2014
0.7
0.7
1.4
0.7
0.7
5.7
1.4
0.7
4.0
Specific courses (e.g. research school, medical Training)
- Molmed introductory course statistics and survival analysis 2010 0.4
Seminars and workshops
- Department Journal club and seminars
- Boerhaave neuromuscular course, Leiden/Amsterdam (9X)
2007-2013
2008-2018
2.0
4.5
Oral presentations (& conference attendance)
- American Academy of Neurology (AAN) Toronto
- Peripheral Nerve Society (PNS) Rotterdam
- Peripheral Nerve Society (PNS) Sitges
2010
2012
2017
1.0
1.0
1.0
Poster presentations (& conference attendance)
- INC meeting Paris (2 posters)
- PNS meeting Würzburg (3 posters)
- PNS/INC meeting Sydney (2 posters)
- PNS/INC meeting Rotterdam (2 posters)
- INC meeting Düsseldorf (1 poster)
- INC meeting Glasgow (1 poster)
2008
2009
2010
2012
2014
2016
1.0
1.5
1.0
1.0
1.0
1.0
(Inter)national conferences
- Scientific meeting NVvN Garderen (Ariëns kappers prize)
- PNS meeting Quebec (SPIN award)
2009
2015
0.5
0.5
Other
- AANEM podcast interview 2010 0.5
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year Workload
(eCTS)
lecturing
- Muscle disease congress Zoetermeer (oral presentation)
- Muscle disease congress Lunteren (oral presentation)
- Neuromuscular Study Group, Utrecht (2 oral presentations)
- Muscle disease congress Veldhoven (poster presentation)
- Muscle disease congress Veldhoven (oral presentation)
- Neuromuscular Study Group, Utrecht (oral presentation)
- Anniversary congress GBS/CIDP Zoetermeer
Continuous activities
- Teaching nurses
- Reviewing papers for international peer-reviewed journals
2008
2009
2009
2014
2015
2015
2016
2006-2016
2010-2017
1.0
1.0
2.0
0.5
1.0
1.0
1.0
0.5
1.0
Total 42.9
GBS and CIDP
Spectrum and IVIg treatment
Krista Kuitwaard
GBS and CIDP
Spectrum and IVIg treatment
Krista Kuitwaard
GBS 
AND
CIDP 
SPECTRUM 
AND IVIG 
TREATMENT
Krista Kuitwaard
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